

School of Medical & Allied Sciences

Diploma in Pharmacy (D. Pharm)

Program Code: 31

2023-2025

PREFACE

The objective of any program at Higher Education Institute is to prepare their students for the society at large. The K. R. Mangalam University envisions all its programs in the best interest of their students and in this endeavour it offers a new vision to all its Under-Graduate courses. The Under-Graduate Programmes will prepare the students for both, academia and employability. Each programme vividly elaborates its nature and promises the outcomes that are to be accomplished by studying the courses. The programmes also state the attributes that it offers to inculcate at the diploma level. The diploma attributes encompass values related to critical thinking and skills for employability. In short, each programme prepares students for sustainability and life-long learning. The PCI approved curriculum of D. Pharmacy offer in depth knowledge of ever changing field of pharmacy with focus on latest developments in drug design and discovery. After D Pharm, students get registered in state pharmacy council and as registered Pharmacist may work at drug stores in Government Hospitals, Private Hospitals, Clinics, Community Health Centers or Private Drug Stores. They may even start their own Drug store (Entrepreneurship) and online Pharmacy. Pharmacist can also work as Medical sales Representative and as Manufacturing and Quality Control Chemist in Pharmaceutical Industries. The K. R. Mangalam University hopes the curriculum of the programme D. Pharmacy will help students in making an informed decision at the time of working in any private or government services.

ACKNOWLEDGEMENT

The development of Curriculum for Undergraduate diploma course in Pharmacy is a result of thoughtful deliberations at various stages of dedicated and specialized experts. This curriculum has been framed to meet the expectations of an academically challenging environment, develop problem-solving skills by students, align with current standards and to enrich the students to make them self-enablers and/or match job requirements on successful completion of their degrees.

I wish to acknowledge all our experts who have been involved in the process of developing this outcome-based curriculum for D. Pharmacy. We are thankful to all the faculty members, team of Academic and Industry experts who were devotedly committed towards framing this curriculum.

Special thanks and gratitude to Prof. C. S. Dubey, Vice Chancellor, K.R. Mangalam University, who have been instrumental and encouraging throughout the process of developing this curriculum.

.

Dean
School of Medical & Allied Sciences

CONTENTS

| S. | Particulars | Page No. |
|----|----------------------------|----------|
| 1. | Introduction | 5-5 |
| 2. | About School | 5-6 |
| 3. | Programs Offered by School | 6-6 |
| 4. | Program Duration | 7-7 |
| 5. | Class Timings | 7-7 |
| 6. | Syllabus of D. Pharmacy | 9-163 |

1. INTRODUCTION

The K.R. Mangalam Group has made a name for itself in the field of education. The K.R. Mangalam story goes back to the chain of schools that offered an alternative option of world-class education, pitching itself against the established elite schools, which had enjoyed a position of monopoly till then. Having blazed a new trail in school education, the focus of the group was aimed at higher education.

K.R. Mangalam University is the fastest-growing higher education institute in Gurugram, India. K. R. Mangalam University was established under the Haryana Private University Act 2006, received the approval of Haryana Legislature vide Amendment Act # 36 of 2013 and consent of the Hon'ble Governor of Haryana on 11th April 2013, which was published in the Gazette notification vide Leg. No.10/2013, dated 3rd May 2013.

Since its inception in 2013, the University has been striving to fulfil its prime objective of transforming young lives through ground-breaking pedagogy, global collaborations, and world-class infrastructure. Resources at K.R Mangalam University have been continuously upgraded to optimize opportunities for the students. Our students are groomed in a truly interdisciplinary environment where they grow up with integrative skills through interaction with students from engineering, social sciences, management and other study streams.

K. R. Mangalam University is unique because of its

- 1. Enduring legacy of providing education to high achievers who demonstrate leadership in diverse fields.
- 2. Protective and nurturing environment for teaching, research, creativity, scholarship, social and economic justice.

Objectives

- 1. Enhance leadership qualities among the youth having understanding of ethical values and environmental realities.
- 2. Foster employability and entrepreneurship through futuristic curriculum and progressive pedagogy with cutting-edge technology.
- 3. Instill notion of lifelong learning through stimulating research, outcomes-based education and innovative thinking.
- 4. Integrate global needs and expectations through collaborative programs with premier universities, research centers, industries and professional bodies.

2. About School

The School of Medical & Allied Sciences (SMAS) at K. R. Mangalam University started in the year 2013 after being duly approved by the Pharmacy Council of India (PCI). The SMAS comprises of modular laboratories equipped with state-of-the-art facilities and infrastructure. The School of Medical and Allied Sciences currently offers D. Pharm, B. Pharm, M. Pharm and PhD courses in Pharmacy. The Centre for Education Growth and

Research adjudged School of Medical & Allied Sciences, as Best Pharmacy College in India in March 2016 at India International Centre, New Delhi.

School Vision

To contribute towards healthcare needs of the society by producing a skilled, motivated and accessible workforce dedicated towards achieving health for all.

School Mission

M1: To produce self-motivated, self-reliant and socially sensitive young healthcare professionals catering to the needs of academia, industry and research.

M2: To create a centre of excellence for learning and research in the field of pharmaceutical and allied health sciences with inter-disciplinary approach in emerging area of science and technology with focus on industry-academia interaction.

M3: To nurture transformational research for the benefit of the society.

M4: To interlink pharmaceutical and allied health sciences with interdisciplinary life sciences.

3. Programs offered by School

3.1. Diploma in Pharmacy

The School of Medical & Allied Sciences (SMAS) at K. R. Mangalam University started in the year 2013 after being duly approved by the Pharmacy Council of India (PCI). The PCI approved D. Pharmacy program started in the year 2017 and aims to provide an extra edge to our students by teaching and training by leading pharma industry experts to facilitate industry academia interaction, participation in conferences / workshops / skill development programs and career guidance. The students are encouraged to participate in various health camps organized by the School to make general awareness amongst people regarding various diseases like diabetes, hypertension, communicable and non-communicable diseases and lay down the platform for students for getting jobs in various government and private institutions.

3.2. D. Pharmacy

Eligibility Criteria

The student should have passed the 10+2 examination conducted by the Central Board of Secondary Education or equivalent examination from a recognized Board in Science stream with an aggregate of 50% or more.

Course Outline: Inorganic chemistry / Organic chemistry / Pharmaceutics / Analysis / Pharmaceutical Chemistry/Pharmacology/ Pharmacognosy

Career Opportunities

Students will get themselves registered in the state pharmacy council and the registered Pharmacists may work at drug stores in Government Hospitals, Private Hospitals, Clinics, Community Health Centers or Private Drug Stores. They may even start their own Pharmacy shop (Entrepreneurship) and online Pharmacy. Pharmacist can also work as Medical sales Representative and as Manufacturing and Quality Control Chemist in Pharmaceutical Industries.

4. PROGRAM DURATION

The program duration of Diploma in Pharmacy is

| Name of the Program | Duration |
|---------------------|----------|
| D. Pharmacy | 2 Years |

5. CLASS TIMINGS

The class will be held from Monday to Friday from 9.10 A.M. to 4.00 P.M.

6. SCHEME OF STUDIES AND SYLLABI

The syllabi of the Pharmacy program offered by School of Medical & Allied Sciences are approved by PCI.

6.1 Syllabus of Diploma Pharmacy

The PCI approved syllabi of the D. Pharmacy programs offered by School of Medical & Allied Sciences is as follows -

| | Year I | Year II |
|---------|--------|---------|
| Courses | 10 | 11 |
| Credits | 0 | 0 |

Scheme of Studies of D. Pharmacy –

D. Pharm- I Year

| Subject Code | Course Title | L | P |
|-----------------|-----------------------------------|---|---|
| ER20-11T | Pharmaceutics – Theory | 4 | |
| ER20-11P | Pharmaceutics – Practical | | 3 |
| ER20-12T | Pharmaceutical Chemistry – Theory | 4 | |

| ER20-12P | Pharmaceutical Chemistry – Practical | | 3 |
|----------|---|----|----|
| ER20-13T | Pharmacognosy – Theory | 4 | |
| ER20-13P | Pharmacognosy – Practical | | 3 |
| ER20-14T | Human Anatomy & Physiology – Theory | 4 | |
| ER20-14P | Human Anatomy & Physiology – Practical | | 3 |
| ER20-15T | Social Pharmacy – Theory | 4 | |
| ER20-15P | Social Pharmacy – Practical | | 3 |
| | | 20 | 15 |
| ER20-21T | Pharmacology –Theory | 4 | |
| ER20-21P | Pharmacology –Practical | | 2 |
| ER20-22T | Community Pharmacy & Management | 4 | |
| ER20-22P | Community Pharmacy & Management – | | |
| EK20-221 | Practical | | 3 |
| ER20-23T | Biochemistry & Clinical Pathology – | 4 | |
| | Theory | 4 | |
| ER20-23P | Biochemistry & Clinical Pathology – practical | | 2 |
| ER20-24T | Pharmacotherapeutics | 4 | |
| ER20-24P | Pharmacotherapeutics- Practical | | 1 |
| ER20-25T | Hospital & Clinical Pharmacy – Theory | 4 | |
| ER20-25P | Hospital & Clinical Pharmacy – Practical | | 1 |
| ER20-26T | Pharmacy Law & Ethics | 4 | - |
| | Total | 24 | 9 |

Programme Outcomes (POs) and Programme Educational Objectives (PEOs)

The entire curriculum of D. Pharmacy is planned to have following programme outcomes

- **PO 1 Pharmacy Knowledge**: Possess the core and basic knowledge associated with the profession of pharmacy.
- **PO 2 Thinking Abilities**: Examine issues rationally and logically; shall acquire, evaluate, and synthesize information and knowledge relevant to an identified problem.
- **PO3 Planning Abilities:** Demonstrate effective planning abilities including time management, resource management, delegation skills and organizational skills.
- **PO 4 Leadership Skills**: Acquire knowledge of leadership traits and skills through curricular and co-curricular activities and develop skills and abilities that will enable him/her to lead or actively contribute to organizational improvement.
- **PO 5 Professional Identity**: Understand, analyze and communicate the value of their professional roles in society.
- **PO 6 Pharmacy and Society:** Apply reasoning informed by the contextual knowledge to assess societal, health, safety and legal issues and the consequent responsibilities relevant to the professional pharmacy practice.
- **PO 7 Environment and sustainability:** Understand the impact of the professional pharmacy solutions in societal and environmental contexts, and demonstrate the knowledge of, and need for sustainable development
- **PO 8 Professional Ethics**: Honor personal values and apply ethical principles in professional and social contexts and take responsibility for the outcomes associated with the decisions.
- **PO 9 Individual or teamwork:** Understand the need for leadership and teambuilding for fulfillment of practice, professional and societal responsibilities.
- **PO 10 Communication:** Develop good communication skills so as to communicate effectively with the pharmacy community and with society at large.
- **PO 11 Modern & Usage:** Learn, select, and apply appropriate methods and procedures, resources, and modern pharmacy-related computing tools with an understanding of the limitations.
- **PO 12 Life-long Learning:** Recognize the need for and have the preparation and ability to engage in independent and life-long learning in the broadest context of technological change. Self-assess and use feedback effectively from others to identify learning needs and to satisfy these needs on an ongoing basis.

Programme Specific Outcomes

PSO1 To impart theoretical & Practical knowledge among students in the various fields of pharmaceutical sciences viz., Pharmaceutics, Pharmaceutical Chemistry,

Pharmacology and Pharmacognosy.

PSO2 To promote the development of communication skills, leadership qualities among the students.

PSO3 To effectively communicate with patients in the hospital pharmacy and guide them regarding medication specifications.

PSO4 To upgrade practical skill of the students in the area of clinical pharmacy and community pharmacy.

PSO5 To make aware the students with fundamental regulatory aspects of Pharmaceuticals.

Programme Educational Objectives (PEOs)

PEO1: To produce pharmacy graduates with profound knowledge and high technical skills to meet various aspects in wide areas of Pharmaceutical industry.

PEO2: To enable pharmacy graduates to gain theoretical and practical knowledge in various subjects to discover novel formulation for the benefits of the society.

PEO3: To prepare entrepreneurs in Pharma sector with effective communication skills, teamwork and ethical attitude with high integrity for the betterment of the community and the society.

PEO4: To promote and train the pharmacy graduates towards contribution of health care system and patient counseling for prevention and treatment of diseases.

PEO5: To encourage the pharmacy graduates for lifelong learning and highly competent career prospect related to interdisciplinary pharmaceutical sciences.

Structure of D. Pharmacy

| SMAS | | D. PHARMACY (Scheme of Studies) | | |
|--------|--------------------------------|---|----|----|
| YEAR | Subject Code | Course Title | L | P |
| | ER20-11T | Pharmaceutics – Theory | 4 | |
| | ER20-11P | Pharmaceutics – Practical | | 3 |
| | ER20-12T | Pharmaceutical Chemistry – Theory | 4 | |
| | ER20-12P | Pharmaceutical Chemistry – Practical | | 3 |
| FIRST | ER20-13T | Pharmacognosy – Theory | 4 | |
| 표 | ER20-13P | Pharmacognosy – Practical | | 3 |
| _ | ER20-14T | Human Anatomy & Physiology – Theory | 4 | |
| | ER20-14P | Human Anatomy & Physiology – Practical | | 3 |
| | ER20-15T | Social Pharmacy – Theory | 4 | |
| | ER20-15P | Social Pharmacy – Practical | | 3 |
| | Total | | 20 | 15 |
| | ER20-21T | Pharmacology –Theory | 4 | |
| | ER20-21P | Pharmacology –Practical | | 2 |
| | ER20-22T | Community Pharmacy & Management | | |
| 0 | ER20-22P | Community Pharmacy & Management – Practical | | 3 |
| SECOND | ER20-23T | Biochemistry & Clinical Pathology – Theory | 4 | |
| SEC | ER20-23P | Biochemistry & Clinical Pathology – Practical | | 2 |
| | ER20-24T | Pharmacotherapeutics | 4 | |
| | ER20-24P | Pharmacotherapeutics- Practical | | 1 |
| | ER20-25T | Hospital & Clinical Pharmacy – Theory | 4 | |
| | ER20-25P | Hospital & Clinical Pharmacy – Practical | | 1 |
| | ER20-26T Pharmacy Law & Ethics | | | |
| | Total | Total | 24 | 9 |

| | Year I | Year II |
|---------|--------|---------|
| Courses | 10 | 11 |
| Credits | 0 | 0 |

Diploma I Year

ER20-11T: PHARMACEUTICS-I Theory

| ER20-11T | Pharmaceutics-I | L | T | P | | |
|----------------------------|-----------------|----------|---|---|--|--|
| Version 2.0 | | 3 | 1 | 0 | | |
| Total Contact Hours | 75 hours | 75 hours | | | | |
| Pre-requisites/Exposure | | | | | | |
| Co-requisites | Pharmaceutics | | | | | |

Course Objectives

Upon completion of this course the student should be able to:

- 1. Basic concepts, types and need.
- 2. Advantages and disadvantages, methods of preparation / formulation.
- 3. Packaging and labeling requirements.
- 4. Types of Tablets and Capsules
- 5. Basic quality control tests, concepts of quality assurance and good manufacturing practices.

Course Outcomes (CO)

On completion of this course, the students will be able to:

- CO1 Describe about the different dosage forms and their formulation aspects.
- CO2 Explain the advantages, disadvantages, and quality control tests of different dosage forms.
- CO3 Discuss the importance of quality assurance and good manufacturing practices

| СО | PO 1 | PO 2 | PO 3 | PO 4 | PO 5 | PO 6 | PO 7 | PO 8 | PO 9 | PO 10 | PO 11 | PO 12 | PSO 1 | PSO 2 | PSO 3 | PSO 4 | PSO 5 |
|---------|---------|---------|---------|---------|---------|---------|------|---------|---------|----------|----------|----------|----------|----------|----------|----------|----------|
| CO 1 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
| CO 2 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
| CO 3 | 3 | 3 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
| | • | 1 | l=ligh | tlv ma | nned | | 2=1 | moder | ately r | nanne | 1 | - | 3=stron | olv mar | ned | • | |

| Unit | | | e local, nat bal develo | | | ce To the Emplo eurship/ Skill De | | Relevance to the Professional Ethics, Gender, Human Values, Environment & Sustainability | | | SDG | NEP | POE/4 th IR | |
|-------------|-----|--------------|----------------------------|---|-----------------------|--------------------------------------|---|--|------------|---|---|--------|---|-----------------|
| ER201 1T | Loc | Regio nal | Nation al | Global | Employab ility | Entrepreneu rship | Skill Developm ent | Professi onal Ethics | Gend er | Human Values | Environm ent & Sustainab ility | | | |
| Unit I | - | | | The history of pharmacy in India dates back to ancient times, with modern developmen ts in education, industry, | | - | Pharmacy in India, rooted in ancient knowledge, saw modernizati on during British rule, leading to robust | | - | Pharmacy in India has ancient roots, but modernizati on began during British rule, leading to robust education, a | | Decent | rProfessio nal (Educatio n (17.1- 17.5) | Developm ent |

| | and practice during British rule. Today, pharmacy offers | education, a thriving industry, diverse practice areas, and | thriving industry, diverse practice areas, and active | |
|-----------|---|---|---|---|
| | diverse career opportuniti es. Pharmacop oeias like IP, | active professional associations . It offers promising career | professional associations. Pharmacy offers promising careers. | |
| | BP, USP, NF set drug standards, with IP ensuring quality in | prospects. Pharmacop oeias like IP, BP, USP, and NF set drug | Pharmacopo eias like IP, BP, USP, and NF set drug standards, with IP | |
| | India's thriving pharmaceut ical industry, vital for | standards, with IP vital for India's skill developmen t and global | addressing human values by ensuring safe and quality | |
| | global health needs. | healthcare needs, ensuring quality medicines. | medicines for healthcare needs. | |
| Unit II - | - Packaging materials vary, including glass (recyclable, | Packaging - materials, including glass (fragile, recyclable), | Packaging - materials like glass (recyclable, inert), plastic | Skills for Professio Skill Decent nal Developm Work (Educatio ent SDG 4.4) n (17.1- 17.5) |

| L | T - T | T., |
|---------------|---------------|---------------|
| fragile), | plastic | (lightweight, |
| plastic | (lightweight | versatility), |
| (lightweight | , diverse), | metal |
| , | metal | (durable, |
| environmen | (durable, | costly), and |
| tal | costly), and | rubber |
| concerns), | rubber | (flexible, |
| metal | (flexible, | limited use) |
| (durable, | specialized), | offer diverse |
| costly), and | vary based | options. |
| rubber | on product | Human |
| (flexible, | needs. Skill | values need |
| limited use). | developmen | eco-friendly, |
| Selection | t in | safe |
| depends on | packaging | packaging |
| product | aligns with | aligning with |
| characteristi | industry | sustainabilit |
| cs. | demands | y, health, |
| Sustainable | for | and ethics, |
| choices | sustainable | addressing |
| align with | materials, | concerns |
| global | innovative | about |
| developmen | design, and | waste, |
| tal needs, | efficient | pollution, |
| reducing | manufacturi | and product |
| waste and | ng, crucial | safety. |
| environmen | for the | |
| tal impact, | packaging | |
| | sector's | |
| _ | growth. | |
| packaging | | |
| solutions. | | |
| | | |

| Unit - | Organolepti | Pharmaceut | Pharmaceuti | |
|--------|--------------|----------------|---------------|--|
| III | c agents | ical aids like | cal aids like | |
| | enhance the | organolepti | organoleptic | |
| | sensory | c agents | agents | |
| | qualities of | (color, | (color, | |
| | medicines | flavor, | flavor, | |
| | (color, | sweetness) | sweetness) | |
| | flavor, | enhance | improve | |
| | sweetness). | drug appeal. | medicine's | |
| | Preservative | Preservative | sensory | |
| | s prevent | s, such as | appeal. | |
| | microbial | parabens | Preservative | |
| | spoilage, | and | s (e.g., | |
| | including | benzalkoniu | parabens, | |
| | parabens | m chloride, | benzalkoniu | |
| | and | extend shelf | m chloride) | |
| | benzalkoniu | life by | ensure | |
| | m chloride. | inhibiting | safety and | |
| | They ensure | microbial | longevity. | |
| | global | growth. Skill | Human | |
| | health | developmen | values need | |
| | needs are | t involves | medicines to | |
| | met by | formulation | be palatable | |
| | extending | expertise, | and safe, | |
| | product | ensuring | enhancing | |
| | shelf life, | safe and | patient | |
| | reducing | appealing | adherence | |
| | waste, and | medicines, | and trust, | |
| | maintaining | aligning | fostering | |
| | drug | with | healthcare | |
| | efficacy and | industry | ethics and | |
| | safety. | demands | values. | |
| | | for quality | | |
| | | and | | |
| | | innovation. | | |

| Unit- | Unit | Unit | Unit | |
|-------|---------------|----------------|----------------|--|
| IV | operations | operations | operations | |
| | are | in | are vital in | |
| | fundamenta | pharmaceut | pharmaceuti | |
| | l in | icals | cals. Size | |
| | pharmaceut | encompass | reduction | |
| | ical | size | (hammer | |
| | manufacturi | reduction | mill, ball | |
| | ng. Size | (e.g., | mill) reduces | |
| | reduction | hammer | particle size. | |
| | (e.g., | mill, ball | Size | |
| | hammer | mill), size | separation | |
| | mill, ball | separation | (cyclone, | |
| | mill) | (cyclone, | sieves) | |
| | reduces | sieves), | ensures | |
| | particle size | mixing | uniformity. | |
| | for drug | (double | Mixing | |
| | formulation. | cone | (double | |
| | Size | blender, | cone | |
| | separation | turbine | blender, | |
| | (cyclone, | mixer, triple | turbine | |
| | sieves) | roller mill, | mixer, triple | |
| | ensures | Silverson | roller mill, | |
| | uniformity. | mixer | homogenize | |
| | Mixing | homogenize | r) | |
| | (cone | r), filtration | homogenize | |
| | blender, | theory | s | |
| | turbine | (membrane, | ingredients. | |
| | mixer, roller | sintered | Filtration | |
| | mill, | glass), | (membrane, | |
| | homogenize | drying | sintered | |
| | r) | (fluidized | glass) | |
| | homogenize | bed, freeze | separates | |
| | S | drying), and | solids. | |
| | ingredients. | extraction. | Drying | |

| | Filtration | Skill | (fluidized | |
|--------|---------------|-----------------|--------------|--|
| | (membrane, | developmen | bed, freeze | |
| | sintered | t in these | drying) | |
| | glass) | operations | removes | |
| | separates | is critical for | moisture. | |
| | solids from | pharmaceut | Extraction | |
| | liquids. | ical | extracts | |
| | Drying | professional | active | |
| | (fluidized | s, ensuring | compounds, | |
| | bed, freeze | quality, | supporting | |
| | drying) | safety, and | health | |
| | removes | efficacy in | needs and | |
| | moisture. | drug | ethical drug | |
| | Extraction | manufacturi | production. | |
| | plays a vital | ng and | | |
| | role in | contributing | | |
| | obtaining | to industry | | |
| | active | growth and | | |
| | compounds | innovation. | | |
| | from | | | |
| | natural | | | |
| | sources, | | | |
| | contributing | | | |
| | to drug | | | |
| | developmen | | | |
| | t and global | | | |
| | health | | | |
| | needs. | | | |
| Unit-V | Pharmaceut | The | Pharmaceuti | |
| | ical product | pharmaceut | cal products | |
| | diversity | ical industry | like tablets | |
| | addresses | requires a | (coated, | |
| | global | highly | uncoated, | |
| | healthcare | skilled | modified), | |
| | challenges. | workforce | capsules | |

| | I. I. | | |
|----------------|--------------|----------------|--|
| Skill | for the | (hard, soft | |
| developmen | developmen | gelatin), | |
| t in dosage | t, | liquid oral | |
| form | manufacturi | preparations | |
| preparation | ng, and | , topical | |
| ensures | quality | products, | |
| accessibility, | control of | nasal and | |
| safety, and | various | ear | |
| efficacy. | dosage | preparations | |
| Immunologi | forms like | , powders, | |
| cal | tablets, | sterile | |
| products, | capsules, | formulations | |
| sterile | liquids, | , and | |
| formulation | topical | immunologi | |
| s, and | preparation | cal products | |
| diverse drug | s, powders, | cater to | |
| delivery | sterile | human | |
| systems | formulation | health | |
| contribute | s, and | needs. | |
| to global | immunologi | Ensuring | |
| health, | cal | their quality, | |
| emphasizing | products. | safety, and | |
| equitable | Skill | efficacy | |
| access and | developmen | aligns with | |
| quality | t is crucial | ethical | |
| healthcare. | to ensure | values in | |
| | safe and | healthcare, | |
| | effective | prioritizing | |
| | drug | patient well- | |
| | production, | being and | |
| | meeting | trust. | |
| | global | | |
| | healthcare | | |
| | standards, | | |
| | and | | |

| | | fostering | | |
|-------|--------------|--------------|---------------|--|
| | | innovation | | |
| | | in the | | |
| | | pharmaceut | | |
| | | ical sector. | | |
| Unit- | Pharmaceut | Pharmaceut | Pharmaceuti | |
| VI | ical | ical | cal | |
| | manufacturi | manufacturi | manufacturi | |
| | ng plants | ng plants | ng plants | |
| | have | have | are | |
| | specific | distinct | organized | |
| | layouts and | layouts with | with | |
| | sections for | production, | production, | |
| | production, | quality | quality | |
| | quality | control, and | control, and | |
| | control, and | assurance | assurance | |
| | assurance. | sections. | sections. | |
| | Quality | Quality | Quality | |
| | control | control | control | |
| | ensures | maintains | maintains | |
| | product | product | product | |
| | consistency, | quality, | quality, | |
| | while | while | while quality | |
| | quality | quality | assurance | |
| | assurance | assurance | ensures | |
| | focuses on | ensures | process | |
| | process | process | integrity, | |
| | integrity | integrity, | following | |
| | and | adhering to | cGMP. | |
| | regulatory | cGMP. | Calibration | |
| | compliance. | Calibration | and | |
| | Compliance | and | validation | |
| | with cGMP, | validation | uphold | |
| | calibration, | are crucial | human | |
| | and | skills for | values by | |

| | validation | pharmaceu | t guaranteeir | | |
|-------|--------------|---------------|---|---|--|
| | ensures safe | ical | g safe | | |
| | and | professiona | | | |
| | effective | s, ensuring | and ethica | | |
| | medicines, | safe and | drug | | |
| | meeting | effective | production, | | |
| | global | drug | emphasizing | | |
| | healthcare | production | | | |
| | standards, | supporting | · • • • • • • • • • • • • • • • • • • | | |
| | fostering | industry | trust. | | |
| | patient | growth, and | | | |
| | trust, and | fostering | | | |
| | advancing | expertise ir | , | | |
| | global | quality | | | |
| | health | manageme | n l | | |
| | goals. | t. | | | |
| Unit- | Novel drug | Novel drug | Novel dru | σ | |
| VII | delivery | delivery | delivery | | |
| | systems | systems, | systems | | |
| | revolutioniz | such as | improve | | |
| | e healthcare | liposomes | drug | | |
| | globally by | and | effectivenes | | |
| | improving | microspher | | | |
| | drug | es, enhance | | | |
| | effectivenes | drug | compliance | | |
| | s. Examples | efficacy. | They includ | | |
| | include | Skill | oral, | | |
| | nanomedici | developme | | | |
| | ne and | t in their | and | | |
| | implantable | design and | | | |
| | devices. | implement | | | |
| | Benefits | tion is vital | | | |
| | include | aligning | Advantages | | |
| | targeted | with | include | | |
| | therapy and | industry | precise | | |

| reduced | demands | dosing and |
|---------------|--------------|---------------|
| | | |
| side effects, | for | reduced side |
| but | innovative | effects, |
| challenges | drug | while |
| like cost and | delivery | challenges |
| accessibility | solutions, | involve |
| remain. | supporting | complexity. |
| Addressing | pharmaceut | Aligning |
| these needs | ical | with human |
| aligns with | professional | values, |
| global | s in | these |
| healthcare | advancing | systems |
| goals for | patient care | prioritize |
| improved | and | patient well- |
| treatment | treatment | being, |
| outcomes. | outcomes. | safety, and |
| | | convenience |
| | | in |
| | | healthcare. |

ER20-11P: PHARMACEUTICS-I Practical

| ER20-11P | Pharmaceutics-I - Practical | L | Т | P | | | | |
|----------------------------|-----------------------------|---|---|---|--|--|--|--|
| Version 2.0 | | 0 | 0 | 3 | | | | |
| Total Contact Hours | 75 hr | | | | | | | |
| Pre-requisites/Exposure | | | | | | | | |
| Co-requisites | Pharmaceutics | | | | | | | |
| Course Objectives | | | | | | | | |

Upon completion of this course the student should be able to:

- 1. Calculation of working formula from the official master formula
- 2. Formulation of dosage forms based on working formula

- 3. Appropriate Packaging and labeling requirements
- 4. Methods of basic quality control tests

Course Outcomes (CO)

Upon successful completion of this course, the students will be able to

- 1. Calculate the working formula from the given master formula
- 2. Formulate the dosage form and dispense in an appropriate container
- 3. Design the label with the necessary product and patient information
- 4. Perform the basic quality control tests for the common dosage forms

| СО | PO1 | PO2 | PO3 | PO4 | PO5 | PO6 | PO7 | PO8 | PO9 | PO10 | PO11 | PO12 | PSO1 | PSO 2 | PSO 3 | PSO 4 | PSO 5 |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|------|------|------|----------|----------|----------|----------|
| CO1 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
| CO2 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
| CO3 | 3 | 3 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
| CO4 | 3 | 3 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |

1=lightly mapped 2= moderately mapped 3=strongly mapped

| Uı | nit | | ance to the | | | | nce To the Emplo eurship/ Skill Dev | | Relevance to the Professional Ethics, Gender, Human Values, Environment & Sustainability | | | SDG | NEP | POE/4 th IR | | |
|----|------|-----------|--------------|--------------|--------|-------------------|--|--------------------------|--|------------|-----------------|---|-----|---------------------------|--|--|
| 1F | R201 | Loc al | Regio nal | Nation al | Global | Employab ility | Entrepreneu rship | Skill Developm ent | Professi onal Ethics | Gend er | Human Values | Environm ent & Sustainab ility | | | | |

| Unit I | - The history- | - Pharmacy in- | - Pharmacy in- | Skills for Professio Skill |
|--------|----------------|----------------|----------------|----------------------------|
| | of pharmacy | India, | India has | Decent nal Developm |
| | in India | rooted in | ancient | Work (Educatio ent |
| | dates back | ancient | roots, but | SDG 4.4) n (17.1- |
| | to ancient | knowledge, | modernizati | 17.5) |
| | times, with | saw | on began | |
| | modern | modernizati | during | |
| | developmen | on during | British rule, | |
| | ts in | British rule, | leading to | |
| | education, | leading to | robust | |
| | industry, | robust | education, a | |
| | and practice | education, a | thriving | |
| | during | thriving | industry, | |
| | British rule. | industry, | diverse | |
| | Today, | diverse | practice | |
| | pharmacy | practice | areas, and | |
| | offers | areas, and | active | |
| | diverse | active | professional | |
| | career | professional | associations. | |
| | opportuniti | associations | Pharmacy | |
| | es. | . It offers | offers | |
| | Pharmacop | promising | promising | |
| | oeias like IP, | career | careers. | |
| | BP, USP, NF | prospects. | Pharmacopo | |
| | set drug | Pharmacop | eias like IP, | |
| | standards, | oeias like IP, | BP, USP, and | |
| | with IP | BP, USP, | NF set drug | |
| | ensuring | and NF set | standards, | |
| | quality in | drug | with IP | |
| | India's | standards, | addressing | |
| | thriving | with IP vital | human | |
| | pharmaceut | for India's | values by | |
| | ical | skill | ensuring | |
| | industry, | developmen | safe and | |
| | vital for | t and global | quality | |

| | global health needs. | healthcare needs, ensuring quality medicines. | medicines for healthcare needs. | |
|-----------|---|--|--|---|
| Unit II - | - Packaging materials vary, including glass (recyclable, fragile), | Packaging - materials, including glass (fragile, recyclable), plastic | Packaging - materials like glass (recyclable, inert), plastic (lightweight, | Skills for Professio Skill Decent nal Developm Work (Educatio ent SDG 4.4) n (17.1- 17.5) |
| | plastic (lightweight , environmen tal concerns), metal (durable, costly), and rubber (flexible, limited use). | (lightweight, diverse), metal (durable, costly), and rubber (flexible, specialized), vary based on product needs. Skill developmen | versatility), metal (durable, costly), and rubber (flexible, limited use) offer diverse options. Human values need eco-friendly, | |
| | Selection | t in | safe | |

| | | | | |
|--------|---------------|----------------|---------------------------------------|--|
| | depends on | packaging | packaging | |
| | product | aligns with | aligning with | |
| | characteristi | industry | sustainabilit | |
| | cs. | demands | y, health, | |
| | Sustainable | for | and ethics, | |
| | choices | sustainable | addressing | |
| | align with | materials, | concerns | |
| | global | innovative | about | |
| | developmen | design, and | waste, | |
| | tal needs, | efficient | pollution, | |
| | reducing | manufacturi | and product | |
| | waste and | ng, crucial | safety. | |
| | environmen | for the | , , , , , , , , , , , , , , , , , , , | |
| | tal impact, | packaging | | |
| | fostering | sector's | | |
| | eco-friendly | growth. | | |
| | packaging | | | |
| | solutions. | | | |
| | | | | |
| Unit - | Organolepti | Pharmaceut | Pharmaceuti | |
| III | c agents | ical aids like | cal aids like | |
| | enhance the | organolepti | organoleptic | |
| | sensory | c agents | agents | |
| | qualities of | (color, | (color, | |
| | medicines | flavor, | flavor, | |
| | (color, | sweetness) | sweetness) | |
| | flavor, | enhance | improve | |
| | sweetness). | drug appeal. | medicine's | |
| | Preservative | Preservative | sensory | |
| | s prevent | s, such as | appeal. | |
| | microbial | parabens | Preservative | |
| | spoilage, | and | s (e.g., | |
| | including | benzalkoniu | parabens, | |
| | parabens | m chloride, | benzalkoniu | |
| | and | extend shelf | m chloride) | |
| | benzalkoniu | life by | ensure | |
| | Denzarkoniu | lile by | ensure | |

| | 1.1.21. | F. J. 91.212 | | |
|-------|---------------|---------------|----------------|--|
| | m chloride. | inhibiting | safety and | |
| | They ensure | microbial | longevity. | |
| | global | growth. Skill | Human | |
| | health | developmen | values need | |
| | needs are | t involves | medicines to | |
| | met by | formulation | be palatable | |
| | extending | expertise, | and safe, | |
| | product | ensuring | enhancing | |
| | shelf life, | safe and | patient | |
| | reducing | appealing | adherence | |
| | waste, and | medicines, | and trust, | |
| | maintaining | aligning | fostering | |
| | drug | with | healthcare | |
| | efficacy and | industry | ethics and | |
| | safety. | demands | values. | |
| | | for quality | | |
| | | and | | |
| | | innovation. | | |
| Unit- | Unit | Unit | Unit | |
| IV | operations | operations | operations | |
| | are | in | are vital in | |
| | fundamenta | pharmaceut | pharmaceuti | |
| | l in | icals | cals. Size | |
| | pharmaceut | encompass | reduction | |
| | ical | size | (hammer | |
| | manufacturi | reduction | mill, ball | |
| | ng. Size | (e.g., | mill) reduces | |
| | reduction | hammer | particle size. | |
| | (e.g., | mill, ball | Size | |
| | hammer | mill), size | separation | |
| | mill, ball | separation | (cyclone, | |
| | mill) | (cyclone, | sieves) | |
| | reduces | sieves), | ensures | |
| | particle size | mixing | uniformity. | |
| | for drug | (double | Mixing | |
| | 101 0106 | lange | IAIIVIIIP | |

| formulation. | cone | (double |
|---------------|-----------------|---------------|
| Size | blender, | cone |
| separation | turbine | blender, |
| (cyclone, | mixer, triple | turbine |
| sieves) | roller mill, | mixer, triple |
| ensures | Silverson | roller mill, |
| uniformity. | mixer | homogenize |
| Mixing | homogenize | r) |
| (cone | r), filtration | homogenize |
| blender, | theory | s |
| turbine | (membrane, | ingredients. |
| mixer, roller | sintered | Filtration |
| mill, | glass), | (membrane, |
| homogenize | drying | sintered |
| r) | (fluidized | glass) |
| homogenize | bed, freeze | separates |
| s | drying), and | solids. |
| ingredients. | extraction. | Drying |
| Filtration | Skill | (fluidized |
| (membrane, | developmen | bed, freeze |
| sintered | t in these | drying) |
| glass) | operations | removes |
| separates | is critical for | moisture. |
| solids from | pharmaceut | Extraction |
| liquids. | ical | extracts |
| Drying | professional | active |
| (fluidized | s, ensuring | compounds, |
| bed, freeze | quality, | supporting |
| drying) | safety, and | health |
| removes | efficacy in | needs and |
| moisture. | drug | ethical drug |
| Extraction | manufacturi | production. |
| plays a vital | ng and | |
| role in | contributing | |
| obtaining | to industry | |

| active growth and | |
|--|--|
| | |
| compounds innovation. | |
| | |
| natural natura | |
| sources, | |
| contributing | |
| to drug | |
| developmen | |
| t and global | |
| health health | |
| needs. | |
| Unit-V Pharmaceut The Pharmaceuti | |
| | |
| diversity | |
| addresses requires a (coated, | |
| global highly uncoated, | |
| healthcare skilled modified), | |
| challenges. workforce capsules | |
| Skill for the (hard, soft | |
| developmen developmen gelatin), | |
| t in dosage t, liquid oral | |
| form manufacturi preparations | |
| preparation ng, and , topical | |
| ensures quality products, | |
| accessibility, control of nasal and | |
| safety, and various ear | |
| efficacy. dosage preparations | |
| Immunologi forms like , powders, | |
| cal tablets, sterile | |
| products, capsules, formulations | |
| sterile liquids, , and | |
| formulation topical immunologi | |
| s, and preparation cal products | |
| diverse drug s, powders, cater to | |
| delivery sterile human | |

| | | £ | المام مالمام | |
|-------|--------------|--------------|----------------|--|
| | systems | formulation | health | |
| | contribute | s, and | needs. | |
| | to global | immunologi | Ensuring | |
| | health, | cal | their quality, | |
| | emphasizing | products. | safety, and | |
| | equitable | Skill | efficacy | |
| | access and | developmen | aligns with | |
| | quality | t is crucial | ethical | |
| | healthcare. | to ensure | values in | |
| | | safe and | healthcare, | |
| | | effective | prioritizing | |
| | | drug | patient well- | |
| | | production, | being and | |
| | | meeting | trust. | |
| | | global | | |
| | | healthcare | | |
| | | standards, | | |
| | | and | | |
| | | fostering | | |
| | | innovation | | |
| | | in the | | |
| | | pharmaceut | | |
| | | ical sector. | | |
| Unit- | Pharmaceut | Pharmaceut | Pharmaceuti | |
| VI | ical | ical | cal | |
| | manufacturi | manufacturi | manufacturi | |
| | ng plants | ng plants | ng plants | |
| | have | have | are | |
| | specific | distinct | organized | |
| | layouts and | layouts with | with | |
| | sections for | production, | production, | |
| | | | | |
| | production, | quality | quality | |
| | quality | control, and | control, and | |
| | control, and | assurance | assurance | |
| | assurance. | sections. | sections. | |

| control ensures product product consistency, while quality | | | | |
|--|--------------|--------------|-------------|-------------|
| ensures product consistency, while quality ausurance focuses on process integrity and regulatory compliance. Compliance with cGMP, calibration, and validation ensures safe and effective ensures safe and effective medicines, meeting global health for standards, fostering patient trust, and advancing global health for the standards, fostering patient trust, and advancing global health for managemen maintains product quality, product quality, while quality, while quality assurance ensures process process process process integrity, following coGMP. Calibration coGMP. Calibration and validation validation uphold human values by values by values by values by values guaranteein g safe, effective, effective, effective, guaranteein drug production, emphasizing patient well- being and trust. fostering global health managemen | Quality | Quality | Quality | |
| product consistency, while quality while quality assurance focuses on process integrity and and regulatory compliance. Compliance with GGMP, calibration, and validation ensures safe and effective medicines, meeting global health health health leaster product quality, quality, quality, while quality quality assurance ensures process process integrity, following assurance ensures process integrity, following cGMP. CGMP. Calibration cGMP. Calibration and validation validation uphold human validation uphold human skills for values by values by values by quaranteein g safe, and effective s, ensuring and drug production, patient trust. growth, and fostering global health managemen | | | | |
| consistency, while quality quality quality quality assurance focuses on process process integrity and adhering to regulatory compliance. Compliance with cGMP, calibration, and validation ensures safe and validation ensures safe and effective medicines, meeting global healthcare standards, fostering global health resultan legulaty puality quality, while quality assurance ensures process integrity, following cafiler. CafilPration and validation uphold uphold uphold didation uphold u | | | | |
| while quality quality quality assurance assurance ensures process process integrity, following adhering to cGMP. Calibration compliance. Compliance and validation uphold validation ensures safe and effective ensures safe and effective ensures safe and effective ensures standards, fostering patient trust. and advancing global health trust, and advancing global quality passures safe in global deady and advancing global quality passures ensures and please of the procession integrity, integrity, following censures safe and processional ensures safe integrity, following cGMP. Calibration and validation and validation uphold validation uphold validation uphold validation uphold validation values by validation values by ensuring and ethical drug guaranteein ensures safe and growth, and fostering industry trust. | l' | i. | l l' | |
| quality assurance focuses on process integrity and adhering to compliance. Compliance with cGMP, calibration, and adh validation ensures safe and effective medicines, meeting global health fostering patient trust, and advancing global health process process integrity, following compliance process integrity, following following compliance compliance compliance and dashills for validation uphold validation uphold human validation uphold human values by values day and effective, guaranteein guara | | | | |
| assurance focuses on process process process integrity and adhering to compliance. Compliance with cGMP, calibration, and skills for validation ensures safe and professional effective medicines, meeting global health fostering global health managemen | | | | |
| focuses on process process integrity, and adhering to regulatory cGMP. Calibration and validation uphold human skills for values by validation ensures safe and effective meeting meeting meeting meeting global health trust, and advancing global health data data advancing global health data data advancing global health data data advancing global drug menagemen grovess integrity, following calletgrity, following c | quality | quality | | |
| process integrity and and adhering to cGMP. calibration and adhering to cGMP. Calibration and walidation with cGMP, calibration, and adhering to compliance with cGMP, calibration, and and adharing and skills for validation and and skills for validation ensures safe and professional effective medicines, meeting global healthcare standards, fostering patient trust, and advancing global health managemen | assurance | assurance | ensures | |
| integrity and adhering to cGMP. regulatory compliance. Compliance with cGMP, validation and skills for values by validation ensures safe and effective medicines, meeting global health ensures standards, fostering potient trust, and advancing global health trust, and advancing global health for table and trust and trust, and advancing global health desired. ical madhering to cGMP. Calibration cadhering to cGMP. Calibration and cadhering to cGMP. Calibration and walidation uphold uphold human and walidation uphold human skills for values by values by particular trust. Indicate cachering to complete the cachering to cachering the cachering the cachering the cachering the cachering | focuses on | ensures | process | |
| and regulatory compliance. Compliance with cGMP, calibration and validation uphold uphold human skills for values by validation effective and effective medicines, meeting effective global healthcare standards, fostering patient trust, and advancing global health description. and calibration, are crucial human values by values by values by values by values by values by values and effective, guaranteein garanteein garanteein garanteein growth, and fostering effective production, emphasizing patient trust, and advancing global quality managemen | process | process | integrity, | |
| regulatory compliance. Compliance. Compliance with cGMP, calibration and validation uphold uphold human skills for values by validation ensures safe and effective medicines, meeting global health for standards, fostering patient trust, and advancing global health defective in and solve in the standards, fostering global health ensures in and expertise in global health ensure in and expertise in global health in managemen in and validation uphold validation uphold uphold validation uphold values by values and values by values and values by values and values by values and effective, safe, and drefective, sensuring and effective, safe and drug emphasizing production, patient well-being and trust. | integrity | | following | |
| compliance. Compliance with cGMP, calibration, and validation uphold human skills for values by validation ensures safe and effective medicines, meeting global healthcare standards, fostering patient trust, and advancing global health health Calibration and validation uphold human values by values by guaranteein | and | adhering to | cGMP. | |
| Compliance with cGMP, calibration, and skills for validation pharmaceut ensures safe and effective medicines, meeting global health fostering patient trust, and advancing global health health and validation uphold human values by values by guaranteein guaranteein guaranteein effective, s, ensuring and ethical drug emphasizing production, patient well- being and trust. global drustry expertise in global quality managemen | regulatory | cGMP. | Calibration | |
| with cGMP, calibration, are crucial are crucial skills for values by validation ensures safe and effective medicines, meeting global healthcare standards, fostering patient trust, and advancing global health description. | compliance. | Calibration | and | |
| calibration, and skills for values by validation pharmaceut guaranteein ensures safe and effective s, ensuring meeting global health fostering global health managemen | Compliance | and | validation | |
| and validation ensures safe and effective medicines, meeting global health trust, and advancing global health managemen skills for pharmaceut guaranteein g safe, effective, and essemble skills for pharmaceut guaranteein g safe, effective, and effective, and effective, and ethical drug and ethical drug production, emphasizing production, patient well-being and trust. | with cGMP, | validation | uphold | |
| validation ensures safe and effective medicines, meeting global health trust, and advancing global health validation ensures safe ical g safe, effective, and ethical drug production, groduction, supporting industry patient trust, and advancing global health health pharmaceut g guaranteein g safe, effective, and ethical drug production, emphasizing patient well- being and trust. postering growth, and fostering expertise in global health managemen | calibration, | are crucial | human | |
| ensures safe and effective effective medicines, meeting global healthcare standards, fostering patient trust, and advancing global health health managemen | and | skills for | values by | |
| and effective s, ensuring safe and drug production, emphasizing patient trust, and advancing global health | validation | pharmaceut | guaranteein | |
| effective medicines, meeting effective meeting global mealthcare standards, fostering patient trust, and advancing global mealth managemen safe and growth and trust, health managemen safe and drug production, global drug memphasizing production, patient well-patient well-patient well-patient well-patient trust. | ensures safe | ical | g safe, | |
| medicines, meeting global healthcare standards, fostering patient trust, and advancing global health managemen medicines, safe and drug production, growdering production, supporting industry patient trust. managemen drug production, production, patient well- being and trust. | and | professional | effective, | |
| meeting global drug emphasizing healthcare standards, fostering patient trust, and advancing global advancing global health managemen production, emphasizing production, emphasizing patient well-being and trust. | effective | s, ensuring | and ethical | |
| global drug production, standards, supporting industry patient trust, and advancing global albeing global health managemen emphasizing production, supporting patient well-being and trust. | medicines, | | drug | |
| healthcare standards, fostering patient well- being and trust. patient trust, and advancing global global health production, supporting industry trust. production, supporting being and trust. patient well- being and trust. | meeting | effective | production, | |
| healthcare standards, fostering patient well- being and trust. patient trust, and advancing global global health production, supporting industry trust. production, supporting being and trust. patient well- being and trust. | _ | | | |
| standards, fostering industry patient growth, and trust, and advancing global global health standards, fostering and trust. | healthcare | • | | |
| fostering patient growth, and trust, and advancing expertise in global health managemen trust. | standards, | supporting | | |
| patient growth, and trust, and advancing expertise in quality health managemen | • | | | |
| trust, and advancing expertise in global quality health managemen | | | | |
| advancing expertise in global quality health managemen | l' | | | |
| global quality health managemen | | | | |
| health managemen managemen | _ | | | |
| | | | | |
| | goals. | t. | | |

| Unit- | Novel drug | Novel drug | Novel drug | |
|-------|---------------|----------------|---------------|--|
| VII | delivery | delivery | delivery | |
| | systems | systems, | systems | |
| | revolutioniz | such as | improve | |
| | e healthcare | liposomes | drug | |
| | globally by | and | effectivenes | |
| | improving | microspher | s and | |
| | drug | es, enhance | patient | |
| | effectivenes | drug | compliance. | |
| | s. Examples | efficacy. | They include | |
| | include | Skill | oral, | |
| | nanomedici | developmen | transdermal, | |
| | ne and | t in their | and | |
| | implantable | design and | nanotechnol | |
| | devices. | implementa | ogy-based | |
| | Benefits | tion is vital, | systems. | |
| | include | aligning | Advantages | |
| | targeted | with | include | |
| | therapy and | industry | precise | |
| | reduced | demands | dosing and | |
| | side effects, | for | reduced side | |
| | but | innovative | effects, | |
| | challenges | drug | while | |
| | like cost and | delivery | challenges | |
| | accessibility | solutions, | involve | |
| | remain. | supporting | complexity. | |
| | Addressing | pharmaceut | Aligning | |
| | these needs | ical | with human | |
| | aligns with | professional | values, | |
| | global | s in | these | |
| | healthcare | advancing | systems | |
| | goals for | patient care | prioritize | |
| | improved | and | patient well- | |
| | treatment | treatment | being, | |
| | outcomes. | outcomes. | safety, and | |

| | | | | | convenience | | |
|--|--|--|--|--|-------------------|--|--|
| | | | | | in healthcare. | | |
| | | | | | | | |

ER20-12P: Pharmaceutical Chemistry I – Practical

| Subject Code - ER20-12P | Subject Name - Pharmaceutical Chemistry I - Practical | L | Т | P | | | | | |
|----------------------------|---|---------|------------------|---|--|--|--|--|--|
| Version 2.0 | | 0 | 0 | 3 | | | | | |
| Total Contact Hours | 3 hrs. | | | | | | | | |
| Pre-requisites/Exposure | Inorganic | and Med | icinal chemistry | | | | | | |
| Co-requisites | Analytical chemistry | | | | | | | | |
| Course Objectives | | | | | | | | | |

Upon completion of this course the student should be able to:

- 1. To know the methods for identification of impurities in inorganic drugs and pharmaceuticals.
- 2. Volumetric analysis of the chemical substances
- 3. Basics of preparatory chemistry and their analysis
- **4.** Systematic qualitative analysis for the identification of the chemical drugs

Course Outcomes (CO)

On completion of this course, the students will be able to:

CO1: Perform the limit tests for various inorganic elements and report

CO2: Prepare standard solutions using the principles of volumetric analysis

CO3: Test the purity of the selected inorganic and organic compounds against the monograph standards **CO4:** Synthesize the selected chemical substances as per the standard synthetic scheme **CO5:** Perform qualitative tests to systematically identify the unknown chemical substances

| СО | PO1 | PO2 | PO3 | PO4 | PO5 | PO6 | PO7 | PO8 | PO9 | PO10 | PO11 | PO12 | PSO1 | PSO2 | PSO3 | PSO4 | PSO5 |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|------|------|------|------|------|------|------|
| CO1 | 2 | 3 | 2 | | 2 | 3 | | 3 | 2 | | 3 | 2 | 3 | 1 | 2 | 1 | 1 |
| CO2 | 3 | 3 | 2 | | 2 | 1 | | | 2 | | 3 | 2 | 3 | 1 | 2 | 1 | 1 |
| CO3 | 3 | 3 | 1 | | 1 | 2 | | 2 | 2 | | 2 | 3 | 3 | 1 | 2 | 1 | 1 |
| CO4 | 2 | 3 | 2 | | 1 | 2 | 2 | 3 | 3 | 1 | 2 | 2 | 3 | 1 | 2 | 1 | 1 |
| CO5 | 2 | 3 | 2 | | | 3 | 2 | 2 | 1 | | 3 | 2 | 3 | 1 | 2 | 1 | 1 |

1=lightly mapped

2= moderately mapped

3=strongly mapped

| Unit | evance to the al, national, ional and global elopmental needs | Relevance To the Employability/ Entrepreneurship/ Skill Development | Relevance to the rofessional Ethics, Gender, Human alues, Environment & Sustainability | SDG | NEP | POE/4th IR |
|------|--|--|--|-----|-----|------------|
| | Releving Rel | Re En Ski | Re Prof Ge Valu & | | | |

| | Local | Regional | National | Global | Employability | Entrepreneurship | Skill Development | Professional Ethics | Gender | Human Values | Environment & Sustainability | SDG | NEP | POE/4 th IR |
|------------|-------|----------|----------|---|---------------|------------------|---|---------------------|--------|---|------------------------------|---|--|------------------------|
| Unit | | | - | Disciplinary knowledge/ Problem solving/Analytical reasoning | | - | Practical skills for performing limit tests | | | Right Conduct, Truth – Contains values like accuracy, fairness, honesty, justice, quest for knowledge, determination. | | Skills for Decent Work (SDG 4.4) | Professional Education (17.1-17.5) | Skill Development |
| Unit II | - | - | - | Disciplinary knowledge/ Critical thinking/Problem solving/ Analytical reasoning | - | - | The analysis of various drugs in single and combination dosage form, Theoretical and practical skills | - | - | Right Conduct and Truth | - | Skills for Decent Work (SDG 4.4) | Professional Education (17.1-17.5) | Skill Development |

| Unit III | - | - | - | Research-related skills/ Disciplinary knowledge | - | - | Practical skills | - | - | Right Conduct and Truth | - | Skills for Decent Work (SDG 4.4) | Professional Education (17.1-17.5) | Skill Development |
|-------------|---|---|---|--|---|---|--|---|---|---|---|---|--|----------------------------------|
| Unit IV | - | - | - | Disciplinary knowledge/ Critical thinking/Problem solving/ Research-related skills/Analytical reasoning | - | - | The analysis of various chemical compounds form using different techniques. Theoretical and practical skills for instrument handling | - | - | Right Conduct, accuracy, fairness, honesty, justice | - | Skills for Decent Work (SDG 4.4) | Professional Education (17.1-17.5) | Employability |
| Unit v | - | - | - | Disciplinary knowledge/ Research-related skills/Analytical reasoning | | - | Theoretical and practical skills of the instruments | - | - | Right Conduct and Truth | - | Skills for Decent Work (SDG 4.4) | Professional Education (17.1-17.5) | Skill Development, |
| Unit vi | - | - | - | Disciplinary knowledge/ Research-related skills/Analytical reasoning | | | Theoretical and practical skills for synthesis of different compounds | | | Right Conduct, accuracy, fairness, honesty, justice | - | Skills for Decent Work (SDG 4.4) | Professional Education (17.1-17.5) | Skill Development, Employability |
| Unit vii | 1 | - | - | Disciplinary knowledge/ Critical thinking/Problem solving/ Research-related skills/Analytical | | | Develop skills for identification and test for purity of pharmaceuticals in pharmaceutical | | | Right Conduct, accuracy, fairness, honesty, | - | Skills for Decent Work (SDG | Professional Education (17.1-17.5) | Employability |

| | | | | reasoning | | industries | | just | tice | | 4.4) | | |
|------|---|---|---|-------------------|--|-------------------|---|------|---------|---|--------|--------------|---------------|
| | | | | | | | | | | | | | |
| Unit | - | - | - | Disciplinary | | Qualitative | | Rig | ght | - | Skills | Professional | Employability |
| viii | | | | knowledge/ | | analysis of Drugs | | Cor | nduct, | | for | Education | |
| | | | | Critical | | | | acc | euracy, | | Decent | (17.1-17.5) | |
| | | | | thinking/Problem | | | | fair | mess, | | Work | | |
| | | | | solving/ | | | | hon | nesty, | | (SDG | | |
| | | | | Research-related | | | | just | tice | | 4.4) | | |
| | | | | skills/Analytical | | | | | | | | | |
| | | | | reasoning | | | | | | | | | |
| | | | | | | | [| | | | | | |

ER20-13T: Pharmacognosy Theory

| ER20-13T | Pharmacognosy- Theory | L | T | P |
|----------------------------|------------------------|---|---|---|
| Version 2.0 | | 3 | 1 | 0 |
| Total Contact Hours | 75 hours | | | |
| Pre-requisites/Exposure | Herbal Drug Technology | | | |
| Co-requisites | Pharmacognosy | | | |

Course Objectives

Upon completion of this course the student should be able to:

- 1. Knowledge of occurrence, distribution, isolation & identification tests of common Phytoconstituents
- 2. Knowledge of therapeutic potential and pharmaceutical applications of crude drugs
- 3. To understand the monographs of crude drugs
- 4. To understand the basic concepts in quality control of crude drugs

Course Outcomes (CO)

On completion of this course, the students will be able to:

- CO1. Identification of pharmaceutically important crude drugs
- CO2. Knowledge of nutraceutical and cosmeceuticals
- CO3. Understanding the principles of alternative system of medicines
- CO4. Understanding the importance of quality control of drugs

| | PO | PO | PO | PO | PO | PO | PO | PO | PO | PO | PO | PO | PSO | PSO | PSO | PSO | PSO |
|-----|----|----|--------|--------|------|----|----|-------|-------|-------|----|----|---------|--------|-----|-----|-----|
| CO | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 1 | 2 | 3 | 4 | 5 |
| CO1 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | - |
| CO2 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | ı |
| CO3 | 3 | 3 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | ı |
| CO4 | 3 | 2 | - | 2 | 1 | 1 | 3 | 2 | 3 | 2 | 1 | 1 | 2 | - | - | - | - |
| | | 1 | =light | tlv ma | nned | | 2= | modei | ately | manne | d | 3: | =strong | lv man | ned | | |

| Unit | Relevance to local, nation regional and developmen needs | al, global | Entre | elevance To the Employability/ epreneurship/ Sk Development | ill | Relevance | e to the Pro | | nics, Gender, Hu ustainability | ıman Values, E | nvironment | SDG | NE P | POE/4 th | IR |
|-----------|--|---|--------------|--|-----------------------|--------------------------|--------------------------|----------------------------|-----------------------------------|-----------------|-------------------------|-----|-----------------------|-------------------------|--------------------------------|
| ER 2013 P | Local | Regio nal | Nationa l | Global | Emp loya bility | Entrep reneurs hip | Skill Develo pment | Professi onal Ethics | Gender | Human Values | Environme Sustainabi | | | | |
| Unit I | | Study of Crude Drugs develop ment their use as medicina lly.Its help to enhance their knowled | | | | | | | | | | | Global Citizenship | More Holistic and | Educatio n Knowled ge |

| | | | ı | T T | | 1 |
|----------|-------------|--------|---|-----|---------------------|----------|
| Unit II | They | | | | "1.3 Towards | a |
| | address | | | | Implement More | |
| | critical | | | | nationally Holistic | |
| | aspects of | | | | appropriat and | |
| | Raw | | | | e social Multidisci | . |
| | materials | | | | | ' |
| | | | | | protection plinary | |
| | of herbal | | | | systems Education | וו |
| | drugs | | | | and | |
| | ,validation | | | | measures (11.1 | |
| | and their | | | | for all, 11.13) | |
| | purpose | | | | including | |
| | according | | | | floors" | |
| | to WHO. | | | | | |
| Unit III | to willo. | | | | End all | Global |
| OTHE III | | | | | | |
| | | | | | forms of | Educatio |
| | | | | | malnutritio | n |
| | | | | | n (SDG | Knowled |
| | | | | | 2.2) | ge |
| | | | | | | |
| Unit IV | globally | | | | Ensure | |
| | relevant | | | | healthy | |
| | because | they | | | - | |
| | provide | the | | | lives and | |
| | | | | | promote | |
| | knowledg | | | | well-being | |
| | tools nec | | | | for all at | |
| | to evalua | | | | all | |
| | medicinal | | | | | |
| | drugs. S | enerio | | | ages (S | |
| | of herbal | drugs | | | DG 3) | |
| | standardi | ation | | | | |
| | is nessa | | | | | |
| | significan | | | | | |
| | | rbs.as | | | | |
| | global lev | | | | | |
| 11-24 | | :1. | | | (4. 2 | |
| Unit v | health | | | | "1.3 | |
| | systems | | | | Implement | |
| | and | | | | nationally | |
| | ongoing | | | | appropriat | |
| 1 | national | | | | e social | |

| | health programs in India is of national relevance as it directly affects the well-being of the population | protection systems and measures for all, including floors" |
|---------|--|--|
| | healthcare access, and the nation's overall developm ent. It also highlights the important role of herbs and crude drugs used as neutraceu | |
| Unit-VI | ticals. It informs healthcare decision- making, resource allocation, and policy development, ultimately impacting the | |

| | accessibility, affordability, and quality of healthcare services worldwide. | | | | | |
|----------|--|----------|--|--|---|----------|
| Unit VII | | By the | | | | Global |
| | | study of | | | E | Educatio |
| | | the | | | r | - |
| | | course | | | k | Knowled |
| | | as | | | g | ge |
| | | employ | | | | |
| | | bility | | | | |
| | | related | | | | |
| | | to | | | | |
| | | health | | | | |
| | | sector | | | | |
| | | will be | | | | |
| | | enhanc | | | | |
| | | ed | | | | |

ER20-13P: Pharmacognosy Practical

| ER20-13P | Pharmacognosy– Practical | L | T | P |
|----------------------------|--------------------------|---|---|---|
| Version 2.0 | | 0 | 0 | 3 |
| Total Contact Hours | 75 hours | | | |
| Pre-requisites/Exposure | Herbal Drug Technology | | | |
| Co-requisites | | | | |
| | Course Objectives | | | |

Upon completion of this course the student should be able to:

- 1. Practical knowledge of microscopical and macroscopical evaluation crude drugs
- 2. Practical knowledge of extraction of crude drugs

Course Outcomes (CO)

On completion of this course, the students will be able to:

- CO1. Identification of pharmaceutically important crude drugs
- CO2. Understanding the various processes involved in extraction of crude drugs
- CO3. Evaluation and quality control of crude drugs

| СО | PO 1 | PO 2 | PO 3 | PO 4 | PO 5 | PO 6 | PO 7 | PO 8 | PO 9 | PO 10 | PO 11 | PO 12 | PSO 1 | PSO 2 | PSO 3 | PSO 4 | PSO 5 |
|---------|---------|---------|---------|---------|---------|---------|------|---------|---------|----------|----------|----------|----------|----------|----------|----------|----------|
| CO 1 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | _ |
| CO 2 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | - |
| CO 3 | 3 | 3 | 1 | _ | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | - |

1=lightly mapped 2= moderately mapped 3=strongly mapped

| nit | the l nation region glob | onal and oal elopment | Em Entre | vance To ployabili epreneurs Developi | ty/ ship/ | | | | | | | | NEP | | POE/4 th IR | |
|-----------------|-----------------------------------|--|---|--|-----------------------|----------------------|--------------------------|------------------------------------|----------------|---------------------------------|---------------|--------------------------------|--|---------------------------------------|--|--|
| ER 2013 P | Lo ca l | Regi onal | Natio nal | Glob al | Emplo yabilit y | Entrepre neurship | Skill Develo pment | Profe ssion al Ethic s | Ge nd er | Hu ma n Va lue s | nm & Su | viro nent stain ility | | | | |
| Unit I | | Study of Crude Drugs develop ment their use as medicin ally.Its help to enhance their knowle dge | | | | | | | | | | | Citizenship | nt Nobala N SDG r | More Holistic and Multidisciplina | tion Knowl edge |
| Unit II | | | They address critical aspects of Raw material s of herbal drugs ,validati on and their purpose accordin g to WHO. | | | | | | | | | | "1.3 Implement nationally appropriate social protection systems measures all, include floors" | n a r r E and for 1 | Towards a More Holistic and Multidisciplina Y Education (11.1- | |
| Unit III | | | ¥¥11O. | | | | | | | | | | End all fo of malnutri (SDG 2.2) | | | Global Educa tion Knowl edge |

| | | | | 1 | |
|-----------|--|-----|------|--|--|
| Unit | globally | | | Ensure | |
| IV | relevant | | | healthy lives | |
| | because | | | | |
| | | | | and promote | |
| | they | | | well-being for | |
| | provide | | | all at all | |
| | the | | | | |
| | knowled | | | ages (SDG | |
| | ge and | | | 3) | |
| | tools | 1 | | | |
| | | | | | |
| | necessar | | | | |
| | y to | | | | |
| | evaluati | | | | |
| | on o | f l | | | |
| | medicin | | | | |
| | al heba | | | | |
| | | | | | |
| | drugs. | | | | |
| | Senerio | | | | |
| | of | | | | |
| | herbal | | | | |
| | drugs | | | | |
| | standar | | | | |
| | dization | | | | |
| | | | | | |
| | is | | | | |
| | nessary | | | | |
| | to | | | | |
| | significa | | | | |
| | nt role | | | | |
| | of | | | | |
| | | | | | |
| | | | | | |
| | herbs.as | , | | | |
| | herbs.as global | | | | |
| | herbs.as global level. | | | | |
| Unit | herbs.as global | | | "1.3 | |
| | herbs.as global level. health | | | | |
| Unit v | herbs.as global level. health systems | | | Implement | |
| | herbs.as global level. health systems and | | | Implement nationally | |
| | herbs.as global level. health systems and ongoing | | | Implement nationally appropriate | |
| | herbs.as global level. health systems and ongoing national | | | Implement nationally appropriate social | |
| | herbs.as global level. health systems and ongoing national health | | | Implement nationally appropriate social protection | |
| | herbs.as global level. health systems and ongoing national health program | | | Implement nationally appropriate social protection systems and | |
| | herbs.as global level. health systems and ongoing national health | | | Implement nationally appropriate social protection | |
| | herbs.as global level. health systems and ongoing national health program s in India | | | Implement nationally appropriate social protection systems and measures for | |
| | herbs.as global level. health systems and ongoing national health program s in India is of | | | Implement nationally appropriate social protection systems and measures for all, including | |
| | herbs.as global level. health systems and ongoing national health program s in India is of national | | | Implement nationally appropriate social protection systems and measures for | |
| | herbs.as global level. health systems and ongoing national health program s in India is of national relevanc | | | Implement nationally appropriate social protection systems and measures for all, including | |
| | herbs.as global level. health systems and ongoing national health program s in India is of national relevanc e as it | | | Implement nationally appropriate social protection systems and measures for all, including | |
| | herbs.as global level. health systems and ongoing national health program s in India is of national relevanc e as it directly | | | Implement nationally appropriate social protection systems and measures for all, including | |
| | herbs.as global level. health systems and ongoing national health program s in India is of national relevanc e as it directly affects | | | Implement nationally appropriate social protection systems and measures for all, including | |
| | herbs.as global level. health systems and ongoing national health program s in India is of national relevanc e as it directly | | | Implement nationally appropriate social protection systems and measures for all, including | |
| | herbs.as global level. health systems and ongoing national health program s in India is of national relevanc e as it directly affects the well- | | | Implement nationally appropriate social protection systems and measures for all, including | |
| | herbs.as global level. health systems and ongoing national health program s in India is of national relevanc e as it directly affects the wellbeing of | | | Implement nationally appropriate social protection systems and measures for all, including | |
| | herbs.as global level. health systems and ongoing national health program s in India is of national relevanc e as it directly affects the wellbeing of the | | | Implement nationally appropriate social protection systems and measures for all, including | |
| | herbs.as global level. health systems and ongoing national health program s in India is of national relevanc e as it directly affects the well-being of the populati | | | Implement nationally appropriate social protection systems and measures for all, including | |
| | herbs.as global level. health systems and ongoing national health program s in India is of national relevanc e as it directly affects the wellbeing of the populati on, | | | Implement nationally appropriate social protection systems and measures for all, including | |
| | herbs.as global level. health systems and ongoing national health program s in India is of national relevanc e as it directly affects the well-being of the populati | | | Implement nationally appropriate social protection systems and measures for all, including | |
| | herbs.as global level. health systems and ongoing national health program s in India is of national relevanc e as it directly affects the wellbeing of the populati on, | | | Implement nationally appropriate social protection systems and measures for all, including | |
| | herbs.as global level. health systems and ongoing national health program s in India is of national relevanc e as it directly affects the wellbeing of the populati on, healthca re | | | Implement nationally appropriate social protection systems and measures for all, including | |
| | herbs.as global level. health systems and ongoing national health program s in India is of national relevanc e as it directly affects the wellbeing of the populati on, healthca re access, | | | Implement nationally appropriate social protection systems and measures for all, including | |
| | herbs.as global level. health systems and ongoing national health program s in India is of national relevanc e as it directly affects the wellbeing of the populati on, healthca re | | | Implement nationally appropriate social protection systems and measures for all, including | |

| | | | | | | | | |
|----------|-----------|------------|-------------|--|--|--|------|--------|
| | overall | | | | | | | |
| | develop | | | | | | | |
| | ment. It | | | | | | | |
| | also | | | | | | | |
| | | | | | | | | |
| | highlight | | | | | | | |
| | s the | | | | | | | |
| | importa | | | | | | | |
| | nt role | | | | | | | |
| | of herbs | | | | | | | |
| | | | | | | | | |
| | and | | | | | | | |
| | crude | | | | | | | |
| | drugs | | | | | | | |
| | used as | | | | | | | |
| | neutrace | | | | | | | |
| | uticals. | | | | | | | |
| 1.1 | | 14. | | | | | | |
| Unit- | | lt | | | | | | |
| VI | | informs | | | | | | |
| | | healthca | | | | | | |
| | | re | | | | | | |
| | | decision | | | | | | |
| | | -making, | | | | | | |
| | | | | | | | | |
| | | resource | | | | | | |
| | | allocatio | | | | | | |
| | | n, and | | | | | | |
| | | policy | | | | | | |
| | | develop | | | | | | |
| | | ment, | | | | | | |
| | | ultimate | | | | | | |
| | | | | | | | | |
| | | ly | | | | | | |
| | | impactin | | | | | | |
| | | g the | | | | | | |
| | | accessibi | | | | | | |
| | | lity, | | | | | | |
| | | affordab | | | | | | |
| | | | | | | | | |
| | | ility, and | | | | | | |
| | | quality | | | | | | |
| | | of | | | | | | |
| | | healthca | | | | | | |
| | | re | | | | | | |
| | | services | | | | | | |
| | | worldwi | | | | | | |
| | | | | | | | | |
| <u> </u> | | de. | | | | | | |
| Unit | | | By the | | | | | Global |
| VII | | | study of | | | | | Educa |
| | | | the | | | | | tion |
| | | | course as | | | | | Knowl |
| | | | employbil | | | | | edge |
| | | | | | | | | cuge |
| | | | ity related | | | | | |
| | | | to health | | | | | |
| | | | sector will | | | | | |
| | | | be | | | | | |
| | | | enhanced | | | | | |
| | | | | | | | | |

ER20-14T: Human Anatomy & Physiology Theory

| ER2014 T | Human Anatomy and Physiology- Theory | L | T | P |
|----------------------------|---|---|---|---|
| Version 2.0 | | 3 | 1 | 0 |
| Total Contact Hours | 75 Hr | | | |
| Pre-requisites/Exposure | Basic knowledge of Biology | | | |
| Co-requisites | Knowledge of biology | | | |
| | Course Objectives | | | |

-Culting and a superior of the superior

Upon completion of this course the student should be able to

- 1. Pedagogical learning of Structure and functions of the various organ systems and organs of the human body
- 2. Understanding Homeostatic mechanisms and their imbalances in the human body
- 3. Explaining various vital physiological parameters of the human body and their significances
- 4. Explain the gross morphology, structure and functions of various organs of the human body.
- 5. Describe the various homeostatic mechanisms and their imbalances.
- 6. Identify the various tissues and organs of different systems of human body.
- 7. Perform the various experiments related to special senses and nervous system.

Course Outcomes

On completion of this course, the students will be able to:

CO1: This subject is designed to impart fundamental knowledge on the structure and functions of the various systems of the human body.

CO2: It also helps in understanding both homeostatic mechanisms.

CO3: The subject provides the basic knowledge required to understand the various disciplines of pharmacy.

CO4: It enlightens the students about the cells, various types of tissues in human body, skeleton system, skeletal and smooth muscles.

CO5: It also deals with the composition of blood, blood groups, blood coagulation, various disease causing agents and preventive measures, balanced diet, disorders and treatment involve in

nutritional deficiency.

| Course Code | Course Outcome | PO 1 | PO 2 | PO 3 | PO 4 | PO 5 | PO 6 | PO 7 | PO 8 | PO 9 | PO 10 | PO 11 | PO 12 | PS O1 | PSO2 | PSO3 | PSO4 | PS05 |
|----------------|-------------------|---------|---------|---------|---------|---------|---------|------|---------|---------|----------|----------|----------|----------|------|------|------|------|
| ER2014T | CO1 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | - | 1 |
| | CO2 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | - | - |
| | CO3 | 3 | 2 | 1 | - | 3 | 3 | 2 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | - | - |
| | CO4 | 3 | 2 | 1 | - | 2 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | - | - |
| | CO5 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 3 | - | - |

1=weakly mapped, 2= moderately mapped, 3=strongly mapped

| Unit | | | o the local, national, regional Relevance To the Employability/ Relevance to the Professional Ethics, Gender, Human Values, Environment & Sustainability | | | | | | | SDG | NEP | POE/4 th IR | | |
|-------------|-----------|--------------|--|---|-------------------|----------------------|--|----------------------------|--------|---------------------------------|---|---|--|--------------------------|
| ER201 4T | Loc al | Regio nal | National | Global | Employa bility | Entrepreneu rship | Skill Develop ment | Professi onal Ethics | Gender | Hu ma n Va lue s | Environ ment & Sustainab ility | | | |
| Unit I | | - | _ | anatomy and physiology contribute to addressing public health challenges and promoting global health equity. Understand ing the human body's structure and functions is essential for | | - | Education initiatives at the student level often emphasiz e these subjects to produce healthcare profession als skill. | | | - | | 4.1(educa tion and promote lifelong learning opportun ities for all) | | Projects/Assig nments |

| Unit II - | addressing global health threats such as infectious diseases, non- communica ble diseases, and emerging pandemics Knowledg | understan | - 4.1(educa - Projects/Assig |
|-----------|---|--|--|
| | e of cellular processes is crucial for developin g personaliz ed treatment plans and implemen ting targeted therapies tailored to | ding of cellular mechanis ms to diagnose and treat diseases effectively within their communit ies. | tion and promote lifelong learning opportun ities for all) |

| | individual patients' needs. | | | |
|----------|--|--|--|--------------------------|
| Unit III | The dissemination of knowledge about tissues on a global scale helps in building a common understand ing among healthcare professionals and understand s the development of therapies, surgeries, and medical technologies that can benefit diverse population | understan - ding and role of tissues in the human body are relevant across various developm ental levels | 4.1(educa - tion and promote lifelong learning opportun ities for all) | Projects/Assig nments |

| | s worldwide | | |
|--------|--|---|--|
| Unit | - Understand- ing bone tissue's structure, function, and health determinan ts is essential for promoting musculosk eletal wellness, preventing bone- related disorders | Knowledge - of bone disorders and precaution s and treatment of bone injuries | tion and promote lifelong learning opportun ities for all) |
| Unit v | aimed at improving blood collection and safety, and enhancing the quality of care for | Enhance | - 4.1(educa- tion and promote lifelong learning opportun ities for all) |

| | | | | T |
|------|--------------|------------|-----------|------------------|
| | patients | | | |
| | with blood | | | |
| | disorders | | | |
| | and | | | |
| | hematologi | | | |
| | c | | | |
| | conditions. | | | |
| Unit | Access to | learning - | 4.1(educa | - Projects/Assig |
| VI | diagnostics | the basic | tion and | nments |
| | , treatment | anatomy | promote | |
| | options, | of the | lifelong | |
| | and | lymphatic | learning | |
| | supportive | system, | opportur | |
| | care | including | ities for | |
| | services for | its | all) | |
| | lymphatic | compone | | |
| | conditions | nts such | | |
| | is essential | as lymph | | |
| | for | nodes, | | |
| | reducing | lymphatic | | |
| | disparities | vessels, | | |
| | in | lymphatic | | |
| | healthcare | organs | | |
| | access, | (spleen, | | |
| | improving | thymus, | | |
| | patient | tonsils), | | |
| | outcomes, | and | | |
| | and | lymphatic | | |
| | enhancing | tissues. | | |
| | health | | | |
| | equity | | | |
| | across | | | |

| population s | | |
|---------------------|------------------------|--------------------------|
| lersta Knowledge - | Developin | 4.1(educa - Projects/Ass |
| ng of of the | g skills for | tion and nments |
| diac cardiac | a | promote |
| tomy cycle helps | comprehe | lifelong |
| l healthcare | nsive | learning |
| rsiolog professiona | understan | opportun |
| ls interpret | ding of | ities for |
| prove symptoms, | cardiac | all) |
| diovas perform | anatomy | |
| ar diagnostic | and | |
| Ith tests, and | physiolog | |
| comes develop | y is | |
| oss treatment | essential | |
| plans | for | |
| oulatio tailored to | healthcare | |
| individual | profession | |
| patients' | als, | |
| needs | researcher | |
| | s, and | |
| | students | |
| | interested | |
| | in | |
| | cardiovasc | |
| | ular | |
| | health | |
| | | |
| | | |
| Understand - | | 4.1(educa - Projects/Ass |
| | i I I | tion and nments |
| | Understand- ing the | |

| anatomy | kn | owledg | р | romote | |
|------------|-------|-----------|-----|----------|--|
| and | | ble | l I | felong | |
| physiolog | | oout | | earning | |
| of | | spirator | | pportun | |
| respirator | | anatomy | | ties for | |
| organs is | | - | a | II) | |
| essential | | ysiolog | | | |
| for | y t | | | | |
| addressin | g | ovide | | | |
| global | | fective | | | |
| health | ca | re for | | | |
| challenge | s pa | tients | | | |
| related to | o wi | th | | | |
| respirator | y res | spirator | | | |
| diseases | y i | llnesses. | | | |
| including | | | | | |
| infectious | 5 | | | | |
| diseases | | | | | |
| like | | | | | |
| tuberculo | si | | | | |
| s and | | | | | |
| influenza | | | | | |
| as well as | 5 | | | | |
| chronic | | | | | |
| condition | | | | | |
| like asthm | ia | | | | |
| and | | | | | |
| chronic | | | | | |
| obstructiv | | | | | |
| pulmonar | у | | | | |
| disease | | | | | |
| (COPD). | | | | | |

| Unit | - Many | Understan - | 4.1(educa ⁻ | Projects/Assig |
|------|-------------|-------------|------------------------|----------------|
| IX | infectious | ding how | tion and | nments |
| | diseases, | the GIT | promote | |
| | such as | processes | lifelong | |
| | diarrheal | and | learning | |
| | diseases | absorbs | opportun | |
| | and | nutrients | ities for | |
| | parasitic | is | all) | |
| | infections, | essential | | |
| | affect the | for | | |
| | GIT. | addressin | | |
| | Understand | g global | | |
| | ing GIT | issues | | |
| | anatomy | related to | | |
| | and | malnutriti | | |
| | physiology | on and | | |
| | is critical | food | | |
| | for | insecurity. | | |
| | preventing, | | | |
| | diagnosing, | | | |
| | and | | | |
| | treating | | | |
| | these | | | |
| | diseases, | | | |
| | which | | | |
| | disproporti | | | |
| | onately | | | |
| | affect | | | |
| | population | | | |
| | s in low- | | | |
| | and | | | |
| | middle- | | | |
| | income | | | |

| | | countries. | | | | | | | | | |
|-------|-------------|--------------|---|---|-------------|---|---|---|---|-----------|----------------|
| | | | | | | | | | | | |
| Unit- | The | focus on - | , | - | Utilize | - | - | - | - | 4.1(educa | Projects/Assig |
| X | skeletal | preventing | | | anatomica | | | | | tion and | nments |
| | system | skeletal | | | I models, | | | | | promote | |
| | provides | injuries, | | | diagrams, | | | | | lifelong | |
| | structural | such as | | | and charts | | | | | learning | |
| | support, | fractures | | | to | | | | | opportun | |
| | protects | and | | | visualize | | | | | ities for | |
| | vital | osteoporos | | | the | | | | | all) | |
| | organs, | is, through | | | skeletal | | | | | | |
| | and | education, | | | system in | | | | | | |
| | facilitates | lifestyle | | | three | | | | | | |
| | movemen | interventio | | | dimension | | | | | | |
| | t. | ns, and | | | S. | | | | | | |
| | | access to | | | | | | | | | |
| | | adequate | | | | | | | | | |
| | | healthcare | | | | | | | | | |
| | | services. | | | | | | | | | |
| Unit- | - | Understand- | | - | Learn to | - | - | - | - | 4.1(educa | Projects/Assig |
| ΧI | | ing the | | | interpret | | | | | tion and | nments |
| | | nervous | | | neuroima | | | | | promote | |
| | | system is | | | ging | | | | | lifelong | |
| | | fundament | | | studies | | | | | learning | |
| | | al for | | | and | | | | | opportun | |
| | | diagnosing | | | recognize | | | | | ities for | |
| | | and | | | anatomica | | | | | all) | |
| | | treating | | | I | | | | | | |
| | | neurologic | | | structures, | | | | | | |
| | | al disorders | | | functional | | | | | | |
| | | and mental | | | connectivi | | | | | | |
| | | health | | | ty | | | | | | |

| | | | | conditions, which | | | patterns, and | | | | | |
|-------|---|---|------------|----------------------|---|---|------------------|---|---|---|-----------|----------------|
| | | | | affect | | | abnormali | | | | | |
| | | | | millions of | | | ties in the | | | | | |
| | | | | people | | | nervous | | | | | |
| | | | | worldwide. | | | system. | | | | | |
| | | | | and | | | System. | | | | | |
| | | | | Facilitate | | | | | | | | |
| | | | | the | | | | | | | | |
| | | | | exchange | | | | | | | | |
| | | | | of | | | | | | | | |
| | | | | knowledge, | | | | | | | | |
| | | | | resources, | | | | | | | | |
| | | | | and | | | | | | | | |
| | | | | expertise, | | | | | | | | |
| | | | | leading to | | | | | | | | |
| | | | | breakthrou | | | | | | | | |
| | | | | ghs in | | | | | | | | |
| | | | | treatments | | | | | | | | |
| | | | | and | | | | | | | | |
| | | | | interventio | | | | | | | | |
| | | | | ns for | | | | | | | | |
| | | | | neurologic | | | | | | | | |
| | | | | al | | | | | | | | |
| | | | | conditions. | | | | | | | | |
| Unit- | - | _ | Understa | - | - | - | Sense | - | - | - | 4.1(educa | Projects/Assig |
| XII | | | nding the | | | | organs | | | | tion and | nments |
| | | | anatomy | | | | play a | | | | promote | |
| | | | and | | | | crucial | | | | lifelong | |
| | | | physiolog | | | | role in | | | | learning | |
| | | | y of sense | | | | detecting | | | | opportun | |
| | | | organs is | | | | environm | | | | ities for | |

| | fundame | ental | all) | |
|------|-------------|-------------|----------------------------|----------------|
| | ntal for | stimuli | J, | |
| | diagnosin | and | | |
| | g and | potential | | |
| | treating | health | | |
| | sensory | hazards. | | |
| | impairme | Knowledg | | |
| | nts and | e of | | |
| | disorders | sensory | | |
| | such as | function | | |
| | vision | informs | | |
| | loss, | public | | |
| | hearing | health | | |
| | loss, and | strategies | | |
| | balance | for | | |
| | disorders. | preventin | | |
| | | g injuries | | |
| | | and | | |
| | | environm | | |
| | | ental | | |
| | | exposures | | |
| | | that can | | |
| | | affect | | |
| | | sensory | | |
| | | organs. | | |
| Unit | - Understan | - Understan | 4.1(educa ⁻ | Projects/Assig |
| XIII | ding the | d the | tion and | nments |
| | anatomy | physiologi | promote | |
| | and | cal | lifelong | |
| | physiolog | functions | learning | |
| | y of the | of the | opportun | |
| | I F | urinary | ities for | |
| | urinary | | | |

| system is essential for diagnosin g and treating urinary tract infections, kidney diseases, | system, including urine formation, filtration, reabsorpti on, secretion, and excretion of metabolic | all) | |
|---|---|------|--|
| worldwide .and Focus on improving access to kidney care services, including screenings , diagnostic | | | |

| | T T | T T | | 1 | 1 |
|-------|---|-----|--|--|------------------|
| | s, dialysis, | | | | |
| | and | | | | |
| | transplant | | | | |
| | ation, | | | | |
| | particularl | | | | |
| | y in | | | | |
| | underserv | | | | |
| | ed | | | | |
| | communit | | | | |
| | ies where | | | | |
| | renal | | | | |
| | diseases | | | | |
| | are | | | | |
| | prevalent. | | | | |
| | prevalent. | | | | |
| Unit- | - Endocrine | | Develop - | 4.1(educa | - Projects/Assig |
| XIV | disruptors, | | skills in | tion and | nments |
| | | | SKIIIS III | | |
| | environme | | | promote | |
| | | | reading and | | |
| | environme | | reading | promote | |
| | environme ntal toxins, | | reading and critically evaluating | promote lifelong learning opportun | |
| | environme ntal toxins, and | | reading and critically | promote lifelong learning opportun ities for | |
| | environme ntal toxins, and lifestyle factors can impact | | reading and critically evaluating | promote lifelong learning opportun | |
| | environme ntal toxins, and lifestyle factors can impact endocrine | | reading and critically evaluating scientific | promote lifelong learning opportun ities for | |
| | environme ntal toxins, and lifestyle factors can impact endocrine gland | | reading and critically evaluating scientific literature | promote lifelong learning opportun ities for | |
| | environme ntal toxins, and lifestyle factors can impact endocrine gland function | | reading and critically evaluating scientific literature on | promote lifelong learning opportun ities for | |
| | environme ntal toxins, and lifestyle factors can impact endocrine gland function and | | reading and critically evaluating scientific literature on hormone physiolog y, | promote lifelong learning opportun ities for | |
| | environme ntal toxins, and lifestyle factors can impact endocrine gland function and hormone | | reading and critically evaluating scientific literature on hormone physiolog y, endocrine | promote lifelong learning opportun ities for | |
| | environme ntal toxins, and lifestyle factors can impact endocrine gland function and hormone regulation. | | reading and critically evaluating scientific literature on hormone physiolog y, endocrine disorders, | promote lifelong learning opportun ities for | |
| | environme ntal toxins, and lifestyle factors can impact endocrine gland function and hormone | | reading and critically evaluating scientific literature on hormone physiolog y, endocrine | promote lifelong learning opportun ities for | |

| endocrine physiology informs strategies for preventing endocrine- related diseases, promoting hormonal balance, and reducing the risk factors associated with endocrine disorders. | |
|--|------|
| informs strategies for preventing endocrine- related diseases, promoting hormonal balance, and reducing the risk factors associated with endocrine disorders. | |
| strategies for preventing endocrine- related diseases, promoting hormonal balance, and reducing the risk factors associated with endocrine disorders. | |
| for preventing endocrine-related diseases, promoting hormonal balance, and reducing the risk factors associated with endocrine disorders. | |
| for preventing endocrine-related diseases, promoting hormonal balance, and reducing the risk factors associated with endocrine disorders. | |
| endocrine- related diseases, promoting hormonal balance, and reducing the risk factors associated with endocrine disorders. | |
| endocrine- related diseases, promoting hormonal balance, and reducing the risk factors associated with endocrine disorders. | |
| diseases, promoting hormonal balance, and reducing the risk factors associated with endocrine disorders. | |
| diseases, promoting hormonal balance, and reducing the risk factors associated with endocrine disorders. | |
| promoting hormonal balance, and reducing the risk factors associated with endocrine disorders. | |
| hormonal balance, and reducing the risk factors associated with endocrine disorders. | |
| balance, and reducing the risk factors associated with endocrine disorders. | |
| and reducing the risk factors associated with endocrine disorders. | |
| reducing the risk factors associated with endocrine disorders. | |
| the risk factors associated with endocrine disorders. | |
| factors associated with endocrine disorders. | |
| associated with endocrine disorders. | |
| with endocrine disorders. | |
| endocrine disorders. | |
| disorders. | |
| | |
| Unit Education Study the Projects/Assig | Unit |
| XV and physiologi Knowledge nments | xv |
| informatio cal about | |
| changes gender | |
| reproductive that occur (Differntiat) | |
| | |
| | |
| | |
| menstruati both of male on cycle, males and and | |
| pregnancy females, female) | |
| and including | |
| parturition the | |

| | | | developm | | | | |
|--|--|--|------------|--|--|--|--|
| | | | ent of | | | | |
| | | | secondary | | | | |
| | | | sexual | | | | |
| | | | characteri | | | | |
| | | | stics, | | | | |
| | | | hormonal | | | | |
| | | | fluctuatio | | | | |
| | | | ns, and | | | | |
| | | | reproducti | | | | |
| | | | ve | | | | |
| | | | maturity. | | | | |

ER20-14P: Human Anatomy & Physiology Practical

| ER2014 P | Human Anatomy and Physiology-Practical | L | T | P |
|----------------------------|--|---|---|---|
| Version 2.0 | | 0 | 0 | 3 |
| Total Contact Hours | 75 Hr | | | |
| Pre-requisites/Exposure | Pharmacology | | | |
| Co-requisites | Human Anatomy | | | |
| | Course Objectives | | | |

- 1. General blood collection techniques and carrying out various haematological assessments and interpreting the results
- 2. Recording and monitoring the vital physiological parameters in human subjects and the basic interpretations of the results
- 3. Microscopic examinations of the various tissues permanently mounted in glass slides
- 4. Discuss the anatomical and physiological characteristics of various organ systems of the body using models, charts, and other teaching aids.

Course Outcomes (CO)

On completion of this course, the students will be able to:

- CO1. Perform the haematological tests in human subjects and interpret the results
- CO2. Record, monitor and document the vital physiological parameters of human subjects and interpret the results
- CO3. Describe the anatomical features of the important human tissues under the microscopically conditions
- CO4. Discuss the significance of various anatomical and physiological characteristics of the human body

| Course Code | Course Outcome | PO1 | PO2 | PO3 | PO4 | PO5 | PO6 | PO7 | PO8 | PO9 | PO10 | PSO1 | PSO2 | PSO3 | PSO4 | PSO5 |
|----------------|-------------------|-----|-----|-----|-----|-----|-----|-----|-----|-----|------|------|------|------|------|------|
| | CO1 | 2 | 3 | 2 | - | 2 | 3 | | 3 | 2 | | 3 | 2 | 2 | - | - |
| ER20- 14P | CO2 | 3 | 3 | 2 | - | 2 | 1 | | | 2 | | 3 | 2 | 2 | - | - |
| | CO3 | 3 | 3 | 1 | - | 1 | 2 | | 2 | 2 | | 2 | 3 | 2 | - | - |
| | CO4 | 2 | 3 | 2 | - | 1 | 2 | 2 | 3 | 3 | 1 | 2 | 2 | 1 | - | - |

1=weakly mapped, 2= moderately mapped, 3=strongly mapped

| Unit | Relevance to the local, national, regional and global developmental needs Loc Regio National Global | | | | Releva: Entrepren | Relevance to the Professional Ethics, Gender, Human Values, Environment & Sustainability | | | | SDG | NEP | POE/4 th IR | | |
|-------------|--|--------------|----------|--|----------------------|--|--|----------------------------|------------|-------------------------|---|---------------------------|---|-----------------|
| ER201 4P | Loc al | Regio nal | National | Global | Employa bility | Entrepreneu rship | Skill Developm ent | Professi onal Ethics | Gen der | Hu man Valu es | Environ ment & Sustainab ility | | | |
| Unit I | - | - | - | use microscopy techniques to analyze raw materials, inspect product integrity, assess product purity, and investigate material properties at the microscopi c level. | - | - | microscopy techniques into curricula to enhance students' understand ing of biological concepts, cell biology, histology, and microbiolo gy. | | - | - | | promote lifelong | Institutio nal Restructu ring and Consolida tion (10.1- 10.14) 4.1 | 1 |
| Unit II | - | - | - | The techniques for the collection of blood | - | - | Blood collection centers operate in countries worldwide, | _ | - | - | - | | Institutio nal Restructu ring and Consolida tion (10.1- | developm ent |

| | | | | - Ia | | | l | 40.44) | T |
|--------|---|---|--------------|-------------|------|-------|-----------|----------------|----------|
| | | | are crucial | facilitatin | 9 | | | 10.14) | |
| | | | component | voluntary | | | all) | | |
| | | | s of | blood | | | | | |
| | | | healthcare | donation | ; | | | | |
| | | | systems | from | | | | | |
| | | | worldwide, | eligible | | | | | |
| | | | ensuring | donors to | | | | | |
| | | | the safe | meet | | | | | |
| | | | acquisition | transfusio | n | | | | |
| | | | of blood | needs, | | | | | |
| | | | samples for | emergen | :y | | | | |
| | | | diagnostic, | response | | | | | |
| | | | therapeutic | efforts, a | ıd | | | | |
| | | | , and | healthcar | 9 | | | | |
| | | | research | demands | | | | | |
| | | | purposes. | | | | | | |
| Unit - | - | - | | Microsco | oi - | - | 4.1(educa | Institutio | Skills |
| Ш | | | Microscopi | С | | | tion and | nal | developm |
| | | | c | examinat | О | | promote | Restructu | ent |
| | | | examinatio | n of tissu | 9 | | lifelong | ring and | |
| | | | n of tissue | specimer | s, | | learning | Consolida | |
| | | | is a | obtained | | | opportun | tion (10.1- | |
| | | | fundament | through | | | ities for | 10.14) | |
| | | | al aspect of | biopsies, | | | all) | 10.14) | |
| | | | medical | surgical | | | , | | |
| | | | diagnosis, | resection | 5, | | | | |
| | | | research, | or | | | | | |
| | | | and | autopsies | , | | | | |
| | | | education | is essenti | | | | | |
| | | | worldwide, | for | | | | | |
| | | | providing | diagnosir | a | | | | |
| | | | valuable | a wide | ٦ | | | | |
| | | | varaabic | a wide | | | | | |

| | into cellular structures, disease processes, and treatment strategies | range of diseases, including cancer, infectious diseases, autoimmun e disorders, and genetic conditions. | |
|------|--|--|---|
| Unit | - Worldwid - e, the study of the human skeleton is an integral compone nt of medical education. It forms the basis for understan ding anatomy, pathology, and radiology. | the study of the human skeleton, encompass ing the axial and appendicul ar skeleton, transcends geographic al boundaries and cultural contexts, offering profound insights into human biology, | 4.1(educa institutio tion and promote lifelong learning opportun ities for all) 4.1(educa institutio nal developm Restructuring and Consolidation (10.1-10.14) |

| | | Healthcar | evolution, health, and | | | | | |
|--------|---|--------------------------|---------------------------------------|---|--|---------|------------------|----------|
| | | e profession | cultural heritage on | | | | | |
| | | als, including | a global scale. | | | | | |
| | | doctors, | | | | | | |
| | | surgeons, radiologist | | | | | | |
| | | s, and physical | | | | | | |
| | | therapists, globally | | | | | | |
| | | use skeletal | | | | | | |
| | | knowledg | | | | | | |
| | | e to diagnose | | | | | | |
| | | and treat various | | | | | | |
| | | conditions | | | | | | |
| | | , plan surgeries, | | | | | | |
| | | and interpret | | | | | | |
| | | medical imaging. | | | | | | |
| Unit v | | | Discol | | | 4.47. | Inctitutic | Chille |
| | - | The determinati | Blood - group data are utilized | - | | promote | nal Restructu | developm |
| | | | | | | | ring and | 68 |

| | I. | , , , | | | I | | | lic i | Consellate | |
|-------|---------|--------------|---------------|--|---|---|---|-----------|------------|----------|
| | | blood | in | | | | | lifelong | Consolida | |
| | | groups | epidemio | 0 | | | | learning | tion | |
| | | holds | gical | | | | | opportun | 10.14) | |
| | | significant | studies, | | | | | 11163 101 | 10.14) | |
| | - | global | disease | | | | | all) | | |
| | i | mportance | surveillan | ce | | | | | | |
| | | across | programs | | | | | | | |
| | \ | various | and publi | С | | | | | | |
| | s | sectors, | health | | | | | | | |
| | ļi | ncluding | interventi | 0 | | | | | | |
| | ŀ | healthcare, | ns to | | | | | | | |
| | t | transfusion | monitor | | | | | | | |
| | r | medicine, | infectious | | | | | | | |
| | f | forensic | diseases, | | | | | | | |
| | S | science, | assess | | | | | | | |
| | á | and | disease ri | sk | | | | | | |
| | á | anthropolo | factors, ar | nd | | | | | | |
| | | gy. | guide | | | | | | | |
| | | | healthcar | e | | | | | | |
| | | | policy | | | | | | | |
| | | | decisions. | | | | | | | |
| Unit- | - l | Healthcare | Monitorin | g | . | - | _ | 4.1(educa | Institutio | Skills |
| VI | ļ, | orofessiona | changes i | | | | | tion and | nal | developm |
| | ļ j | s around | ESR levels | | | | | promote | Restructu | ent |
| | t | the world | helps | | | | | lifelong | ring and | |
| | | utilize ESR | clinicians | | | | | learning | Consolida | |
| | t | testing as a | assess the | <u>, </u> | | | | opportun | tion | |
| | | screening | response | | | | | ities for | (10.1- | |
| | | tool for a | to | | | | | all) | 10.14) | |
| | | variety of | treatment | | | | | ′ | | |
| | | diseases, | and disea | | | | | | | |
| | | ncluding | progressi | | | | | | | |

| | au e in ry ar | offections, utoimmun disorders, offlammato of diseases, and certain ancers. | | n in conditions such as rheumatoid arthritis, systemic lupus erythemato sus, and giant cell arteritis. | | | | | | |
|--------------|--|--|---|--|---|---|--|---|---|-----------------|
| Unit- VII | de or he n in a cc e m pu he bi re | he etermination of emoglobicontent of blood is prince of clinical nedicine, ublice ealth, and iomedical esearch efforts porldwide. | - | Determine Haemoglobi n content of blood | _ | _ | | promote lifelong learning opportun | Institutio nal Restructu ring and Consolida tion (10.1- 10.14) | developm ent |
| Unit VIII | Bleeding time- assessment is essential for diagnosing and | - | | Bleeding time assessment | - | - | | promote lifelong | Institutio nal Restructu ring and Consolida tion | developm ent |

| Unit | C | The | | monitoring, and manageme nt of | - | | all) 4.1(educa tion and promote | 10.14) | developm |
|------|--------------------------------------|--|--|--|---|--|----------------------------------|--------------------------|----------|
| | s g p a v n s a | ime holds ignificant global prospects across various nedical pecialties and nealthcare | | bleeding disorders, coagulopat hies, and thrombotic conditions. | | | opportun | tion (10.1- 10.14) | |
| | s C C C | ettings, contributin g to the diagnosis, monitoring, | | | | | | | |

| | and manageme nt of bleeding disorders, coagulopat hies, and thrombotic conditions. | | |
|--------|---|---|---|
| Unit-X | Healthcare - providers worldwide use WBC count measureme nts to diagnose and monitor infectious diseases, including bacterial, viral, fungal, and parasitic infections, and to assess the severity and progressio | Determinati - on of WBC count of blood and various diseases | 4.1(educa tion and promote lifelong learning opportun ities for all) 4.1(educa Institutio nal developm ent ring and Consolidation (10.1-10.14) |

| | | I | | | | | | | | | ı | | |
|-------|---|---|---------------|--------------|---|-------------|---|---|---|---|-----------|------------------|----------|
| | | | | n of | | | | | | | | | |
| | | | | inflammato | | | | | | | | | |
| | | | | ry | | | | | | | | | |
| | | | | conditions. | | | | | | | | | |
| Unit- | - | - | - | Healthcare | | Determinati | - | - | - | - | 4.1(educa | | Skills |
| ΧI | | | | providers | | on of RBC | | | | | tion and | nal | developm |
| | | | | worldwide | | count of | | | | | promote | Restructu | ent |
| | | | | use RBC | | blood and | | | | | | ring and | |
| | | | | count | | various | | | | | learning | Consolida | |
| | | | | measureme | | diseases | | | | | opportun | tion | |
| | | | | nts to | | | | | | | ities for | (10.1- 10.14) | |
| | | | | assess the | | | | | | | all) | 10.14) | |
| | | | | severity, | | | | | | | , | | |
| | | | | etiology, | | | | | | | | | |
| | | | | and | | | | | | | | | |
| | | | | response | | | | | | | | | |
| | | | | to | | | | | | | | | |
| | | | | treatment | | | | | | | | | |
| | | | | in patients | | | | | | | | | |
| | | | | with iron | | | | | | | | | |
| | | | | deficiency | | | | | | | | | |
| | | | | anemia, | | | | | | | | | |
| | | | | vitamin | | | | | | | | | |
| | | | | deficiencies | | | | | | | | | |
| | | | | , hemolytic | | | | | | | | | |
| | | | | anemias, | | | | | | | | | |
| | | | | and | | | | | | | | | |
| | | | | chronic | | | | | | | | | |
| | | | | diseases. | | | | | | | | | |
| Unit- | _ | _ | Determination | | _ | various | _ | _ | _ | _ | 4.1(educa | Institutio | Skills |
| XII | | | | on of | | systems of | | | | | tion and | nal | developm |
| | | | | Differential | | the human | | | | | | Restructu | |
| | | | | count of | | body | | | | | | ring and | |

| | blood | lifelong Consolida | |
|--------------|---|--|-----------------|
| | | learning tion opportun (10.1- | |
| | | ities for 10.14) | |
| | | all) | |
| Unit XIII | Recording of- Blood Pressure in various | to optimize 4.1(educa Institutio blood pressure control and lifelong | developm |
| | postures, different arms, before and after exertion and interpreting the results | prevent associated complicatio ns such as heart disease, stroke, and kidney | a |
| Unit | Explore the structure and function of human body systems to elucidate disease mechanism s, develop new therapies, and | nowledge of anatomy and physiology to design personalize d treatment plans for patients recovering from injuries, surgeries, | developm ent |

| improve diagnostic | or chronic health | | |
|-----------------------|----------------------|--|--|
| tools for | conditions. | | |
| diverse | | | |
| medical | | | |
| conditions. | | | |

ER20-15T: Social Pharmacy Theory

| Subject Code: ER20-15T | Social Pharmacy | L 3 | T 1 | P 0 | | | | |
|-------------------------|-----------------|--------|--------|------------|--|--|--|--|
| Version 2.0 | | | | | | | | |
| Total Contact Hours | 75 hrs. | | | | | | | |
| Pre-requisites/Exposure | Social Sciences | | | | | | | |
| Co-requisites | Pharmaceutics | | | | | | | |

Course Objectives

Upon completion of this course the student should be able to:

- 1. Public health and national health programs
- 2. Preventive healthcare
- 3. Food and nutrition related health issues
- 4. Health education and health promotion
- 5. General roles and responsibilities of pharmacists in public health

Course Outcomes (CO)

On completion of this course, the students will be able to:

- CO1. Discuss about roles of pharmacists in the various national health programs
- CO2. Describe various sources of health hazards and disease preventive measures
- CO3. Discuss the healthcare issues associated with food and nutritional substances
- CO4. Describe the general roles and responsibilities of pharmacists in public health
- CO 5. Provide first aid for various emergency conditions

| СО | PO1 | PO2 | PO3 | PO4 | PO5 | PO6 | PO7 | PO8 | PO9 | PO10 | PO11 | PO12 | PSO1 | PSO2 | PSO3 | PSO4 | PSO5 |
|-----|-------|------|------|----------|-------|------|------|------|--------|-------|-------|-------|---------|-------|-------|--------|-------|
| CO | . 0 - | . 0- | . 00 | . • | . 05 | . 00 | . 07 | . 00 | . 03 | . 010 | . 011 | . 011 | . 501 | | . 505 | . 50 - | . 505 |
| CO1 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | - | - |
| CO2 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | - | - |
| CO3 | 3 | 3 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | - | - |
| CO4 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | - | - |
| CO5 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | - | - |
| | | | 1=l | ightly ı | mappe | d | 2= | mode | rately | mappe | t | 3=str | ongly m | apped | | | |

| Unit | | nal and gl | e local, nat obal develo | | | ce To the Emplo eurship/ Skill Dev | | | | alues, E | onal Ethics, invironment | SDG | NEP | POE/ 4 th IR |
|------------------|--------|--------------|-----------------------------|---|-------------------|---------------------------------------|--------------------------|----------------------------|------------|-------------------------|---|--|---|--|
| ER2 0- 15T | Loc al | Regio nal | Nation al | Global | Employa bility | Entrepreneu rship | Skill Develop ment | Professi onal Ethics | Gen der | Hu man Val ues | Environ ment & Sustaina bility | | | |
| Unit I | | | | It encompas ses fundament al principles and practices in public health, healthcare systems, and health policy. The knowledg | | | | | | | | Sustainable Development and Global Citizenship (SDG 4.7) | Towards a More Holistic and Multidisciplinary Education (11.1- 11.13) | Global Educati on Knowle dge |

| | e and insights gained from these areas can be applied across borders to enhance the well-being of people and communiti es worldwide | | |
|------|---|-------------------------|--|
| Unit | They address critical aspects of public health, reproducti ve health, disease preventio n, environm ental sustainabil ity, and the social well-being of the populatio n. A healthy and informed | apı pro sys me | 3 Implement Towards a More Holistic and propriate social Multidisciplinary Education (11.1-11.13) easures for all, cluding floors" |

| | 1 | <u> </u> | 1 | 1 | I | | | | 1 |
|------|---|----------|-------------|---|---|--|--|-------------------|---------|
| | | popu | | | | | | | |
| | | | is a | | | | | | |
| | | | ersto | | | | | | |
| | | ne o | f any | | | | | | |
| | | natio | n's | | | | | | |
| | | | lopm | | | | | | |
| | | | and | | | | | | |
| | | | macis | | | | | | |
| | | | oles in | | | | | | |
| | | these | | | | | | | |
| | | | s are | | | | | | |
| | | esser | | | | | | | |
| | | for | Telai | | | | | | |
| | | achie | ving | | | | | | |
| | | these | | | | | | | |
| | | goals | | | | | | | |
| | | goals | | | | | | - 1 11 6 6 | |
| Unit | | | these | | | | | End all forms of | Global |
| Ш | | | nutrition- | | | | | malnutrition (SDG | Educati |
| | | | related | | | | | 2.2) | on |
| | | | topics are | | | | | | Knowle |
| | | | highly | | | | | | dge |
| | | | relevant | | | | | | |
| | | | to global | | | | | | |
| | | | needs as | | | | | | |
| | | | they | | | | | | |
| | | | address | | | | | | |
| | | | fundamen | | | | | | |
| | | | tal aspects | | | | | | |
| | | | of health, | | | | | | |
| | | | well- | | | | | | |
| | | | being, and | | | | | | |
| | | | food | | | | | | |
| | | | security | | | | | | |
| | | | that | | | | | | |
| | | | impact | | | | | | |
| | | | populatio | | | | | | |
| | | | ns | | | | | | |
| | | | worldwide | | | | | | |
| | | | . Proper | | | | | | |
| | | | . Proper | | | | | | |

| | 1 | | 1 | 1 | | ı | | | T | |
|------|---|------------|---|---|--|---|--|--------------------|---|--|
| | | nutrition | | | | | | | | |
| | | is a | | | | | | | | |
| | | cornersto | | | | | | | | |
| | | ne of | | | | | | | | |
| | | public | | | | | | | | |
| | | health, | | | | | | | | |
| | | and | | | | | | | | |
| | | understan | | | | | | | | |
| | | ding these | | | | | | | | |
| | | principles | | | | | | | | |
| | | can | | | | | | | | |
| | | contribute | | | | | | | | |
| | | to better | | | | | | | | |
| | | health | | | | | | | | |
| | | outcomes | | | | | | | | |
| | | | | | | | | | | |
| | | on a | | | | | | | | |
| | | global | | | | | | | | |
| | | scale. | | | | | | | | |
| Unit | | globally | | | | | | Ensure healthy | | |
| IV | | relevant | | | | | | lives and | | |
| | | because | | | | | | promote | | |
| | | they | | | | | | well-being for all | | |
| | | provide | | | | | | at all | | |
| | | the | | | | | | | | |
| | | knowledg | | | | | | ages (SDG | | |
| | | e and | | | | | | 3) | | |
| | | tools | | | | | | | | |
| | | necessary | | | | | | | | |
| | | to | | | | | | | | |
| | | prevent, | | | | | | | | |
| | | control, | | | | | | | | |
| | | and | | | | | | | | |
| | | respond | | | | | | | | |
| | | to | | | | | | | | |
| | | communic | | | | | | | | |
| | | able | | | | | | | | |
| | | diseases | | | | | | | | |
| | | that can | | | | | | | | |
| | | | | | | | | | | |
| 1 | 1 | affect | | | | | | | | |

| | | 1 | 1 | _ | ı | | 1 | | 1 |
|------|-------------|------------|---|---|---|--|---|--------------------|---|
| | | populatio | | | | | | | |
| | | ns across | | | | | | | |
| | | borders. | | | | | | | |
| | | They are | | | | | | | |
| | | essential | | | | | | | |
| | | for | | | | | | | |
| | | promoting | | | | | | | |
| | | global | | | | | | | |
| | | health | | | | | | | |
| | | | | | | | | | |
| | | equity, | | | | | | | |
| | | reducing | | | | | | | |
| | | the | | | | | | | |
| | | spread of | | | | | | | |
| | | infectious | | | | | | | |
| | | diseases, | | | | | | | |
| | | and | | | | | | | |
| | | safeguardi | | | | | | | |
| | | ng public | | | | | | | |
| | | health on | | | | | | | |
| | | a global | | | | | | | |
| | | scale. | | | | | | | |
| Unit | health | | | | | | | "1.3 Implement | |
| , | systems | | | | | | | nationally | |
| ľ | and | | | | | | | appropriate social | |
| | | | | | | | | protection | |
| | ongoing | | | | | | | | |
| | national | | | | | | | systems and | |
| | health | | | | | | | measures for all, | |
| | programs | | | | | | | including floors" | |
| | in India i | S | | | | | | | |
| | of | | | | | | | | |
| | national | | | | | | | | |
| | relevance | | | | | | | | |
| | as i | t | | | | | | | |
| | directly | | | | | | | | |
| | affects the | e | | | | | | | |
| | well-being | | | | | | | | |
| | of the | ė | | | | | | | |
| | populatio | | | | | | | | |
| | n, | | | | | | | | |
| | 11, | 1 | | 1 | | | | | |

| | | healthcare | | | I | | | | |
|------|---|--------------|--------------------------------------|---|---|--|--|--|--|
| | | | | | | | | | |
| | | access, | | | | | | | |
| | | and the | | | | | | | |
| | | nation's | | | | | | | |
| | | overall | | | | | | | |
| | | developm | | | | | | | |
| | | ent. It also | | | | | | | |
| | | highlights | | | | | | | |
| | | the | | | | | | | |
| | | important | | | | | | | |
| | | role tha | | | | | | | |
| | | pharmacis | | | | | | | |
| | | | | | | | | | |
| | | ts play ir | | | | | | | |
| | | supportin | | | | | | | |
| | | g and | | | | | | | |
| | | contributi | | | | | | | |
| | | ng to | | | | | | | |
| | | these | | | | | | | |
| | | programs. | | | | | | | |
| | | | | | | | | | |
| Unit | | | It informs | | | | | | |
| -VI | | | healthcare | | | | | | |
| | | | decision- | | | | | | |
| | | | making, | | | | | | |
| | | | resource | | | | | | |
| | | | allocation, | | | | | | |
| | | | | | | | | | |
| | | | and policy | | | | | | |
| | | | developm | | | | | | |
| | | | ent, | | | | | | |
| | | | ultimately | | | | | | |
| | | | impacting | | | | | | |
| | | | the | | | | | | |
| | | | accessibili | | | | | | |
| | | | ty, | | | | | | |
| | | | affordabili | | | | | | |
| | | | ty, and | | | | | | |
| | 1 | | | I | 1 | | | | |
| 1 | | | quality of | | | | | | |
| | | | quality of | | | | | | |
| | | | quality of healthcare services | | | | | | |

| | | worldwide | | | | | |
|--|--|-----------|--|--|--|--|--|
| | | • | | | | | |
| | | | | | | | |

Diploma II Year

ER2021T: Pharmacology- Theory

| ER2021 T | Pharmacology – Theory | L | Т | P | | | | | |
|-------------------------|-----------------------|--------------|---|---|--|--|--|--|--|
| Version 2.0 | | 3 | 1 | 0 | | | | | |
| Total Contact Hours | 75 Hr | · | | | | | | | |
| Pre-requisites/Exposure | Ph | Pharmacology | | | | | | | |
| Co-requisites | Ph | Pharmacology | | | | | | | |

Course Objectives

on completion of this course the student should be able to

- 1. Understand the mechanism of drug action and its relevance in the treatment of different diseases
- 2. Demonstrate isolation of different organs/tissues from the laboratory by animals simulated experiments
- 3. Demonstrate the various receptor actions using isolated tissue preparation

Appreciate correlation of pharmacology with related medical sciencesER201

Course Outcomes

On completion of this course, the students will be able to:

- CO1- The subject is designed to strengthen the basic knowledge in the field of pharmacology and to impart recent advances in the drugs used for the treatment of various diseases.
- CO-2In addition, the subject helps the student to understand the concepts of drug action and mechanism involved.
- CO-3This subject provides the knowledge of endocrine pharmacology, chemotherapy, antibiotics, and immunology.
- CO-4Student is able to understand the diseases like Parkinsonism, cancer, Alzheimer, diabetes mellitus and its treatment & It also deals with the free radical pharmacology, its etiology and pathophysiology in various neurodegenerative diseases.

| СО | PO1 | PO2 | PO3 | PO4 | PO5 | PO6 | PO7 | PO8 | PO9 | PO10 | PO11 | PO12 | PSO1 | PSO2 | PSO3 | PSO4 | PSO5 |
|-----------------------|-----|-----|-----|-----|-----|-------|---------|--------|-----|------|---------|-------|----------|------|------|------|------|
| CO1 | 3 | 1 | 2 | 3 | 2 | 1 | 3 | 1 | 2 | 3 | 2 | 3 | 3 | 2 | 1 | 2 | 3 |
| CO2 | 3 | 2 | 3 | 1 | 2 | 3 | 3 | 3 | 2 | 2 | 1 | 3 | 2 | 2 | 2 | 1 | 1 |
| CO3 | 2 | 1 | 2 | 3 | 3 | 3 | 3 | 2 | 3 | 2 | 2 | 2 | 1 | 3 | 3 | 3 | 1 |
| CO4 | 1 | 2 | 3 | 1 | 2 | 2 | 3 | 3 | 1 | 1 | 2 | 3 | 3 | 2 | 1 | 3 | 2 |
| 1=lightly mapped 2= m | | | | | | e mod | deratel | v mapp | ed | 3=s | trongly | mappe | <u> </u> | • | | | |

| Uni t | Relevance to the local, national, | regional and global developmental needs | | | Relevance To the Employability/ | Entrepreneurship/ Skill Development | | Relevance to the Professional Ethics, Gender, Human | Values, Environment | & Sustamanney | | SDG | NEP | POE/4 th IR |
|----------|-----------------------------------|---|----------|--|---------------------------------|--|---|---|---------------------|---------------|------------------------------|---|-----|--|
| | Local | Regional | National | Global | Employability | Entrepreneurshi p | Skill Development | Professional Ethics | Gender | Human Values | Environment & Sustainability | | | |
| Unit | | 1 | | Drugs can be administere d through various routes depending on factors such as the drug's properties, the patient's condition, and the desired onset and duration of | | - | Interpret the dose-dependent responses of drugs | | - | | | 4.1(qu ality education and promote lifelon g learnin g opport unitie) | - | Projects/Assignm ents/Presentation s/soft skills development |

| | | action. | | | | | | | | |
|------|---|---|---|---|---|---|---|---|--|---|
| Unit | - | the pharmacol ogical action of drugs on the PNS underscore s the importance of equitable access to safe and effective medication s, as well as the need for comprehen sive healthcare | Pharmacologic al, classification, mechanism of action, uses, cont raindications of drug | - | - | - | - | 4.1(qu ality educat ion and promo te lifelon g learnin g opport unitie) | Institutional Restructuri ng and Consolidati on (10.1- 10.14) | Projects/Assignm ents/Presentation s/soft skills development |
| | | infrastructu re and education to optimize patient outcomes worldwide. | | | | | | | | |

| Unit | - | - | - | the developme nt of effective strategies for preventing blindness and preserving vision in populations worldwide. | - | - | Understanding the Pharmacologic al action, advesre effect and containdication s of various drug | - | - | - | 4.1(qu ality educat ion and promo te lifelon g learnin g opport unitie) | Institutional Restructuri ng and Consolidati on (10.1- 10.14) | Projects/Assignm ents/Presentation s/soft skills development |
|------|---|---|---|--|---|---|---|---|---|----|---|--|---|
| Unit | - | | | Challenges related to drug safety and misuse of CNS medication s, including addiction, dependenc e, and overdose, require coordinate d efforts to implement appropriate prescribing practices, | - | | Understanding the Pharmacologic al action, advesre effect and containdication s of various drug | - | | I. | 4.1(qu ality educat ion and promo te lifelon g learnin g opport unitie) | Institutional Restructuri ng and Consolidati on (10.1- 10.14) | Projects/Assignm ents/Presentation s/soft skills development |

| | educate healthcare providers and patients, and promote responsible medication use. | | | | | | |
|------|---|---|---|--|---|--|---|
| Unit | drug action on the cardiovascu lar system emphasizes the importance of comprehen sive approaches to cardiovascu lar health promotion, disease prevention, and manageme nt that address the complex interplay of | Understanding the Pharmacologic al action, advesre effect and containdication s of various drug | - | | 4.1(qu ality educat ion and promo te lifelon g learnin g opport unitie) | Institutional Restructuri ng and Consolidati on (10.1- 10.14) | Projects/Assignm ents/Presentation s/soft skills development |

| | biological, behavioral, environme ntal, and social determinan ts of health across diverse populations and settings. | | | |
|-------------|---|---|---|--|
| Unit -VI | drugs acting on blood and blood- forming groups underscore s the importance of comprehen sive approaches to hematologi cal care, including the prevention, diagnosis, and | Understanding the Pharmacologic al action, advesre effect and containdication s of various drug | 4.1(qu ality educat ion and promo te lifelon g learnin g opport unitie) | Projects/Assignm ents/Presentation s/soft skills development |

| | treatment of hematologi cal disorders, as well as the optimizatio n of blood transfusion practices and the promotion of safe and effective pharmacot | | | |
|--------------|---|---|---|--|
| Unit -VII | herapy. a critical role in the symptomati c manageme nt of respiratory conditions and improving quality of life for patients with respiratory diseases | Understanding the Pharmacologic al action, advesre effect and containdication s of various drug | 4.1(qu ality educat ion and promo te lifelon g learnin g opport unitie) | Projects/Assignm ents/Presentation s/soft skills development |

| Unit | healthcare | Understanding | 4.1(qu | Projects/Assignm |
|------|--------------|-----------------|--------------|------------------------------|
| - | disparities, | the | ality | ents/Presentation |
| VIII | promoting | Pharmacologic | educat | s/soft skills |
| | 1 . | al action, | ion | development |
| | access to | advesre effect | | |
| | essential | and | and | |
| | medication | containdication | promo | |
| | s, and | s of various | te | |
| | implementi | drug | lifelon | |
| | ng | | g | |
| | evidence- | | learnin | |
| | based | | g | |
| | treatment | | opport | |
| | strategies | | unitie) | |
| | to improve | | | |
| | patient | | | |
| | outcomes | | | |
| | and quality | | | |
| | of life for | | | |
| | individuals | | | |
| | affected by | | | |
| | gastrointest | | | |
| | inal | | | |
| | disorders | | | |
| Unit | the role of | Understanding | 4.1(qu | Projects/Assignm |
| -IX | drugs in | the | ality | ents/Presentation |
| | kidney | Pharmacologic | educat | s/soft skills development |
| | health | al action, | ion | development |
| | emphasizes | advesre effect | and | |
| | the | containdication | promo | |
| | importance | s of various | te | |
| | of | drug | lifelon | |
| | comprehen | | | |
| | sive, | | g learnin | |
| | Sive, | | learnin | |

| | patient- centered care, access to essential medication s, pharmacovi gilance, and adherence to evidence- based treatment guidelines to optimize outcomes and improve the quality | | g opport unitie) | |
|------------|--|--|----------------------------------|---|
| Unit -X | | Understanding the Pharmacologic al action, | 4.1(qu ality educat ion | Projects/Assignm ents/Presentation s/soft skills development |
| | have diverse roles in maintaining | advesre effect and containdication s of various drug | and promo te lifelon | |

| | physiologic al homeostasi s and treating various medical conditions | | g learnin g opport unitie) | |
|--------------|--|--|---|---|
| Unit -XI | understand ing the pharmacol ogical actions of histamine and serotonin is crucial for the manageme nt of various conditions affecting multiple organ systems | Pharmacologic al,classification , mechanism of action of drug | 4.1(qu ality educat ion and promo te lifelon g learnin g opport unitie) | Projects/Assignm ents/Presentation s/soft skills development |
| Unit -XII | Efforts to improve cancer care infrastructu re, expand access to | Understanding the Pharmacologic al action, advesre effect and containdication s of various | 4.1(qu ality educat ion and promo | Projects/Assignm ents/Presentation s/soft skills development |

| | | dmia | | |
|---|-----------|----------------|---------|------------------------------|
| | | drug | te | |
| | ugs, | | lifelon | |
| | omote | | g | |
| rese | search | | learnin | |
| and | | | g | |
| | evelopme | | opport | |
| | of novel | | unitie) | |
| the | erapies, | | | |
| and | d | | | |
| ado | dress | | | |
| hea | ealthcare | | | |
| dis | sparities | | | |
| are | e l | | | |
| ess | sential | | | |
| for | r | | | |
| adv | lvancing | | | |
| can | ncer | | | |
| trea | eatment | | | |
| and | d | | | |
| imp | proving | | | |
| pat | tient | | | |
| out | itcomes | | | |
| on | a global | | | |
| sca | | | | |
| Unit bio | | Understanding | 4.1(qu | Projects/Assignm |
| | ients | the concept of | ality | ents/Presentation |
| 1 | nresent a | Biological | educat | s/soft skills development |
| | verse and | agents | ion | at , cropment |
| | pidly | | and | |
| | panding | | promo | |
| | ass of | | te | |
| | edication | | lifelon | |
| S W | | | g | |

| | broad | | | | learnin | |
|--|--------------|--|--|--|---------|--|
| | therapeutic | | | | g | |
| | application | | | | opport | |
| | s across | | | | unitie) | |
| | various | | | | | |
| | medical | | | | | |
| | specialties. | | | | | |
| | Their | | | | | |
| | developme | | | | | |
| | nt and use | | | | | |
| | have | | | | | |
| | revolutioniz | | | | | |
| | ed the | | | | | |
| | treatment | | | | | |
| | landscape | | | | | |
| | for | | | | | |
| | numerous | | | | | |
| | diseases, | | | | | |
| | offering | | | | | |
| | new | | | | | |
| | treatment | | | | | |
| | options | | | | | |
| | and | | | | | |
| | improved | | | | | |
| | outcomes | | | | | |
| | for patients | | | | | |

ER2021P: Pharmacology Practical

| ER2021 P | Pharmacology Practical | L | Т | Р | | | | | |
|-------------------------|------------------------|------------------------------|---|---|--|--|--|--|--|
| Version 2.0 | | 0 | 0 | 2 | | | | | |
| Total Contact Hours | 50 hr | 50 hr | | | | | | | |
| Pre-requisites/Exposure | Human Anatomy ar | Human Anatomy and Physiology | | | | | | | |
| Co-requisites | Pharmacy Practice | | | | | | | | |

Course Objectives

is course will demonstrate / provide hands-on experience in the virtual platform using appropriate software on the following Study of pharmacological effects of drugs like local anaesthetics, mydriatic and mitotic on rabbit eye

Screening the effects of various drugs acting in the central nervous system

Study of drug effects on isolated organs / tissues

4. Study of pyrogen testing on rabbit

Course Outcome

Upon successful completion of this course, the students will be able to

- CO1. Study and report the local anaesthetic, mydriatic and mitotic effects of the given drug on the rabbit eye
- CO2. Choose appropriate animal experiment model to study the effects of the given drugs acting on the central nervous system and submit the report
- CO3. Perform the effects of given tissues (simulated) on isolated organs / tissues and interpret the results
- CO4. Interpret the dose dependent responses of drugs in various animal experiment models

| СО | PO1 | PO2 | PO3 | PO4 | PO5 | PO6 | PO7 | PO8 | PO9 | PO10 | PO11 | PO12 | PSO1 | PSO2 | PSO3 | PSO4 | PSO5 |
|------------------|-----|-----|-----|-----|-----|----------------------|-----|-----|-----|-------------------|------|------|------|------|------|------|------|
| CO1 | 3 | 1 | 2 | 3 | 2 | 1 | 3 | 1 | 2 | 3 | 2 | 3 | 3 | 2 | 1 | 2 | 3 |
| CO2 | 3 | 2 | 3 | 1 | 2 | 3 | 3 | 3 | 2 | 2 | 1 | 3 | 2 | 2 | 2 | 1 | 1 |
| CO3 | 2 | 1 | 2 | 3 | 3 | 3 | 3 | 2 | 3 | 2 | 2 | 2 | 1 | 3 | 3 | 3 | 1 |
| CO4 | 1 | 2 | 3 | 1 | 2 | 2 | 3 | 3 | 1 | 1 | 2 | 3 | 3 | 2 | 1 | 3 | 2 |
| 1=lightly mapped | | | | d | 2= | 2= moderately mapped | | | t | 3=strongly mapped | | | | | | | |

| Unit | | nce to the lobal develo | | nal, regional reds | | Relevance To the Employability/ Entrepreneurship/ Skill Development | | | Relevance to the Professional Ethics, Gender, Human Values, Environment & Sustainability | | Gender, Human Values, Environment & | | | | | POE/4 th IR |
|-------------|-----------|-------------------------|--------------|--|-------------------|---|--|----------------------------|--|-------------------------|---|---|--|--------------------------------|--|---------------------------|
| ER202 1P | Loca l | Region al | Nation al | Global | Employabil ity | Entrepreneurs hip | Skill Developm ent | Professio nal Ethics | Gend er | Hum an Value s | Environme nt & Sustainabil ity | | | | | |
| Unit I | - | - | | studying the effects of local anesthetics on the rabbit eye serves important scientific, clinical, and regulatory purposes, contributing | | - | Interpret the dose- dependent responses of drugs | - | - | - | | 4.4(Ski lls for Decent Work) | | Soft skills developm ent | | |

| | to the development of safe and effective ophthalmic anesthesia techniques, surgical procedures, and ocular drug formulations | | |
|-----------|--|---|--|
| Unit II - | studying the mydriatic effects of drugs on rabbit eyes serves important scientific, clinical, and regulatory purposes, contributing to the development of safe and effective mydriatic agents, | Interpret the dose dependent responses of drugs | 4.4(Ski - Soft skills developm Decent Work) |

| | | y, and promo patier in | nacolog I oting nt safety | | | | | | | |
|------------|---|--|---|---|---|---|---|---|---|-------------------------------|
| Unit III - | | mydri and m effects the ra eye is essent advan our under g of o pharm y, imp the sa and et of ophth | niotic s on bbit tial for ncing estandin ocular nacolog oroving | - | Interpret the dose dependent responses of drugs | | - | 4.4(Ski - lls for Decent Work) | d | oft skills levelopm ent |
| Unit IV - | - | | ing the - s of | - | experiment - model to study the effects of | - | | 4.4(Ski - lls for Decent Work | d | oft skills levelopm ent |

| | using analgesiomet ers and | the given () () () () () () () () () (| |
|--------|---|--|--|
| | animal models is essential for advancing our understandin | central nervous system | |
| | g of pain mechanisms, developing effective pain management strategies, and translating preclinical research findings into | | |
| | clinical practice. | | |
| Unit v | - | Hands on 4.4(Ski - Soft sk training of different Decent Echniques, s that students can learn the in vivo, ex and invivo techniques | |

| Unit-VI - | - | - Epilepsy - | - Hands on | - - | ` | Soft skills |
|-----------|---|-----------------|--------------------------|------|------|-------------|
| | | encompasses | training of | | | developm |
| | | a spectrum | different | | | ent |
| | | of syndromes | techniques, s | | Work | |
| | | with varying | that students | |) | |
| | | | can learn the | | | |
| | | etiologies | in vivo, ex | | | |
| | | and | and invivo techniques | | | |
| | | manifestatio | techniques | | | |
| | | ns. Different | | | | |
| | | regions may | | | | |
| | | have higher | | | | |
| | | prevalence | | | | |
| | | rates of | | | | |
| | | specific | | | | |
| | | epilepsy | | | | |
| | | syndromes | | | | |
| | | due to | | | | |
| | | genetic | | | | |
| | | predispositio | | | | |
| | | ns or | | | | |
| | | environment | | | | |
| | | | | | | |
| | | al factors. A | | | | |
| | | global | | | | |
| | | perspective | | | | |
| | | facilitates the | | | | |
| | | identification | | | | |
| | | of anti- | | | | |
| | | convulsant | | | | |
| | | drugs | | | | |
| | | effective | | | | |

| | of seiz and e syndr | us types | | | | | |
|----------|--|---|--|--|--|---------|--------------------------------|
| Unit VII | muscle relaxation using Rod appartenable researched to additionable cause culture factor respondent seconsides associated with respondent seconsides appartenable respondent seconsides associated appartenable respondent seconsides associated appartenable respondent seconsides associated appartenable respondent seconsides appartenable respondent seconsides appartenable respondent resp | ants a Rota- ratus les rchers dress iverse es, ral rs, drug onses, cafety deration ociated muscle ms and icity. | Hands on training of different techniques, s that students can learn the in vivo, ex and invivo techniques | | | 4.4(Ski | Soft skills developm ent |

| Unit- VIII | _ | of effective, safe, and accessible treatment options for individuals affected by these conditions across different regions and healthcare settings the screening of CNS stimulants and depressants using an Actophotom eter enhances our understandin g of drug | | Hands on training of different techniques, s that students can learn the in vivo, ex and invivo techniques | - | - | - | 4.4(Ski lls for Decent Work) | Soft skills developm ent |
|---------------|---|--|--|--|---|---|---|---|--------------------------------|
| | | g of drug effects, individual variability, cultural influences, | | | | | | | |

| | and public health implications associated with these drugs. This approach facilitates the development of tailored interventions and treatment strategies for CNS disorders that are responsive to the needs of diverse populations | | |
|-----------|--|--|--|
| | around the world. | | |
| Unit-IX - | studying - anxiolytic activity using the elevated plus maze method is critical for | Hands on training of different techniques, s that students can learn the in vivo, ex and invivo techniques | 4.4(Ski - Soft skills developm Decent Work) |

| Lipit VI | and contributes to the prevention and treatment of cardiovascula r diseases | Hands on | 4 4/Clri Coft chille |
|-----------|--|--|--|
| Unit-XI - | - studying the effects of drugs on ciliary motility in the frog's buccal cavity to enhances understandin g of fundamental biological processes, informs drug discovery and development , addresses environment al and health concerns, and | Hands on training of different techniques, s that students can learn the in vivo, ex and invivo techniques | - 4.4(Ski - Soft skills developm Decent Work) |

| | contributes to the conservation of frog species and their habitats | | 4.4(Ski - Soft skills |
|-------------|--|--|---|
| Unit XII | pyrogen testing by the rabbit method is essential for harmonizing regulatory standards, promoting international trade, facilitating cross-border research collaboration , ensuring consistent safety assessments, addressing ethical concerns, and enhancing | Hands on training of different techniques, s that students can learn the in vivo, ex and invivo techniques | - 4.4(Ski - Soft skills flls for developm Decent Work) |

| | emergency | | | | | |
|--|-----------------|--|--|--|--|--|
| | response | | | | | |
| | capabilities in | | | | | |
| | the global | | | | | |
| | healthcare | | | | | |

ER2022T: Community Pharmacy and Management Theory

| Subject Code: ER20-22T | Community Pharmacy and Management- Theory | L 3 | T 1 | P 0 |
|-------------------------|--|--------|--------|--------|
| Version 2.0 | | | | |
| Total Contact Hours | 75 hrs. | | | • |
| Pre-requisites/Exposure | Social Pharmacy | | | |
| Co-requisites | Pharmacy Management | | | |
| | Course Objectives | | | |

Course Objectives

- 1. Professional handling and filling prescriptions
- 2. Patient counseling on diseases and minor ailments
- 3. Patient counseling on prescription and / or non-prescription medicines
- 4. Preparation of counseling materials such as patient information leaflets
- 5. Performing basic health screening tests

Course Outcomes (CO)

On completion of this course, the students will be able to:

- CO1. Handle and fill prescriptions in a professional manner.
- CO2. Counsel patients on various diseases and minor ailments.
- CO3. Counsel patients on prescription and or non-prescription medicines.
- CO4. Design and prepare patient information leaflets.
- CO5. Perform basic health screening tests.

| СО | PO1 | PO2 | PO3 | PO4 | PO5 | PO6 | PO7 | PO8 | PO9 | PO10 | PO11 | PO12 | PSO1 | PSO2 | PSO3 | PSO4 | PSO5 |
|-----|-----|-----|-----|-------|-------|-----|-----|------|--------|-------|------|------|---------|--------|------|------|------|
| CO1 | 3 | 2 | 3 | - | 3 | 3 | 2 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 2 | 2 | 2 |
| CO2 | 3 | 3 | 3 | - | 3 | 3 | 2 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | - |
| CO3 | 3 | 3 | 3 | - | 3 | 3 | 2 | 3 | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 3 | - |
| CO4 | 3 | 3 | 2 | - | 3 | 3 | 2 | 3 | 2 | 3 | 2 | 3 | 3 | 3 | 2 | 1 | - |
| CO5 | 3 | 1 | 2 | - | 3 | 3 | 1 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 1 | - |
| | | | 1_1 | iah+l | manna | . d | 2- | mode | rotoly | manna | ٦ | 2-c+ | onalı n | aanaad | | | |

1=lightly mapped 2= moderately mapped 3=strongly mapped

| Un it | Relevance to the | local, national, | regional and grobal developmental needs | | Relevance To the | Employability/ | Entrepreneurship/ Skill Development | Relevance to the Professional Ethics, Gender, Human | Values, Environment | & Sustainability | | SDG | NEP | POE/4 th IR |
|----------|------------------|------------------|--|--|------------------|------------------|--|---|---------------------|------------------|------------------------------|--|--|--------------------------------------|
| | Local | Regional | National | Global | Employability | Entrepreneurship | Skill Development | Professional Ethics | Gender | Human Values | Environment & Sustainability | | | |
| Un it I | | | | The study and understa nding of commun ity pharmac y practice, both in internati onal and Indian contexts, have broad implicati ons for addressi ng global healthca re needs, promoti ng public health, and contribut ing to | | | The relevance of communit y pharmacy practice to skill developm ent is evident across a spectrum of clinical, communi cation, cultural, technolog ical, and collaborat ive skills. As the healthcar e landscape evolves, continuou s skill | The compre hensive understa nding of the definitio n, history, and develop ment of community pharma cy in internati onal and Indian contexts is crucial for pharma cists to navigate ethical challeng | | | | Sustainable Development and Global Citizenship (SDG 4.7) | Professional Education (17.1-17.5) | Global Education Knowledg e |

| | 1 | | | | 1 | T | | 1 | 1 | | | | 1 |
|----|---|---|---|---------------|---|----------------|-----------|---|---|---|-------------|-----------------|-----------|
| | | | | the | | developm | es and | | | | | | |
| | | | | overall | | ent is | uphold | | | | | | |
| | | | | efficienc | | essential | the | | | | | | |
| | | | | y and | | for | principl | | | | | | |
| | | | | effective | | pharmaci | es of | | | | | | |
| | | | | ness of | | sts to | patient- | | | | | | |
| | | | | healthca | | provide | centered | | | | | | |
| | | | | re | | high- | care, | | | | | | |
| | | | | systems | | quality | integrity | | | | | | |
| | | | | worldwi | | and | , and | | | | | | |
| | | | | de. | | | · · | | | | | | |
| | | | | | | patient- | professi | | | | | | |
| | | | | | | centered | onal . | | | | | | |
| | | | | | | care. | responsi | | | | | | |
| | | | | | | | bility. | | | | | | |
| Un | - | - | - | The | | The | They | - | - | - | Sustainable | Towards a | Global |
| it | | | | professi | | professio | guide | | | | Development | More Holistic | Education |
| II | | | | onal | | nal | pharma | | | | and Global | and | Knowledg |
| | | | | responsi | | responsi | cists in | | | | Citizenship | Multidisciplina | e |
| | | | | bilities | | bilities | ethical | | | | (SDG | ry | |
| | | | | of | | of | decisio | | | | 4.7) | Education | |
| | | | | commun | | commun | n- | | | | | (11.1- | |
| | | | | ity | | ity | making | | | | | 11.13) | |
| | | | | pharmac | | pharmac | , | | | | | | |
| | | | | ists, | | ists, | ensurin | | | | | | |
| | | | | especiall | | along | g the | | | | | | |
| | | | | y when | | with the | deliver | | | | | | |
| | | | | introduci | | introduct | y of | | | | | | |
| | | | | ng GPP | | ion to | high- | | | | | | |
| | | | | and | | GPP and | quality, | | | | | | |
| | | | | SOPs, | | SOPs, | patient- | | | | | | |
| | | | | directly | | are | centere | | | | | | |
| | | | | contribut | | integral | d care | | | | | | |
| | | | | e to | | to skill | while | | | | | | |
| | | | | addressi | | develop | upholdi | | | | | | |
| | | | | ng | | ment | ng the | | | | | | |
| | | | | global | | across | integrit | | | | | | |
| | | | | develop | | various | y and | | | | | | |
| | | | | ment | | domains, | values | | | | | | |
| | | | | needs by | | includin | of the | | | | | | |
| | | | | enhancin | | g clinical | profess | | | | | | |
| | | | | g | | practice, | ion. | | | | | | |
| | | | | g healthca | | commun | 1011. | | | | | | |
| | | | | re | | ication, | | | | | | | |
| | | | | quality, | | ethics, | | | | | | | |
| | | | | ensuring | | technolo | | | | | | | |
| | | | | regulator | | gy, and | | | | | | | |
| | | | | _ | | continuo | | | | | | | |
| | | | | y | | | | | | | | | |
| | | | | complia | | us loorning | | | | | | | |
| | | | | nce, | | learning. | | | | | | | |
| | | | | fostering | | These | | | | | | | |
| | | | | a skilled | | skills | | | | | | | |
| | | | | workfor | | contribut | | | | | | | |
| | Ì | | | ce, and | | e to the | 1 | Ì | 1 | | | | |

| | | | supporti ng public health initiative s. | | overall compete ncy and effective ness of commun ity pharmac ists in meeting the healthcar e needs of the commun ity. | | | | | |
|-----------|--|---|--|--|---|--|----------------------------|---|------------------------------------|--------------------------|
| Un it III | | the proper handling of prescript ions, adheren ce to legal and regulato ry require ments, and the impleme ntation of Good Dispensi ng Practice s are nationall y relevant because they impact patient safety, public health, complia nce with | | | Develop ing these skills will not only enhance your role as a pharma cist but also contribu te to the safe and effectiv e provisio n of healthca re services at the national level. | | Righ t Con duct and Trut h | Skills for Decent Work (SDG 4.4) | Professional Education (17.1-17.5) | Skill Develop ment |

| | | | the law, and the overall quality and efficienc y of healthca re services | | | | | | | | | | |
|---------------|---|---|---|---|---|---|---|---|--|---|---|--|--|
| Un it IV | | | | These skills are critical for fosterin g underst anding, collabor ation, and positive outcom es in a world that is increasi ngly intercon nected and diverse. | | These skills are critical for fosterin g understa nding, collabor ation, and positive outcom es in a world that is increasi ngly intercon nected and diverse. | | | Righ t Con duct, accu racy, fairn ess, hone sty, justi ce | | Skills for Decent Work (SDG 4.4) | Professional Education (17.1-17.5) | Employ ability |
| Un it v | - | - | - | contrib utes to improvi ng patient outcom es, public health, and the effectiv eness of healthc are | 1 | these skills will not only enhance your ability to provide effectiv e patient counsell ing but | 1 | - | Righ t Con duct and Trut h | 1 | Skills for Decent Work (SDG 4.4) | Professional Education (17.1-17.5) | Skill Develop ment, Employ ability |

| | | | systems in diverse global context s. | | also contribu te to better patient outcom es and satisfact ion, improve d public health, and the overall quality of healthca re services . | | | | | | |
|---------|---|--|---|--|--|---|--|---|---|------------------------------------|--|
| Un it v | - | | contrib utes to improvi ng patient outcom es, public health, and the effectiv eness of healthc are systems in diverse global context s. | | these skills will not only enhance your ability to provide effective patient counsell ing but also contribute to better patient outcomes and satisfaction, improved public health, and the overall quality | - | Righ t Con duct and Trut h | - | Skills for Decent Work (SDG 4.4) | Professional Education (17.1-17.5) | Skill Develop ment, Employ ability |

| | | | | | | | of healthca re services | | | | | | | |
|----------------------|---|---|--|--|---|---|--|---|---|---|---|---|--|--------------------------|
| Un it- VI | | | | it affects healthc are outcom es, costs, and the overall well-being of individ uals and commu nities worldw ide. Strategi es to improv e adheren ce must conside r the diverse | | | these skills will enable healthca re professi onals to play a pivotal role in improvi ng medicat ion adheren ce, thereby contributing to better patient outcom es, reduced healthca re costs, and improve d public health on a global scale. | - | | | | Skills for Decent Work (SDG 4.4) | Professional Education (17.1-17.5) | Skill Develop ment |
| Un it- VI I | - | - | health screenin g services in commun ity pharmac ies have national | l. | - | 1 | valuable health screenin g services , contribu te to early disease | - | - | 1 | - | Skills for Decent Work (SDG 4.4) | Professional Education (17.1-17.5) | Skill Develop ment |

| | | relevanc e as they promote preventi ve care, accessib ility, early detectio n, and the overall health and well- being of the populati on | T. | | detectio n, and promote healthie r commu nities. | | | | Ductional | CL:II |
|--------------|---|--|---|--|--|--|--|---|------------------------------------|--------------------------|
| Un it- VI II | - | | It impact the public health, healthc are regulati ons, and the role of pharma cists in patient care across borders. | | It enable healthca re professi onals to provide compre hensive and patient-centered care related to OTC medicat ions, empowe ring patients to make informe d decision s about self-medicat ion while ensurin | | | Skills for Decent Work (SDG 4.4) | Professional Education (17.1-17.5) | Skill Develop ment |

| | | | | 1 | 1 | | | ı | 1 | 1 | | 1 | 4 | |
|-----|---|---|-----------|---|---|---|-----------|---|---|---|---|------------|--------------|---------|
| | | | | | | | g their | | | | | | | |
| | | | | | | | safety | | | | | | | |
| | | | | | | | and | | | | | | | |
| | | | | | | | well- | | | | | | | |
| | | | | | | | being. | | | | | | | |
| Un | - | - | Effectiv | - | - | - | effectiv | - | - | - | - | Skills for | Professional | Skill |
| it- | | | e | | | | e | | | | | Decent | Education | Develop |
| IX | | | manage | | | | manage | | | | | Work | (17.1-17.5) | ment |
| | | | ment | | | | ment of | | | | | (SDG 4.4) | | |
| | | | ensures | | | | commu | | | | | | | |
| | | | the | | | | nity | | | | | | | |
| | | | continue | | | | pharma | | | | | | | |
| | | | d | | | | cies, | | | | | | | |
| | | | provisio | | | | provide | | | | | | | |
| | | | n of | | | | high- | | | | | | | |
| | | | essential | | | | quality | | | | | | | |
| | | | pharmac | | | | patient | | | | | | | |
| | | | eutical | | | | care, | | | | | | | |
| | | | services | | | | and | | | | | | | |
| | | | to the | | | | contribu | | | | | | | |
| | | | populati | | | | te to the | | | | | | | |
| | | | on. | | | | well- | | | | | | | |
| | | | | | | | being of | | | | | | | |
| | | | | | | | the | | | | | | | |
| | | | | | | | commu | | | | | | | |
| | | | | | | | nity | | | | | | | |
| | | | | | | | while | | | | | | | |
| | | | | | | | ensurin | | | | | | | |
| | | | | | | | g | | | | | | | |
| | | | | | | | regulato | | | | | | | |
| | | | | | | | ry | | | | | | | |
| | | | | | | | complia | | | | | | | |
| | | | | | | | nce and | | | | | | | |
| | | | | | | | financia | | | | | | | |
| | | | | | | | 1 | | | | | | | |
| | | | | | | | sustaina | | | | | | | |
| | | | | | | | bility. | | | | | | | |

ER20-22P: Community Pharmacy and Management – Practical

| ER20-22 P | COMMUNITY PHARMACY AND MANAGEMENT – PRACTICAL | L | T | P |
|----------------------------|--|---------|---|---|
| Version 2.0 | | 0 | 0 | 3 |
| Total Contact Hours | 75 Hr. | | | |
| Pre-requisites/Exposure | Hospital P | roducts | | |
| Co-requisites | Pharm | acy | | |

Course Objectives

- 1. Professional handling and filling prescriptions
- 2. Patient counseling on diseases and minor ailments
- 3. Patient counseling on prescription and / or non-prescription medicines
- 4. Preparation of counseling materials such as patient information leaflets
- 5. Performing basic health screening tests

Course Outcome

- CO1. Handle and fill prescriptions in a professional manner.
- CO2. Counsel patients on various diseases and minor ailments.
- CO3. Counsel patients on prescription and or non-prescription medicines.
- CO4. Design and prepare patient information leaflets.
- CO5. Perform basic health screening tests.

| СО | PO 1 | PO 2 | PO 3 | PO 4 | PO 5 | PO 6 | PO 7 | PO 8 | PO 9 | PO 10 | PO 11 | PO 12 | PSO 1 | PSO 2 | PSO 3 | PSO 4 | PSO 5 |
|---------|---------|---------|---------|---------|---------|---------|---------|---------|---------|----------|----------|----------|----------|----------|----------|----------|----------|
| CO 1 | 2 | - | - | - | - | - | - | - | - | - | 2 | - | - | - | 2 | 3 | 1 |
| CO 2 | 3 | 2 | - | - | 1 | 2 | - | 1 | - | 3 | 1 | 2 | - | 3 | 3 | 3 | - |
| CO 3 | 2 | 2 | - | - | 1 | 2 | - | 1 | - | 3 | 1 | 2 | - | 3 | 3 | 3 | - |
| CO 4 | 2 | 3 | - | - | - | 2 | - | 2 | - | - | 2 | - | - | - | - | 3 | - |
| CO 5 | 2 | 2 | 2 | - | - | - | - | - | - | 1 | 2 | - | - | - | - | 3 | - |
| | | | | 1=ligh | tly map | ped | 2 | 2= mod | erately | mapped | | 3=stro | ngly ma | pped | | | |

| U ni t | Relevance to the local, national, regional and global | developmental needs | | | | Relevance To the | Employability/ Entrepreneurship/ Skill Development | | | Relevance to the Professional Ethics, | Gender, Human | Values, Environment & Sustainability | SDG | | NEP | POE/4 th IR |
|--------------|---|---------------------|----------|--------|--|------------------|--|-------------------|------------|---------------------------------------|---------------|--------------------------------------|-----|--------------------------------|-----|------------------------|
| | Local | Regional | National | Global | | Employability | Entrepreneurship | Skill Development | D f 1 1741 | rrotessional Ethics | Gender | Human Values | | Environment & & Sustainability | | |

| U | | | | | T۰۰ | Handl | Handli | | | Dec | Susta | Profes | Ment |
|-----|--------------------|---|---|---|-----|------------------|----------|---|---------------------|-------------|----------------|-----------------|-------|
| _ | - Handlin | - | | | In | | | - | - | Pro vidi | Susta inabl | sional | oring |
| ni | g of | | | | fut | e and | ng the | | | ng | e | Educa | by |
| t I | prescript | | | | ure | fill | prescri | | | ara | Deve | tion | Alum |
| | ions with | | | | wil | prescr | ptions | | | wen | lopm | (17.1- | n |
| | professio | | | | 1 | iption | ethicall | | | ess | ent | 17.5) | |
| | nal | | | | be | s in a | У | | | to | and | , | |
| | standard | | | | abl | profes | | | | the | Glob | | |
| | s, | | | | e | sional | | | | pati | al | | |
| | reviewin | | | | to | mann | | | | ent | Citiz | | |
| | g . | | | | ru | er | | | | for | enshi | | |
| | prescript | | | | n a | | | | | retu | p | | |
| | ions,che | | | | me | | | | | rnin | (SD | | |
| | cking for legalcom | | | | dic | | | | | g the | G 4.7) | | |
| | pliance | | | | al | | | | | me | 4.7) | | |
| | and | | | | ret | | | | | dici | | | |
| | complete | | | | ail | | | | | nes | | | |
| | ness | | | | | | | | | if | | | |
| | | | | | dr | | | | | not | | | |
| | | | | | ug | | | | | in | | | |
| | | | | | sto | | | | | use | | | |
| | | | | | re | | | | | | | | |
| U | - | - | Identification of drug-drug | - | - | The | - | - | The | - | Susta | Profes | Ment |
| ni | | | interactions is of paramount | | | identif | | | identifi | | inabl | sional | oring |
| t | | | importance in healthcare | | | icatio | | | cation | | e | Educa | by |
| II | | | globally due to several | | | n of | | | of | | Deve | tion | Alum |
| | | | reasons like patient safety, optimizing treatment | | | drug- drug | | | drug- drug | | lopm ent | (17.1- 17.5) | n |
| | | | outcomes and drug | | | intera | | | interact | | and | 17.5) | |
| | | | development and regulatory | | | ctions | | | ions | | Glob | | |
| | | | processes | | | (DDIs | | | (DDIs) | | al | | |
| | | | | | |) is | | | is | | Citiz | | |
| | | | | | | highly | | | closely | | enshi | | |
| | | | | | | releva | | | tied to | | p | | |
| | | | | | | nt to | | | several | | (SD | | |
| | | | | | | skills | | | funda | | G | | |
| | | | | | | devel | | | mental | | 4.7) | | |
| | | | | | | opme | | | human | | | | |
| | | | | | | nt in | | | values, reflecti | | | | |
| | | | | | | severa 1 | | | ng | | | | |
| | | | | | | profes | | | ethical | | | | |
| | | | | | | sional | | | consid | | | | |
| | | | | | | domai | | | eration | | | | |
| | | | | | | ns, | | | s and | | | | |
| | | | | | | includ | | | prioriti | | | | |
| | | | | | | ing | | | es in | | | | |
| | | | | | | pharm | | | healthc | | | | |
| | | | | | | acy, | | | are | | | | |
| | | | | | | medic | | | deliver | | | | |
| | | | | | | ine, | | | у. | | | | |
| | | | | | | nursin | | | | | | | |
| | | | | | | g, and health | | | | | | | |
| | | | | | | care | | | | | | | |
| | | | | | | infor | | | | | | | |
| 1 | 1 | 1 | | • | | | 1 | | | | | • | |
| | | | | | | matics | | | | | | | |

| U ni t | - | - | The preparation of clear, multilingual dispensing labels ensures patient safety, | - | - | Prepar ation of | Ensurin g precise | - | - | - | Susta inabl e | Profes sional Educa | Ment oring by |
|------------------------|---|---|--|---|---|---|--|---|---|---|--|--|----------------------------------|
| II | | | facilitates global healthcare access, and promotes medication adherence across diverse linguistic and cultural contexts. | | | accura te labels enhan ces health | labelin g aligns with profess ional | | | | Deve lopm ent and Glob al | tion (17.1- 17.5) | Alum n |
| | | | | | | care profes sional s' skills in comm | ethics, prioriti zing patient safety, autono my, | | | | Citiz enshi p (SD G 4.7) | | |
| | | | | | | unicat ion, attenti on to detail, and patien | and inform ed consent while upholdi | | | | | | |
| | | | | | | t safety, fosteri ng profic iency | standar ds of accurac y and transpa rency | | | | | | |
| | | | | | | in medic ation mana geme nt and | in medica tion admini stration | | | | | | |
| | | | | | | adher ence promo tion. | | | | | | | |
| U ni t I V | Offering diverse health screenin g services locally promote s preventi ve care, early detection of health issues, and personali zed intervent | - | | | - | Cond ucting health screen ings devel ops health care profes sional s' profic iency in vital sign assess ment, | Perfor ming thoroug h health screeni ngs demons trates commit ment to patient welfare , respecti ng autono my, | - | | - | Susta inabl e Deve lopm ent and Glob al Citiz enshi p (SD G 4.7) | Profes sional Educa tion (17.1- 17.5) | Ment oring by Alum n |

| | 1 | | | | | | | T | | , | | | | 1 |
|----|-----------|---|----------|---|--------------|---|---------|-----------|---|---|---|-------|----------|-------|
| | fostering | | | | | | atory | g | | | | | | |
| | commun | | | | | | functi | accurat | | | | | | |
| | ity | | | | | | on | e data | | | | | | |
| | wellness | | | | | | evalua | collecti | | | | | | |
| | and | | | | | | tion, | on, and | | | | | | |
| | reducing | | | | | | glucos | maintai | | | | | | |
| | healthcar | | | | | | _ | ning | | | | | | |
| | | | | | | | e | | | | | | | |
| | e | | | | | | monit | confide | | | | | | |
| | dispariti | | | | | | oring, | ntiality, | | | | | | |
| | es. | | | | | | and | upholdi | | | | | | |
| | | | | | | | BMI | ng | | | | | | |
| | | | | | | | calcul | ethical | | | | | | |
| | | | | | | | ation, | standar | | | | | | |
| | | | | | | | enhan | ds in | | | | | | |
| | | | | | | | cing | healthc | | | | | | |
| | | | | | | | compr | are | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | ehensi | deliver | | | | | | |
| | | | | | | | ve . | У | | | | | | |
| | | | | | | | patien | | | | | | | |
| | | | | | | | t care | | | | | | | |
| | | | <u> </u> | | | | skills. | | | | | | <u> </u> | |
| U | Conducti | - | | | Offerin | - | | Deliver | - | - | - | Susta | Profes | Ment |
| ni | ng | | | | g | | | ing | | | | inabl | sional | oring |
| | counseli | | | | counsel | | | counsel | | | | e | Educa | by |
| t | ng | | | | ing on | | | ing | | | | Deve | tion | Alum |
| V | sessions | | | | chronic | | | session | | | | | (17.1- | n |
| | | | | | | | | | | | | lopm | | II |
| | for | | | | diseases | | | s for | | | | ent | 17.5) | |
| | chronic | | | | and | | | chronic | | | | and | | |
| | diseases | | | | device | | | disease | | | | Glob | | |
| | fosters | | | | use | | | s, | | | | al | | |
| | local | | | | enhance | | | incorpo | | | | Citiz | | |
| | develop | | | | S | | | rating | | | | enshi | | |
| | ment by | | | | healthc | | | device | | | | p | | |
| | empowe | | | | are | | | educati | | | | (SD | | |
| | ring | | | | professi | | | on, | | | | G | | |
| | | | | | onals' | | | | | | | | | |
| | patients | | | | | | | aligns | | | | 4.7) | | |
| | with | | | | employ | | | with | | | | | | |
| | knowled | | | | ability | | | profess | | | | | | |
| | ge for | | | | by | | | ional | | | | | | |
| | self- | | | | honing | | | ethics | | | | | | |
| | manage | | | | patient | | | by | | | | | | |
| | ment, | | | | commu | | | promot | | | | | | |
| | improvin | | | | nication | | | ing | | | | | | |
| | g | | | | | | | patient | | | | | | |
| | treatmen | | | | , educati | | | autono | | | | | | |
| | | | | | | | | | | | | | | |
| | t | | | | on, and | | | my, | | | | | | |
| | adherenc | | | | device | | | inform | | | | | | |
| | e, and | | | | training | | | ed | | | | | | |
| | reducing | | | | skills, | | | decisio | | | | | | |
| | healthcar | | | | meeting | | | n- | | | | | | |
| | e burden | | ĺ | | diverse | | | making | | | | | | |
| | through | | ĺ | | patient | | | , and | | | | | | |
| | proactiv | | ĺ | | needs | | | ensurin | | | | | | |
| | e disease | | | | and | | | g | | | | | | |
| | | | ĺ | | improvi | | | | | | | | | |
| | manage | | ĺ | | | | | compre | | | | | | |
| | ment | | ĺ | | ng | | | hensive | | | | | | |
| | strategie | | | | overall | | | care | | | | | | |
| | S. | | | | care | | | tailored | | | | | | |
| 1 | | 1 | l | 1 | quality. | | | to | Ì | | | | 1 | 1 |

| | 1 | | | | , | | | 1 | | 1 | | |
|----|------------|----------|----------|---------------|---|---------------------|----------|---|---|-------|--------|-------|
| | | | | | | individ | | | | | | |
| | | | | | | ual | | | | | | |
| | | | | | | needs, | | | | | | |
| | | | | | | fosterin | | | | | | |
| | | | | | | g trust | | | | | | |
| | | | | | | and | | | | | | |
| | | | | | | integrit | | | | | | |
| | | | | | | y in | | | | | | |
| | | | | | | healthc | | | | | | |
| | | | | | | are | | | | | | |
| | | | | | | practic | | | | | | |
| | | | | | | e. | | | | | | |
| U | Conducti | - | | Deliveri | - | Providi | - | - | - | Susta | Profes | Ment |
| ni | ng | | | ng | | ng | | | | inabl | sional | oring |
| t- | counseli | | | counsel | | counsel | | | | e | Educa | by |
| V | ng | | | ing on | | ing for | | | | Deve | tion | Alum |
| | sessions | | | minor | | minor | | | | lopm | (17.1- | n |
| Ι | for | | | ailment | | ailment | | | | ent | 17.5) | |
| | minor | | | S | | S | | | | and | | |
| | ailments | | | enhance | | uphold | | | | Glob | | |
| | supports | | | S | | S | | | | al | | |
| | local | | | employ | | profess | | | | Citiz | | |
| | develop | | | ability | | ional | | | | enshi | | |
| | ment by | | | by | | ethics | | | | p | | |
| | improvin | | | develop | | by | | | | (SD | | |
| | g | | | ing | | promot | | | | Ğ | | |
| | commun | | | commu | | ing | | | | 4.7) | | |
| | ity | | | nication | | patient | | | | , | | |
| | health | | | skills, | | educati | | | | | | |
| | literacy, | | | clinical | | on, | | | | | | |
| | reducing | | | knowle | | autono | | | | | | |
| | unnecess | | | dge, | | my, | | | | | | |
| | ary | | | and | | and | | | | | | |
| | healthcar | | | patient- | | inform | | | | | | |
| | е | | | centere | | ed | | | | | | |
| | utilizatio | | | d care | | decisio | | | | | | |
| | n, | | | approac | | n- | | | | | | |
| | empowe | | | hes, | | making | | | | | | |
| | ring | | | fosterin | | | | | | | | |
| | individu | | | g | | , ensurin | | | | | | |
| | als for | | | compet | | g | | | | | | |
| | self-care, | | | ence in | | accurat | | | | | | |
| | and | | | addressi | | e | | | | | | |
| | addressi | | | ng | | diagnos | | | | | | |
| | ng | | | diverse | | is, | | | | | | |
| | prevalen | | | health | | appropr | | | | | | |
| | t health | | | concern | | iate | | | | | | |
| | concerns | | | s and | | treatme | | | | | | |
| | effective | | | improvi | | nt, and | | | | | | |
| | ly, thus | | | | | confide | | | | | | |
| | enhancin | | | ng overall | | ntiality | | | | | | |
| | g overall | | | patient | | while | | | | | | |
| | well- | | | satisfact | | fosterin | | | | | | |
| | being | | | ion. | | g trust | | | | | | |
| | and | | | 1011. | | and | | | | | | |
| | producti | | | | | and patient- | | | | | | |
| | vity. | | | | | patient- provide | | | | | | |
| | vity. | | | | | | | | | | | |
| 1 | | | | | | r relation | | | | | | |
| | | <u> </u> | <u> </u> | | | 1Clatioil | <u> </u> | | | | | |
| | | | | | | | | | | | | 122 |

| | | | | | | | ships. | | | | | | |
|---------|----------------------|---|--|---|---|---------------|-----------------|---|---|---|-------------|---------------|---------------|
| | | | | | | | sinps. | | | | | | |
| | | | | | | | | | | | | | |
| T.T. | D C' | | | | | Maria | | | | | G .4. | D. C. | Mond |
| U ni | Proficien | - | | - | - | Maste ring | Compe tent | - | - | - | Susta inabl | Profes sional | Ment oring |
| t- | t handling | | | | | the | handlin | | | | e | Educa | by |
| V | of | | | | | handli | g of | | | | Deve | tion | Alum |
| İ | dummy | | | | | ng | dummy | | | | lopm | (17.1- | n |
| | dosage | | | | | and | dosage | | | | ent | 17.5) | |
| | forms | | | | | admin | forms | | | | and | ĺ | |
| | and | | | | | istrati | and | | | | Glob | | |
| | correct | | | | | on of | correct | | | | al | | |
| | administ | | | | | variou | admini | | | | Citiz | | |
| | ration | | | | | S | stration | | | | enshi | | |
| | techniqu | | | | | dumm | techniq | | | | p | | |
| | es are | | | | | У | ues | | | | (SD | | |
| | crucial | | | | | dosag | align | | | | G | | |
| | for local develop | | | | | e forms | with profess | | | | 4.7) | | |
| 1 | ment as | | | | | enhan | ional | | | | | | |
| 1 | they | | | | | ces | ethics | | | | | | |
| | ensure | | | | | skills | by | | | | | | |
| | healthcar | | | | | devel | ensurin | | | | | | |
| | e | | | | | opme | g | | | | | | |
| | practitio | | | | | nt by | patient | | | | | | |
| | ners | | | | | honin | safety, | | | | | | |
| | deliver | | | | | g | respecti | | | | | | |
| | safe and | | | | | profic | ng | | | | | | |
| | effective | | | | | iency | autono | | | | | | |
| | care, | | | | | in | my, | | | | | | |
| | improve medicati | | | | | medic ation | promot | | | | | | |
| | on | | | | | mana | ing inform | | | | | | |
| | adherenc | | | | | geme | ed | | | | | | |
| | e, reduce | | | | | nt, | consent | | | | | | |
| | medicati | | | | | dosag | , | | | | | | |
| | on | | | | | e | maintai | | | | | | |
| | errors, | | | | | calcul | ning | | | | | | |
| | and | | | | | ation, | confide | | | | | | |
| | enhance | | | | | patien | ntiality, | | | | | | |
| | patient | | | | | t | and | | | | | | |
| | outcome | | | | | educat | deliveri | | | | | | |
| | s, contribut | | | | | ion, and | ng | | | | | | |
| | ing to | | | | | ana device | quality care, | | | | | | |
| | the | | | | | operat | thus | | | | | | |
| | overall | | | | | ion, | upholdi | | | | | | |
| | health | | | | | ensuri | ng the | | | | | | |
| | and | | | | | ng | principl | | | | | | |
| | well- | | | | | safe | es of | | | | | | |
| | being of | | | | | and | benefic | | | | | | |
| | the | | | | | effecti | ence | | | | | | |
| | commun | | | | | ve | and | | | | | | |
| | ity. | | | | | health | non- | | | | | | |
| | | | | | | care | malefic | | | | | | |
| | | | | | | delive | ence in | | | | | | |
| | | | | | | ry | healthc | | | | | | |
| | | | | | | across | are | | | | | | |

| | ı | 1 | 1 | T | 1 | | | | 1 | | | | 1 | |
|------|---------------|---|---|---|---|---|---------|-------------|---|---|---|-------|--------|-------|
| | | | | | | | divers | practic | | | | | | |
| | | | | | | | e | e. | | | | | | |
| | | | | | | | clinic | | | | | | | |
| | | | | | | | al | | | | | | | |
| | | | | | | | settin | | | | | | | |
| | | | | | | | | | | | | | | |
| T.T. | G | | | | | | gs. | | | | | α . | D C | 3.6 |
| U | Commu | - | | | - | - | The | Comm | - | - | - | Susta | Profes | Ment |
| ni | nity | | | | | | use of | unity | | | | inabl | sional | oring |
| t- | pharmac | | | | | | comm | pharma | | | | e | Educa | by |
| V | y | | | | | | unity | cy | | | | Deve | tion | Alum |
| II | software | | | | | | pharm | softwar | | | | lopm | (17.1- | n |
| I | and | | | | | | acy | e and | | | | ent | 17.5) | ** |
| 1 | | | | | | | | | | | | and | 17.5) | |
| | digital | | | | | | softw | digital | | | | | | |
| | health | | | | | | are | health | | | | Glob | | |
| | tools | | | | | | and | tools | | | | al | | |
| | improve | | | | | | digital | uphold | | | | Citiz | | |
| | access to | | | | | | health | profess | | | | enshi | | |
| | healthcar | | | | | | tools | ional | | | | p | | |
| | e, | | | | | | foster | ethics | | | | (SD | | |
| | | | | | | | | | | | | (SD | | |
| | enhance | | | | | | S | by | | | | G | | |
| | patient | | | | | | skills | promot | | | | 4.7) | | |
| | care, | | | | | | devel | ing | | | | | | |
| | streamli | | | | | | opme | patient | | | | | | |
| | ne | | | | | | nt by | privacy | | | | | | |
| | workflo | | | | | | enhan | | | | | | | |
| | working w, | | | | | | cing | , inform | | | | | | |
| | | | | | | | | | | | | | | |
| | promote | | | | | | profic | ed | | | | | | |
| | medicati | | | | | | iency | consent | | | | | | |
| | on | | | | | | in | , | | | | | | |
| | safety, | | | | | | techn | accurat | | | | | | |
| | and | | | | | | ology | e data | | | | | | |
| | support | | | | | | utiliza | manage | | | | | | |
| | chronic | | | | | | tion, | ment, | | | | | | |
| | disease | | | | | | data | and | | | | | | |
| | | | | | | | | | | | | | | |
| | manage | | | | | | analys | equitab | | | | | | |
| | ment | | | | | | is, | le | | | | | | |
| | locally. | | | | | | patien | healthc | | | | | | |
| | | | | | | | t | are | | | | | | |
| | | | | | | | engag | | | | | | | |
| | | | | | | | ement | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | , and | | | | | | | |
| | | | | | | | collab | | | | | | | |
| | | | | | | | orativ | | | | | | | |
| | | | | | | | e | | | | | | | |
| | | | | | | | health | | | | | | | |
| | | | | | | | care | | | | | | | |
| | | | | | | | delive | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | | | | ry. | | | | | | | |

${\bf ER20\text{-}23T:\ Biochemistry\ and\ Clinical\ Pathology-Theory}$

| Subject Code: ER20-23T | Subject Name: Biochemistry and Clinical Pathology – Theory | L | T | P |
|----------------------------|---|---|---|---|
| Version 2.0 | | 3 | 1 | 0 |
| Total Contact Hours | 75 hr | • | | _ |

| Pre-requisites/Exposure | Pharmaceutical Chemistry- Theory |
|-------------------------|----------------------------------|
| Co-requisites | Pharmacology – Theory |
| | Course Objectives |

This course will discuss about basic concepts of

- 1. Structure and Functions of biomolecules
- 2. Catalytic activity, diagnostic and therapeutic importance of enzymes
- 3. Metabolic pathways of biomolecules in health and illness (metabolic disorders)
- 4. Biochemical principles of organ function tests and their clinical significance
- 5. Qualitative and quantitative determination of biomolecules / metabolites in the biological sample

6. Clinical pathology of blood and urine

Course Outcomes (CO)

Upon successful completion of this course, the students will be able to

- CO1. Describe the functions of biomolecules
- CO2. Discuss the various functions of enzymes in the human system
- CO3. Explain the metabolic pathways of biomolecules in both physiological and pathological conditions
- CO4. Describe the principles of organ function tests and their clinical significances.
- CO5.Determine the biomolecules / metabolites in the given biological samples, both qualitatively and quantitatively.

CO6.Describe the clinical pathology of blood and urine

| Course | Course | PO | PSO1 | PSO2 | PSO3 | PSO4 | PSO5 |
|---------------------------------------|---------|----|----|----|----|----|----|----|----|----|----|----|-------|-------|-------|------|------|------|
| Code | Outcome | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | | | | | |
| | CO1 | 3 | 2 | - | - | 3 | 3 | 1 | - | - | - | - | 1 | 3 | - | 3 | 1 | - |
| | CO2 | 3 | 2 | - | - | 3 | 3 | 1 | - | - | - | - | 1 | 3 | - | 3 | 1 | - |
| | CO3 | 3 | 3 | - | - | 3 | 3 | 1 | - | - | - | - | 1 | 3 | - | 3 | 1 | - |
| | CO4 | 3 | 2 | - | - | 3 | 3 | 1 | - | - | - | - | 1 | 3 | - | 3 | 1 | - |
| | CO5 | 3 | 2 | - | - | 3 | 3 | 1 | - | - | - | - | 1 | 3 | - | 3 | 1 | - |
| | CO6 | 3 | 2 | - | - | 3 | - | 1 | - | - | - | - | 1 | 3 | - | 3 | 1 | - |
| 1=lightly mapped 2= moderately mapped | | | | | | | | | | | | | 3=stı | ongly | mappe | ed | | |

| Unit | Relevance to the | local, national, regional and global | developmental needs | | Relevance To the | Employaoliity/ Entrepreneurship/ | Relevance to the Professional Ethics, Gender, Human Values, Environment | & Sustainability | | | | SDG | NEP | POE/4 th IR |
|-----------|------------------|---|---------------------|--|------------------|-------------------------------------|--|---------------------|--------|--------------|------------------------------|---|---|------------------------|
| | Local | Regional | National | Global | Employability | Entrepreneurship | Skill Development | Professional Ethics | Gender | Human Values | Environment & Sustainability | | | - |
| Unit I | - | - | - | - | - | - | - | - | - | 1 | - | - | Professiona 1 Education (17.1-17.5) | Skill Development |
| Unit | | | | Carbohydrates are a major source of energy for the human body. Understanding carbohydrate biochemistry is crucial for nutrition and maintaining a healthy diet. Issues related to carbohydrates, such as obesity, diabetes, and metabolic disorders, have global health implications. Research in carbohydrate biochemistry contributes to addressing these health challenges. | | | Basics knowledge of biomolecule s present in our body | | | | | Sk ill s fo r D ec en t W or k (S D G 4. 4) | Professiona 1 Education (17.1-17.5) | Skill Development |

| Unit Many diseases, Basic Sk Professiona including metabolic knowledge ill 1 Education | |
|--|--------------|
| | |
| | У |
| disorders, are linked of protein s (17.1-17.5) | |
| to protein function structure fo | |
| and structure. which help r | |
| Research in protein in drug D | |
| biochemistry discovery ec | |
| contributes to the en | |
| understanding of t | |
| disease mechanisms, W | |
| leading to the or | |
| development of k | |
| diagnostics and (S | |
| | |
| therapeutics with D | |
| global health G | |
| implications. | |
| | |
| Unit Lipids play a crucial Basics Sk Professiona | Employabilit |
| IV role in drug delivery knowledge ill 1 Education | у |
| systems, of s (17.1-17.5) | |
| pharmaceutical biomolecule fo | |
| formulations, and s present in r | |
| the development of our body D | |
| lipid-based and role of ec | |
| | |
| | |
| in lipid research body and t | |
| contribute to the diseases W | |
| global associated or | |
| pharmaceutical and with it. k | |
| biotechnology (S | |
| industries. D | |
| | |
| | |
| | |
| Unit The nucleic acid Basics Sk Professiona | Employabilit |
| v chapter has knowledge ill 1 Education | |
| | y |
| | |
| | |
| impacting various s present in r | |
| aspects of science, our body D | |
| medicine, and role of ec | |
| agriculture, DNA and en | |
| biotechnology, and RNA in our t | |
| more. body. W | |
| Nucleic acids, or | |
| specifically DNA, k | |
| carry genetic (S | |
| information. | |
| | |
| | |
| structure and 4. | |
| function of nucleic 4) | |

| | | | | acids is | | | | | | | | | | |
|------|---|---|---|--|---|---|-------------------------------------|---|---|---|---|---------|-------------|-------------|
| | | | | fundamental for | | | | | | | | | | |
| | | | | unraveling the | | | | | | | | | | |
| | | | | • | | | | | | | | | | |
| | | | | 1 | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | | | genetics on a | | | | | | | | | | |
| | | | | global scale. | | | | | | | | | | |
| Unit | - | - | - | Enzymes are | - | - | Basic | - | - | - | - | Sk | Professiona | - |
| -VI | | | | essential in the | | | knowledge | | | | | ill | 1 Education | |
| | | | | production of | | | of enzyme | | | | | S | (17.1-17.5) | |
| | | | | biopharmaceutical | | | structure | | | | | fo | | |
| | | | | s, including | | | which help | | | | | r | | |
| | | | | therapeutic | | | in drug | | | | | D | | |
| | | | | proteins and | | | discovery | | | | | ec | | |
| | | | | enzymes used in | | | | | | | | en | | |
| | | | | medical | | | | | | | | t W | | |
| | | | | treatments. Global | | | | | | | | or | | |
| | | | | healthcare benefits | | | | | | | | k | | |
| | | | | | | | | | | | | (S | | |
| | | | | from research in | | | | | | | | D | | |
| | | | | enzyme | | | | | | | | G | | |
| | | | | biochemistry for | | | | | | | | 4. | | |
| | | | | the development of | | | | | | | | 4) | | |
| | | | | new drugs and | | | | | | | | | | |
| | | | | therapies. | | | | | | | | | | |
| Unit | - | - | - | Vitamins are | - | - | Basics | - | - | - | - | Sk | Professiona | Skill |
| -VII | | | | essential for proper | | | knowledge | | | | | ill | 1 Education | Development |
| | | | | growth, | | | of | | | | | S | (17.1-17.5) | |
| | | | | development, and overall health. | | | biomolecule | | | | | fo | | |
| | | | | Understanding | | | s present in | | | | | r | | |
| | | | | vitamin | | | our body | | | | | D | | |
| | | | | requirements and | | | and role of | | | | | ec | | |
| | | | | deficiencies is | | | vitamins in our body | | | | | en | | |
| | | | | crucial for | | | our body and diseases | | | | | t W | | |
| | | | | addressing global | | | associated | | | | | or | | |
| | | | | public health | | | with | | | | | k | | |
| | | | | challenges related | | | deficiency | | | | | (S | | |
| | | | | to malnutrition and | | | of vitamins. | | | | | D | | |
| | | | | micronutrient | | | | | | | | G | | |
| | | | | deficiencies. | | | | | | | | 4. | | |
| | | | | | | | | | | | | 4) | | |
| Unit | - | - | - | Metabolism (Study | - | - | Basics | - | - | - | - | Sk | Professiona | Skill |
| - | | | | of cycle/pathways | | | knowledge | | | | | ill | 1 Education | Development |
| VIII | | | | without chemical | | | of | | | | | s | (17.1-17.5) | |
| | | | | structures) | | | metabolism | | | | | fo | | |
| | | | | Metabolism of | | | of | | | | | r | | |
| Ī | | | | | | | | | | | | | | |
| | | | | Carbohydrates | | | biomolecule | | | | | D | | |
| | | | | Carbohydrates Metabolism of lipids | | | biomolecule s and involvement | | | | | D ec | | |

| | | | | | | | , | | | | 1 | | T | |
|------|---|---|---|-----------------------|---|---|--------------|---|---|---|---|-----|-------------|--------------|
| | | | | Metabolism of | | | of these | | | | | t | | |
| | | | | Amino acids | | | process in | | | | | W | | |
| | | | | Biological | | | various life | | | | | or | | |
| | | | | oxidation | | | process of | | | | | k | | |
| | | | | | | | our body | | | | | (S | | |
| | | | | | | | and role of | | | | | D | | |
| | | | | | | | and fole of | | | | | G | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | 4. | | |
| | | | | | | | | | | | | 4) | | |
| Unit | - | - | - | Minerals are vital | - | - | Basics | - | - | - | - | Sk | Professiona | Employebilit |
| -IX | | | | for plant growth | | | knowledge | | | | | ill | 1 Education | у |
| | | | | and development. | | | of minerals, | | | | | s | (17.1-17.5) | |
| | | | | Research on | | | electrolyte | | | | | fo | , | |
| | | | | mineral nutrition | | | present in | | | | | r | | |
| | | | | in agriculture | | | our body | | | | | D | | |
| | | | | contributes to | | | and role of | | | | | | | |
| | | | | optimizing crop | | | | | | | | ec | | |
| | | | | yields, improving | | | these in our | | | | | en | | |
| | | | | soil fertility, and | | | body and | | | | | t | | |
| | | | | | | | diseases | | | | | W | | |
| | | | | ensuring global | | | associated | | | | | or | | |
| | | | | food security. | | | with | | | | | k | | |
| | | | | | | | deficiency | | | | | (S | | |
| | | | | | | | of minerals. | | | | | D | | |
| | | | | | | | or inneruis. | | | | | G | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | 4. | | |
| | | | | | | | | | | | | 4) | | |
| Unit | - | - | - | Organ function | - | - | Laboratory | - | - | - | - | Sk | Professiona | |
| -X | | | | tests are integral to | | | tests which | | | | | ill | 1 Education | |
| | | | | medical research, | | | help to | | | | | s | (17.1-17.5) | |
| | | | | enabling scientists | | | diagnose the | | | | | fo | | |
| | | | | and healthcare | | | diseases. | | | | | r | | |
| | | | | professionals to | | | | | | | | D | | |
| | | | | study patterns of | | | | | | | | ec | | |
| | | | | organ dysfunction, | | | | | | | | | | |
| | | | | identify risk | | | | | | | | en | | |
| | | | | factors, and | | | | | | | | t | | |
| | | | | develop strategies | | | | | | | | W | | |
| | | | | for disease | | | | | | | | or | | |
| | | | | | | | | | | | | k | | |
| | | | | prevention and | | | | | | | | (S | | |
| | | | | management. | | | | | | | | Ď | | |
| | | | | | | | | | | | | G | | |
| | | | | | | | | | | | | 4. | | |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | 4) | | |

ER20-23P: BIOCHEMISTRY & CLINICAL PATHOLOGY – PRACTICAL

| Subject Code: ER20- | Subject Name: BIOCHEMISTRY & CLINICAL | L | т | Р |
|----------------------------|---------------------------------------|---|---|---|
| 23P | PATHOLOGY – PRACTICAL | | 1 | • |
| Version 2.0 | | 0 | 0 | 2 |
| Total Contact Hours | 50 hours | | | |
| Pre- | Pharmaceutical | | | |
| | Chemistry- | | | |
| requisites/Exposure | Theory | | | |
| Co-requisites | Pharmacology – Theory | | | |

Course Objectives

Upon completion of this course the student should be able to:

- 1. Physical, chemical properties and qualitative tests of lipids, carbohydrates, proteins,
- 2. Analysis of normal and abnormal constituents of blood and urine
- 3. Microscopic examination of sputum and faecus
- 4. Practice in injecting drugs by intramuscular, subcutaneous and intravenous routes.
- 5. Withdrawal of blood sample

Course Outcomes (CO)

This subject is designed to impart fundamental knowledge on

- 1. The tests involved in detection of different food constituents like carbohydrates, proteins and lipids.
- 2.Different techniques employed in withdrawal of blood sample
- 3. Qualitative test for normal and abnormal constituents of urine
- 4. Chemical examination of sputum at microscopic level.

| Cour Code | se 📭 | ourse itcom | P | 01 | PO2 | PO3 | PO4 | P O 5 | PO 6 | P O 7 | P O 8 | P O 9 | PO 10 | P O 1 1 | P O 1 2 | PSO 1 | P S O 2 | PS O3 | P S O 4 | PSO5 |
|-----------|--------|----------------|---|----|-------|---------|-------|-------------|---------|-------------|-------------|-------------|----------|------------------|------------------|----------|------------------|----------|------------------|------|
| | CC |) 1 | 2 | | 3 | 2 | | 2 | 3 | | 3 | 2 | | 1 1 | 1 1 | 3 | 2 | | | |
| ER20 |)_ C(|) 2 | 3 | | 3 | 2 | | 2 | 1 | | | 2 | | | - | 3 | 2 | | | |
| 23P | CC |)3 | 3 | | 3 | 1 | | 1 | 2 | | 2 | 2 | | - | - | 2 | 3 | | | |
| | CC |) 4 | 2 | | 3 | 2 | | 1 | 2 | 2 | 3 | 3 | 1 | - | - | 2 | 2 | | | |
| | • | | • | | 1=lig | htly ma | apped | | 2= | mo | derat | elyı | nappe | d | | 3= | stro | ngly m | appe | ed |

| Unit | Relevance to the | local, national, | regional and global | developmental needs | Relevance To the | Employability/ | Skill Development | Relevance to the | Professional | Eunics, Gender, Human Values, Environment & Sustainability | | SDG | NEP | POE/4 th IR |
|------------------|------------------|------------------|------------------------|---|------------------|------------------|---|---------------------|--------------|--|------------------------------|--|--|--------------------------|
| ER2 0- 23P | Local | Regional | National | Global | Employability | Entrepreneurship | Skill Development | Professional Ethics | Gender | Human Values | Environment & Sustainability | | | |
| Unit | | | | Qualitative analysis of carbohydrates Understanding carbohydrate composition is crucial for assessing the nutritional content of foods globally, aiding in dietary planning and addressing issues related to malnutrition. Qualitative analysis of Proteins and amino acids Protein analysis is crucial in the food industry, quality control, and research globally. | | | The tests involved in detection of different food constituen ts like carbohydr ates, proteins and lipids. | | | Used to identify the patholog ical Conditio n of diseases | | Skill s for Dec ent Wor k (SD G 4.4) | Professi onal Educati on (17.1- 17.5) | Skill Develop ment |

| | Understanding protein content aids in addressing nutritional needs, ensuring food safety, and developing new products. Qualitative analysis of lipids Lipid analysis is critical in understanding dietary fats, ensuring food quality, and promoting heart health globally. It also has applications in industries such as cosmetics and biofuel production, contributing to diverse sectors on a worldwide scale. | | | | | CI :II | | |
|--------------|--|--|---|---|---|--|--|--------------------------|
| Unit II | Qualitative analysis of urine for normal and abnormal constituents | Analysis of normal and abnormal constituen ts of blood and urine | - | Help to diagnos e the various disease which ultimate ly help to treat the patient | - | Skill s for Dec ent Wor k (SD G 4.4) | Professi onal Educati on (17.1- 17.5) | Skill Develop ment |
| Unit -III | Determination of constituents of blood/serum (simulated) | Analysis of normal and abnormal | | Help to diagnos e the various | | Skill s for Dec ent | Professi onal Educati on | Employa bility |

| | (Creatine, | constituen | disease | Wor | (17.1- | |
|--|--|--|---|--------------|--------|--|
| | choles terol, Calciu m, Urea, SGOT /SGPT) | ts of blood and urine Microsco pic examinati on of sputum and faecus | which ultimate ly help to treat the patient | k (SD G 4.4) | 17.5) | |

ER2024T: Pharmacotherapeutics- Theory

| | ====================================== | | | |
|-------------------------|--|---|---|---|
| Subject Code: ER20-24T | Subject Name: PHARMACOTHERAPEUTICS - THEORY | L | Т | P |
| Version 2.0 | | 3 | 1 | 0 |
| Total Contact Hours | 75 hours | | | |
| Pre-requisites/Exposure | Human Anatomy and Physiology | | | |
| Co-requisites | Pharmacology | | | |
| | | | | |

Course Objectives

Upon completion of this course the student should be able to:

- 1. Etiopathogenesis of selected common diseases and evidence-based medicine therapy
- 2. Importance of individualized therapeutic plans based on diagnosis
- 3. Basic methods for assessing the clinical outcomes of drug therapy

Course Outcomes (CO)

On completion of this course, the students will be able to:

- CO1. Help assessing the subjective and objective parameters of patients in common disease conditions
- CO2. Assist other healthcare providers to analyse drug related problems and provide therapeutic interventions
- CO3. Participate in planning the rational medicine therapy for common diseases
- CO4. Design and deliver discharge counselling for patients

| СО | PO1 | PO2 | PO3 | PO4 | PO5 | PO6 | PO7 | PO8 | PO9 | PO10 | PO11 | PO12 | PSO1 | PSO2 | PSO3 | PSO4 | PSO5 |
|------------------|-----|-----|-----|-----|-----|-----|----------------------|-----|-----|------|-------------------|------|------|------|------|------|------|
| CO1 | 3 | 2 | 1 | _ | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
| CO2 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
| CO3 | 3 | 3 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
| CO4 | 3 | 2 | 1 | _ | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
| 1=lightly mapped | | | | | | | 2= moderately mapped | | | | 3=strongly mapped | | | | | | |

| Unit | | onal and | | al, national, developmental | | | o the Employability/ nip/ Skill Development | | | the Professional Ethics, s, Environment & Susta | | SDG | NEP | POE/ 4 th IR |
|-------------|-----------|--------------|--------------|---|-----------------------|--------------------------|--|----------------------------|------------|--|--|-----------------------------|---------|----------------------------|
| ER20 24T | Lo cal | Regi onal | Nati onal | Global | Empl oyabi lity | Entrep reneur ship | Skill Development | Profes sional Ethics | Gen der | Human Values | Enviro nment & Sustain ability | | | |
| Unit | | | | The unit includes the study of medication use in treating medical conditions. It encompasses drug classes, mechanisms of action, pharmacokinetics, adverse reactions, and rational drug use. Healthcare professionals must understand these principles to ensure safe and effective medication therapy, improving patient outcomes and minimizing adverse events. | | - | Studying pharmacotherapeutics provides essential knowledge for healthcare professionals. It enhances employability by enabling them to make informed medication decisions. Entrepreneurs can establish pharmaceutical ventures. Skill development in evidence-based medicine, essential medicines, and treatment guidelines fosters expertise and innovation, vital for career growth and improving healthcare | | | It is deeply intertwined with professional ethics by emphasizing responsible medication use. It also relates to gender, as healthcare should be equitable. Human values are upheld through patientcentered care. Environment considerations include proper disposal of pharmaceuticals. Sustainability involves ensuring ongoing access to essential medications while minimizing environmental impact | | Decent Work (SDG 4.4) | Educati | Develop |

| | | quality. | | |
|------|------------------------|-------------------------|---------------------------|--------------------------|
| | | | | |
| | | | | |
| | | | | |
| Unit | The unit includes- | Comprehending disease - | - Disease understanding- | Skills for Profess Skill |
| П | studying disease | (definition, etiology), | (definition, etiology), | Decent ional Develop |
| | management, | recognizing clinical | clinical presentation, | Work Educati ment |
| | which involves | symptoms, and | and management | (SDG on |
| | understanding | implementing | (nonpharmacological/ph | 4.4) (17.1- |
| | disease causes, | management strategies | armacological) are vital | 17.5) |
| | recognizing clinical | (nonpharmacological/ph | in healthcare. Ethical | |
| | manifestations, | armacological) are | care ensures equity, | |
| | and using | pivotal for healthcare | informed consent, and | |
| | interventions. | professionals. These | confidentiality. Gender | |
| | Ethical dimensions | skills enhance | fairness addresses | |
| | involve providing | employability by | health disparities. | |
| | equitable, patient- | meeting patient needs | Human values uphold | |
| | centered care | effectively. | patient dignity and | |
| | while respecting | Entrepreneurship | empathy. Environment- | |
| | autonomy. Gender | opportunities arise in | friendly practices reduce | |
| | equity ensures | healthcare services and | healthcare's ecological | |
| | equal access to | pharmaceuticals. Skill | footprint. Sustainability | |
| | care, while human | development is crucial | means maintaining | |
| | values promote | for career advancement | quality care while | |
| | empathy and | and innovation in | conserving resources for | |
| | dignity. | healthcare delivery. | future generations | |
| | Environmental | | | |
| | concerns include | | | |
| | sustainable | | | |
| | healthcare | | | |
| | practices, ensuring | | | |
| | ongoing access to | | | |
| | treatments | | | |
| | without resource | | | |
| | depletion. | | | |

ER2024P: Pharmacotherapeutics - Practical

| Subject Code: ER20-24P | Subject Name: Pharmacotherapeutics - Practical | L | Т | Р |
|-------------------------|--|---|---|---|
| Version 2.0 | | 0 | 0 | 1 |
| Total Contact Hours | 25 hr | | | |
| Pre-requisites/Exposure | Human Anatomy and Physiology | | | |
| Co-requisites | Pharmacology | | | |
| | | | | |

Course Objectives

Upon completion of this course the student should be able to:

- 1. How to prepare a SOAP (Subjective, Objective, Assessment and Plan) note for clinical cases of selected common diseases
- 2. Patient counselling techniques/methods for common disease conditions

Course Outcomes (CO)

On completion of this course, the students will be able to:

- CO1. Write SOAP (Subjective, Objective, Assessment and Plan) notes for the given clinical cases of selected common diseases
- CO2. Counsel the patients about the disease conditions, uses of drugs, methods of handling and administration of drugs, lifestyle modifications, and monitoring parameters.

| СО | PO1 | PO2 | PO3 | PO4 | PO5 | PO6 | PO7 | PO8 | PO9 | PO10 | PO11 | PO12 | PSO1 | PSO2 | PSO3 | PSO4 | PSO5 |
|-----|-----|-----|-----|----------|-------|-----|-----|------|--------|--------|------|-------|---------|-------|------|------|------|
| CO1 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 1 | 1 |
| CO2 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 2 | 2 |
| | | | 1=l | ightly ı | mappe | d | 2= | mode | rately | mapped | t | 3=str | ongly m | apped | | | |

| Unit | regi | evance ional ai elopme | ıd glob | | | | Employability/ kill Development | Relevance to the Professional Ethics, Gender, Human Value Environment & Sustainability | | | | SDG | | NEP | POE/4 th IR |
|-------------|---------------|------------------------------|------------------|---|-----------------------|----------------------|--|--|--------|--|------------------------------|--|--------------|--|--------------------------|
| ER2 024P | L oc al | Reg iona l | Nat ion al | Global | Emplo yabilit y | Entrepren eurship | Skill Development | Profess ional Ethics | Gender | Human Values | Environment & Sustainability | | | | |
| Unit I | | | | The unit includes studying and developing SOAP notes for six clinical cases, real or hypothetical, addressing healthcare needs at local, national, regional, and global levels. This process enhances healthcare documentation and communication skills, contributing to improved patient care and bolstering healthcare systems worldwide. | | - | The unit includes studying and creating SOAP notes for six clinical cases, whether real or hypothetical. This practice enhances employability by refining critical documentation and communication skills. Additionally, it can support entrepreneurship by advocating for healthcare quality and efficiency | | | Studying and preparing SOAP notes for six clinical cases, whether real or hypothetical, is crucial for professional ethics, patient confidentiality, gender equity, human values like empathy, and environmentally conscious practices. This contributes to sustainability by improving healthcare efficiency and quality. | | Good health well being 3.7 | and | Professional Education (17.1-17.5) | Skill Develop ment |
| Unit II | | _ | - | Patient counseling through role-playing in real or hypothetical clinical settings is crucial for addressing healthcare needs | | | Participating in patient counseling via role plays in actual or hypothetical clinical | _ | - | Patient counseling exercises, including role plays, support professional ethics through informed consent and | | Skills Decen Work SDG 3. | t (3) | Towards More Holist and Multidisciplina ry Education (11.13) | n Knowled ge |

| | at all levels. It improves communication skills among healthcare professionals, ensuring effective patient education, better health outcomes, and stronger healthcare systems to tackle global healthcare challenges. | situations is vital for addressing healthcare needs at various levels. It provides healthcare professionals with vital communication skills, enhancing patient education and health outcomes, bolstering global healthcare | patient autonomy, while promoting gender equity and human values like empathy in communication. Environmentally friendly approaches minimize medication waste, fostering sustainability. | |
|-------|---|--|--|--|
| Unit- | Employing | systems. The unit | The unit includes | Skills forProfessional Skill |
| III | simulated cases for dosage calculations in pediatrics and geriatrics, considering diverse medical conditions, is | includes practicing simulated cases for dose calculation in pediatrics and geriatrics, covering various pathologies. | studying simulated scenarios for dosage calculations in pediatrics and geriatrics, covering diverse medical conditions. This | Decent Education Develop Work ((17.1-17.5) ment SDG 3.3) |

| T T | T T | T | l I | |
|------------------|----------------|----------------------|-----|--|
| crucial for | This enhances | practice adheres | | |
| meeting local, | employability | to professional | | |
| national, | by equipping | ethics, prioritizing | | |
| regional, and | healthcare | patient well-being | | |
| global | professionals | and fostering | | |
| healthcare | with practical | gender equality by | | |
| development | skills. | addressing | | |
| needs. It | | individual | | |
| enhances | | healthcare needs. | | |
| healthcare | | | | |
| professionals' | | | | |
| skills, ensuring | | | | |
| safe and | | | | |
| effective | | | | |
| medication | | | | |
| administration, | | | | |
| ultimately | | | | |
| contributing to | | | | |
| improved | | | | |
| global | | | | |
| healthcare | | | | |
| systems and | | | | |
| better patient | | | | |
| outcomes | | | | |
| worldwide. | | | | |

ER2025T: Hospital and Clinical Pharmacy - Theory

| Subject Code: ER20-25T | Subject Name: Hospital and Clinical Pharmacy theory | L | T | P |
|------------------------|---|---|---|---|
| Version 2.0 | | 3 | 1 | 0 |

| Total Contact Hours | 75 hr | | | | | | |
|-------------------------|-------------------|--|--|--|--|--|--|
| Pre-requisites/Exposure | Clinical Pharmacy | | | | | | |
| Co-requisites | Hospital Pharmacy | | | | | | |
| Course Objectives | | | | | | | |

Upon completion of this course the student should be able to:

- 1. Learn about infection control measures, especially in the context of sterile compounding and healthcare-associated infections.
- 2. Learn how to monitor patients' response to medications through laboratory tests and clinical assessments.
- 3. Develop advocacy skills to ensure patients receive appropriate and affordable medications.
- 4. Learn how to assess patients' medical conditions and medication needs, considering factors like age, weight, allergies, and comorbidities.

Course Outcomes (CO)

Upon completion of this course the student should be able to:

- CO1. This entails supervising pharmaceutical services within a hospital environment, which encompasses managing the supply chain and working closely with healthcare providers.
- CO2. Hospital pharmacy administrators have the duty of effectively managing the acquisition, storage, and dissemination of medications within the hospital.
- CO3. Describe the involvement of other healthcare professionals in monitoring patient drug therapy and resolving drug-related issues.
- CO4. Hospital pharmacy administrators guarantee the secure and punctual distribution of medications to different hospital departments.

| CO | PO1 | PO2 | PO3 | PO4 | PO5 | PO6 | PO7 | PO8 | PO9 | PO10 | PO11 | PO12 | PSO1 | PSO2 | PSO3 | PSO4 | PSO5 |
|-----|-----|-----|-----|-----|----------|---------|-----|--------|----------|--------|------|------------|--------|------|------|------|------|
| CO1 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
| CO2 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
| СОЗ | 3 | 3 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
| CO4 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
| | | | | | 1=lightl | y mappe | d | 2= mod | derately | mapped | 3=8 | strongly m | napped | | | | |

| Unit | Relevance to the local, national, | Relevance To the Employability/ | Relevance to the Professional Ethics, | SD | NEP | POE/4 ^t |
|------|-----------------------------------|-------------------------------------|---------------------------------------|----|-----|--------------------|
| | regional and global developmental | Entrepreneurship/ Skill Development | Gender, Human Values, Environment & | G | | ^h IR |
| | needs | | Sustainability | | | |
| | | | | | | |

| ER202 5T | Loc al | Regio nal | Natio nal | Global | Employa bility | Entreprene urship | Skill Developm ent | Profess ional Ethics | Gen der | Human Values | Environ ment & Sustaina bility | | | |
|-------------|-----------|--------------|--------------|----------------|-------------------|----------------------|--------------------------|----------------------------|------------|-----------------|---|--------|----------|---------|
| Unit I | - | - | _ | in systematic | - | - | Develop | - | - | Human | _ | Skills | Professi | Skill |
| | | | | drug | | | skills in | | | values in | | for | onal | Develop |
| | | | | information | | | systematic | | | systematic | | Decen | Educati | ment |
| | | | | queries and | | | drug | | | drug | | t | on | |
| | | | | laboratory | | | information | | | information | | Work | | |
| | | | | report | | | queries by | | | queries and | | | 17.5) | |
| | | | | interpretation | | | mastering | | | laboratory | | (SDG | | |
| | | | | prioritize | | | search | | | report | | 4.4) | | |
| | | | | patient | | | techniques, | | | interpretatio | | | | |
| | | | | safety, | | | evaluating | | | n include | | | | |
| | | | | evidence- | | | primary, | | | patient- | | | | |
| | | | | based | | | secondary, | | | centered | | | | |
| | | | | practice, and | | | and tertiary | | | care, | | | | |
| | | | | ethical | | | resources, | | | empathy, | | | | |
| | | | | conduct. | | | and | | | accuracy, | | | | |
| | | | | These values | | | providing | | | transparency, | | | | |
| | | | | ensure | | | evidence- | | | ethical | | | | |
| | | | | accurate | | | based | | | conduct, and | | | | |
| | | | | information | | | information. | | | a | | | | |
| | | | | retrieval and | | | Enhance | | | commitment | | | | |
| | | | | informed | | | laboratory | | | to evidence- | | | | |
| | | | | decision- | | | report | | | based | | | | |
| | | | | making to | | | interpretatio | | | decision- | | | | |
| | | | | optimize drug | | | n skills | | | making. | | | | |
| | | | | therapy and | | | through | | | These values | | | | |
| | | | | provide high- | | | understandin | | | ensure safe | | | | |
| | | | | quality | | | g test results, | | | and effective | | | | |
| | | | | patient care. | | | identifying | | | patient care | | | | |
| | | | | of patients, | | | clinical | | | and respect | | | | |
| | | | | ensuring that | | | implications, | | | for | | | | |
| | | | | their needs, | | | and tailoring | | | individual | | | | |
| | | | | preferences, | | | drug therapy | | | needs. | | | | |
| | | | | and safety are | | | for optimal | | | | | | | |
| | | | | at the | | | patient care. | | | | | | | |

| | | | forefront of all pharmacy activities. | | | | | | | | |
|------|---|---|---------------------------------------|---|---------------|----|--------------|---|--------|----------|---------|
| Unit | - | - | PTCs and - | - | Stay updated | | Recognize | _ | Skills | Professi | Skill |
| II | | | hospital | | with the | | and | | for | onal | Develop |
| | | | formulary | | latest | ŀ | empathize | | Decen | Educati | ment |
| | | | management | | medical and | ļ | with the | | t | on | |
| | | | should be | | pharmaceuti | ı | needs, | | Work | (17.1- | |
| | | | guided by | | cal | ŀ | concerns, | | | 17.5) | |
| | | | evidence- | | information, | l; | and | | (SDG | | |
| | | İ | based | | including | 1 | perspectives | | 4.4) | | |
| | | | medicine, | | emerging | | of patients | | • | | |
| | | | ensuring that | | therapies and | ŀ | and their | | | | |
| | | | medications | | treatment | j | families | | | | |
| | | | and therapies | | guidelines, | ŀ | when | | | | |
| | | | are selected, | | to make | 1 | making | | | | |
| | | | evaluated, | | informed | j | formulary | | | | |
| | | | and included | | decisions | ŀ | decisions | | | | |
| | | | in the | | about | | and | | | | |
| | | | formulary | | formulary | 1 | therapeutic | | | | |
| | | | based on the | | inclusions | 1 | recommenda | | | | |
| | | | best available | | and | | tions. Show | | | | |
| | | | scientific | | therapeutic | ļ | respect for | | | | |
| | | | evidence. | | recommenda | 1 | the | | | | |
| | | | Prioritizing | | tions. | | autonomy | | | | |
| | | | the well- | | Enhance | | and dignity | | | | |
| | | | being and | | skills in | | of patients | | | | |
| | | | safety of | | critically | | by involving | | | | |
| | | | patients is | | evaluating | | them in | | | | |
| | | | paramount. | | scientific | ŀ | decision- | | | | |
| | | | Medication | | evidence, | ļ | making | | | | |
| | | | and | | clinical | | processes | | | | |
| | | | therapeutic | | trials, and | | and | | | | |
| | | | decisions | | research | ļ | respecting | | | | |
| | | | should | | studies to | ļ | their | | | | |
| | | | always | | make | ŀ | cultural, | | | | |

| | consider individual patient needs, preferences, and safety. | evidence- based decisions regarding medication selection and use. | religious. | |
|-------------|---|---|--|---|
| Unit III | The global values of drug distribution in hospitals encompass principles and ethical standards that transcend national boundaries and guide the practice of pharmacy in healthcare settings worldwide. These values emphasize universal principles and ethical standards that should be upheld by healthcare professionals involved in drug | Skill development in the context of drug distribution in hospitals is essential to ensure that healthcare professionals involved in this process can effectively and safely manage medication distribution. | distribution in hospitals involves a complex process that directly impacts patient care and safety. Upholding human values is essential to ensure that this process is conducted with integrity, compassion, and a focus on patient well-being . | Skills for onal Develop Decen Educati t on Work (17.1-17.5) (SDG 4.4) |

| | distribution in hospitals across diverse cultural and healthcare environments | | | |
|---------|---|---|--|---|
| Unit IV | Supply chain management in hospital pharmacy involves the procurement, storage, distribution, and management of pharmaceutic als and medical supplies to ensure that healthcare facilities can provide safe and effective patient care. Global values in hospital pharmacy supply chain management encompass principles and ethical | skills in supply chain management is crucial for professionals looking to excel in this field, as it encompasses various aspects of planning, sourcing, production, logistics, and distribution | Supply chain management is not just about logistics and operations; it also involves a set of human values and ethical considerations. These values guide professionals in making responsible decisions and conducting their work in a way that respects the welfare of individuals, communities , and the environment | Skills Professi Skill Develop Decen Educati t on Work (17.1-17.5) (SDG 4.4) |

| | | | | | | 1 | | | | | | 1 |
|------|---|---|-----------------|---|---|----------------|---|---|----------------|------------|----------|---------|
| | | | standards that | | | | | | | | | |
| | | | transcend | | | | | | | | | |
| | | | national | | | | | | | | | |
| | | | boundaries | | | | | | | | | |
| | | | and guide the | | | | | | | | | |
| | | | practice of | | | | | | | | | |
| | | | pharmacy in | | | | | | | | | |
| | | | healthcare | | | | | | | | | |
| | | | settings | | | | | | | | | |
| | | | worldwide. | | | | | | | | | |
| | | | These values | | | | | | | | | |
| | | | emphasize | | | | | | | | | |
| | | | universal | | | | | | | | | |
| | | | principles | | | | | | | | | |
| | | | and ethical | | | | | | | | | |
| | | | standards that | | | | | | | | | |
| | | | should be | | | | | | | | | |
| | | | upheld by | | | | | | | | | |
| | | | healthcare | | | | | | | | | |
| | | | professionals | | | | | | | | | |
| | | | engaged in | | | | | | | | | |
| | | | supply chain | | | | | | | | | |
| | | | management | | | | | | | | | |
| | | | in hospitals | | | | | | | | | |
| | | | across | | | | | | | | | |
| | | | diverse | | | | | | | | | |
| | | | cultural and | | | | | | | | | |
| | | | healthcare | | | | | | | | | |
| | | | environments | | | | | | | | | |
| | | | Cirvironinients | | | | | | | | | |
| | | | | | | | | | | | | |
| Unit | - | - | "Compoundi | - | - | Developing | - | - | Compoundin | Skills | Professi | |
| V | | | ng" in the | | | the skills | | | g in hospitals | for | onal | Develop |
| | | | context of | | | required for | | | involves the | Decen | Educati | ment |
| | | | hospitals | | | pharmaceuti | | | preparation | | on | |
| | | | typically | | | cal | | | of | Work | | |
| | | | refers to the | | | compoundin | | | customized | | 17.5) | |
| | | | process of | | | g in hospitals | | | medications | (SDG | , | |
| | | | brocess or | | | g in nospitals | | | medications | טעט | | |

| | preparing medications or pharmaceutic als by combining different ingredients to create customized medications for individual patients. It is a critical function in healthcare, especially in hospitals, as it ensures that patients receive the right dosage and form of medication to meet their specific medical needs. | involves a combination of knowledge, technical expertise, and attention to detail. Acquire a strong foundation in pharmaceuti cal science, including pharmacolog y, pharmaceuti cs, and pharmacokin etics. | several human values and ethical principles, which prioritize patient safety, well- being, and ethical conduct. | | Due Contribution |
|------------|--|--|---|---------------------------|--|
| Unit VI | Radiopharma - ceutics is a specialized field within healthcare that involves the use of radioactive | skills in radiopharma ceutics encompass radiation safety, patient-centered | The human values of radiopharma ceutics prioritize patient well-being, safety ethics, and | for Decen t Work | Professi Skill onal Develop Educati ment on (17.1- 17.5) |

| | | | materials | | care, | | | informed | | | |
|------|--|---|-----------------------|---|--------------------------|---|---|-----------------------------|-----------|-----------------|---------|
| | | | (radioisotope | | regulatory | | | consent. | | | |
| | | | s) for | | compliance, | | | They | | | |
| | | | diagnostic | | ethical | | | promote | | | |
| | | | and | | conduct, | | | transparency, | | | |
| | | | therapeutic | | quality, and | | | respect for | | | |
| | | | purposes. | | continuous | | | patient | | | |
| | | | The global | | learning. | | | rights, | | | |
| | | | values | | Professionals | | | environment | | | |
| | | | associated | | must excel in | | | al | | | |
| | | | with | | these areas | | | responsibilit | | | |
| | | | radiopharmac | | to ensure | | | y, and global | | | |
| | | | eutics are | | safe, | | | collaboration | | | |
| | | | shaped by the | | effective, | | | , ensuring | | | |
| | | | need to | | and ethical | | | responsible | | | |
| | | | balance the | | use of | | | and ethical | | | |
| | | | potential | | radioactive | | | use of | | | |
| | | | benefits of | | materials in | | | use or radioactive | | | |
| | | | nuclear | | materials in healthcare. | | | materials in | | | |
| | | | | | nealincare. | | | | | | |
| | | | medicine | | | | | healthcare. | | | |
| | | | with safety, | | | | | | | | |
| | | | ethical | | | | | | | | |
| | | | consideration | | | | | | | | |
| | | | s, and patient | | | | | | | | |
| | | | care. | | | | | | | | |
| Unit | | | Global values - | | Develop | | | Human | C1::11c | Professi | C1;:11 |
| VII | | _ | in clinical | Ī | skills in | - | - | values in | | | Develop |
| V II | | | pharmacy | | clinical | | | clinical | | Educati | |
| | | | | | | | | | | | mem |
| | | | emphasize patient- | | pharmacy by | | | pharmacy | ι Work | on (17.1 | |
| | | | centered care, | | mastering patient | | | prioritize patient well- | | (17.1- 17.5) | |
| | | | evidence- | | | | | | (SDG | 17.5) | |
| | | | | | assessment, | | | being, | ` | | |
| | | | based | | drug therapy | | | respect for | 4.4) | | |
| | | | practice, | | management, | | | autonomy, | | | |
| | | | ethical | | and | | | empathy, | | | |
| | | | conduct, | | medication | | | and ethical | | | |
| | | | interdisciplin | | counseling. | | | conduct. | | | |

| | | OPT/ | Enhance | Values | |
|------|---|--|---|--|-----------------------|
| | | ary collaboration, | | include | |
| | | - I | your | | |
| | | and . | knowledge | transparency, | |
| | | continuous | of evidence- | confidentialit | |
| | | learning. | based | y, patient | |
| | | These values | medicine, | education, | |
| | | drive high- | communicati | and | |
| | | quality | on, | collaborative | |
| | | healthcare, | interdisciplin | care, | |
| | | improve | ary | ensuring that | |
| | | patient | teamwork, | healthcare | |
| | | outcomes, | and staying | professionals | |
| | | and ensure | updated with | provide | |
| | | the | pharmaceuti | compassiona | |
| | | responsible | cal advances | te and ethical | |
| | | use of | to provide | pharmaceuti | |
| | | medications | optimal | cal care. | |
| | | worldwide. | patient care. | | |
| | | | | | |
| Unit | - | - Pharmacovig - | - Develop | - | Skills Professi Skill |
| VIII | | ilance | skills in | Human | for onal Develop |
| | | prioritize | pharmacovig | values in | Decen Educati ment |
| | | patient | ilance by | pharmacovig | t on |
| | | safety, | mastering | ilance | Work (17.1- |
| | | transparency, | adverse | prioritize | 17.5) |
| | | ethical | event | patient | (SDG |
| | | | CVCIIC | patient | |
| | | conduct, | | <u> </u> | 1 |
| | | conduct, collaboration, | reporting, data | safety, | 4.4) |
| | | collaboration, | reporting, data | safety, transparency, | 1 |
| | | collaboration, and | reporting, data analysis, | safety, transparency, and ethical | 1 |
| | | collaboration, and regulatory | reporting, data analysis, regulatory | transparency, and ethical conduct. | 1 |
| | | collaboration, and regulatory compliance. | reporting, data analysis, regulatory compliance, | safety, transparency, and ethical conduct. Values | 1 |
| | | collaboration, and regulatory compliance. These values | reporting, data analysis, regulatory compliance, and signal | safety, transparency, and ethical conduct. Values include | 1 |
| | | collaboration, and regulatory compliance. These values drive | reporting, data analysis, regulatory compliance, and signal detection. | safety, transparency, and ethical conduct. Values include empathy for | 1 |
| | | collaboration, and regulatory compliance. These values drive accurate data | reporting, data analysis, regulatory compliance, and signal detection. Enhance | safety, transparency, and ethical conduct. Values include empathy for patients, | 1 |
| | | collaboration, and regulatory compliance. These values drive accurate data reporting, | reporting, data analysis, regulatory compliance, and signal detection. Enhance communicati | safety, transparency, and ethical conduct. Values include empathy for patients, responsibilit | 1 |
| | | collaboration, and regulatory compliance. These values drive accurate data reporting, continuous | reporting, data analysis, regulatory compliance, and signal detection. Enhance communicati on, critical | safety, transparency, and ethical conduct. Values include empathy for patients, responsibilit y in | 1 |
| | | collaboration, and regulatory compliance. These values drive accurate data reporting, | reporting, data analysis, regulatory compliance, and signal detection. Enhance communicati | safety, transparency, and ethical conduct. Values include empathy for patients, responsibilit | 1 |

| | | assessment, | assessment | events, | |
|------|---|----------------|----------------|---------------|-----------------------|
| | | and public | abilities, | integrity in | |
| | | health | along with | data | |
| | | protection, | staying | analysis, and | |
| | | ensuring safe | updated with | a | |
| | | medication | global | commitment | |
| | | use and | pharmacovig | to public | |
| | | enhanced | ilance | health, | |
| | | healthcare | guidelines | ensuring safe | |
| | | quality | and | and ethical | |
| | | globally | emerging | medication | |
| | | | drug safety | use | |
| | | | issues | worldwide. | |
| | | | | | |
| Unit | - | - Global - | - Skills to - | | Skills Professi Skill |
| IX | | values | prevent | Human | for onal Develop |
| | | regarding | medication | values in | Decen Educati ment |
| | | medication | errors | preventing | t on |
| | | errors | encompass | medication | Work (17.1- |
| | | prioritize | medication | errors | 17.5) |
| | | patient | management, | include | (SDG |
| | | safety, | communicati | empathy for | 4.4) |
| | | transparency, | on, critical | patient | |
| | | error | thinking, | safety, | |
| | | prevention, | attention to | honesty in | |
| | | quality | detail, | reporting | |
| | | improvement, | standardizati | errors, | |
| | | education, | on, | responsibilit | |
| | | interdisciplin | continuous | y in | |
| | | ary | learning, | medication | |
| | | collaboration, | interdisciplin | management, | |
| | | reporting | ary | respect for | |
| | | systems, | collaboration | patients' | |
| | | technology, | , patient | rights, | |
| | | standardizati | education, | integrity in | |
| | | on, patient | accurate | communicati | |
| | | involvement, | reporting, | on, and a | |
| | | and | and active | commitment | |

| regulatory | participation | to |
|--------------|---------------|-------------|
| oversight. | in quality | continuous |
| These values | improvement | improvement |
| ensure safe | efforts, | , ensuring |
| and high- | ensuring safe | safe and |
| quality | and effective | compassiona |
| healthcare | medication | te |
| | use. | healthcare. |
| | | |

ER2025P: Hospital and Clinical Pharmacy Practical

| Subject Code: ER20-25P | Subject Name: Hospital and Clinical Pharmacy Practical | L | T | P |
|-------------------------|--|---|---|---|
| Version 2.0 | | - | - | 1 |
| Total Contact Hours | 25hr | | | |
| Pre-requisites/Exposure | Hospital and Clinical Pharmacy | | | |
| Co-requisites | Pharmacology, social pharmacy | | | |
| | Course Objectives | | | |

Upon completion of this course the student should be able to:

- 1. Systematic approaches for addressing drug information queries
- 2.Interpretation of routine laboratory reports to optimize dosage regimens
- 3.Reporting procedures for suspected adverse drug reactions to relevant authorities
- 4. Utilization and management of diverse medical/surgical aids and devices

Course Outcomes (CO)

Upon completion of this course the student should be able to:

- CO1. Respond to drug information queries in a professional manner, providing accurate and informed answers.
- CO2. Understand and analyze routine laboratory reports.
- CO3. Comprehend the purposes and techniques for managing different medical and surgical tools and equipment.
- CO4. Analyze and communicate drug-drug interactions in the treatment of prevalent diseases to enhance drug therapy.

| CO | PO1 | PO2 | PO3 | PO4 | PO5 | PO6 | PO7 | PO8 | PO9 | PO10 | PO11 | PO12 | PSO1 | PSO2 | PSO3 | PSO4 | PSO5 |
|-----|-----|-----|-----|-----|-----------|--------|-----|---------|-----------|-------|--------|-----------|------|------|------|------|------|
| CO1 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
| CO2 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
| CO3 | 3 | 3 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
| CO4 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 2 | 1 |
| • | • | • | • | | l=lightly | mapped | | 2= mode | rately ma | apped | 3=stro | ngly mapp | ed | • | | • | |

| Un it | regio | Relevance to the local, national, regional and global developmental needs Loc Regio National Global | | * | Relevance To the Employability/ Entrepreneurship/ Skill Development | | | Relevance to the Professional Ethics, Gender, Human Values, Environment & Sustainability | | | | SDG | NEP | POE/4 th IR |
|----------|-----------|--|---|--|--|----------------------|--|--|------------|-------------------------|---|--------------------------------------|------------------|---|
| | Loc al | Regio nal | National | Global | Employa bility | Entreprene urship | Skill Developm ent | Profess ional Ethics | Gen der | Hu man Val ues | Environ ment & Sustaina bility | | | |
| Un it I | | | primary, secondary, and tertiary resources, is pivotal for efficient pharmaceutic al information retrieval. This enhances healthcare decision- making, directly benefiting the national | queries, utilizing diverse resources, establishes a standardized model for international collaboration . This promotes evidence- based practices, ensuring | | | This experiment cultivates critical skills, honing information retrieval proficiency, analytical thinking, and effective reporting. Participants develop expertise in interpreting medical data, enhancing their ability to contribute meaningfully to healthcare decision- making on both national and global scales. | | | | | Good Health and Well- Being | nal Restructu | Corporate/Co mpany Trips/Project s |

| | | | Г | ı | | | | | | |
|---------|-------------|---------------|---|---------------|---|---|---|-----------|----------|---------------|
| | | universal | | | | | | | | |
| ele | evating | model. This | | | | | | | | |
| pat | tient care | promotes | | | | | | | | |
| sta | andards. | collaborative | | | | | | | | |
| | | knowledge | | | | | | | | |
| | | sharing, | | | | | | | | |
| | | facilitates | | | | | | | | |
| | | evidence- | | | | | | | | |
| | | based | | | | | | | | |
| | | practices, | | | | | | | | |
| | | and | | | | | | | | |
| | | establishes | | | | | | | | |
| | | consistent | | | | | | | | |
| | | standards in | | | | | | | | |
| | | pharmaceutic | | | | | | | | |
| | ľ | al | | | | | | | | |
| | | information | | | | | | | | |
| | | | | | | | | | | |
| | | management, | | | | | | | | |
| | | contributing | | | | | | | | |
| | | to the | | | | | | | | |
| | | advancement | | | | | | | | |
| | | of global | | | | | | | | |
| | | healthcare. | | | | | | | | |
| | | | | | | | | | | |
| Un - Le | everaging | Tailoring - | - | Developing | - | - | - | | | Corporate/Co |
| it lab | oratory | drug | | skills in | | | | being for | | mpany |
| II fin | idings to | therapies | | clinical data | | | | | | Trips/Project |
| | timize | based on | | interpretatio | | | | | ring and | S |
| dru | | laboratory | | n, treatment | | | | SDG | Consolid | |
| | eatment in | findings is | | optimization, | | | | | ation | |
| | nical cases | crucial for | | and aligning | | | | | (10.1- | |
| | essential | national | | healthcare | | | | | 10.14) | |
| | r meeting | development | | strategies | | | | | | |
| | tional | , enhancing | | with national | | | | | | |
| | velopment | healthcare | | and global | | | | | | |
| | eds. This | efficiency, | | priorities is | | | | | | |
| | proach | and aligning | | essential for | | | | | | |
| | proden | with global | | contributing | | | | | | |

| | enhances healthcare efficacy, refines appro treatment strategies, and aligns with the broader goals of advancing the nation's healthcare infrastructure and well- being, emphasizing national skills. | ities. nis oach ures ctive ment egies, buting overall cement the on's hcare or in nony global opment | divers | opment texts the care | | | | |
|-------------------|--|--|---|---|--|---------------------------------|-----|---|
| Un - it III | Implementin g this ADR approach, reporting forms a diverse diverse globall treatment, aligns with national development goals. It enhances Utilizing Utilizing forms a diverse causali assessment globall treatment, aligns with national development goals. It drug sa and | ng and e ity ments ly ees acovig | g ADI report forms causal assess hones in | ing and lity ments skills nacovig , cing tise in safety | | healthy lives and promote | nal | Corporate/Co mpany Trips/Project s |

| | | strengthens | for better | | | | | |
|--------|---------------|----------------|--------------|----------|-----|------------|------------|---------------|
| e | | international | healthcare | | | | | |
| re | | collaboration | outcomes. | | | | | |
| tı tı | | in healthcare. | | | | | | |
| Si | 0 | This | | | | | | |
| | | proactive | | | | | | |
| | ontributes | approach | | | | | | |
| to | o advancing | aligns with | | | | | | |
| | | global | | | | | | |
| | | development | | | | | | |
| | nfrastructure | | | | | | | |
| | Similarly, | for safer and | | | | | | |
| | | more | | | | | | |
| | | effective | | | | | | |
| | 1 | medical | | | | | | |
| | | treatments. | | | | | | |
| | trengthens | | | | | | | |
| | harmacovig | | | | | | | |
| | lance, | | | | | | | |
| | upporting | | | | | | | |
| | vidence- | | | | | | | |
| | ased | | | | | | | |
| | olicies | | | | | | | |
| | rucial for | | | | | | | |
| | oublic health | | | | | | | |
| | rogress and | | | | | | | |
| | ational | | | | | | | |
| d | levelopment | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |
| Un (| Commencin | Hands-on | | .]- | - 7 | well- | Institutio | Corporate/Co |
| it g | with this | training | 1.Hands-on | | | being for | | mpany |
| IV m | nethodology | ensures | training in | | | all at all | Restructu | Trips/Project |
| | furnishing | healthcare | medical aids | | | ages (| ring and | s |

| practical | professionals | | ultivates | | 1 | SDG | Consolid | |
|--------------------------|---------------|---|-------------------|--|---|-----|----------|--|
| experience in | 1 | | ssential | | | | ation | |
| | adhere to | | kills in | | | | (10.1- | |
| | standardized | | ealthcare | | | | 10.14) | |
| aids, surgical | | | rofessionals | | | | 10.14) | |
| | | P | rofessionals | | | | | |
| instruments, and medical | | , | n a a managain | | | | | |
| | and elevating | | ncompassin | | | | | |
| supplies cultivates the | | | the dentification | | | | | |
| | | | | | | | | |
| competence | | | application, | | | | | |
| of healthcare | | | nd | | | | | |
| professionals | | | nanagement | | | | | |
| , in harmony | | | f diverse | | | | | |
| with national | | | nedical | | | | | |
| | promotes | | quipment | | | | | |
| | collaboration | | or | | | | | |
| development | | | omprehensi | | | | | |
| | knowledge | | e patient | | | | | |
| 1 1 - | exchange | C | are | | | | | |
| | among | | | | | | | |
| | healthcare | | | | | | | |
| and supplies | | | | | | | | |
| | globally, | | | | | | | |
| | contributing | | | | | | | |
| | to a shared | | | | | | | |
| | understandin | | | | | | | |
| | g of best | | | | | | | |
| | practices | | | | | | | |
| | Globally | | | | | | | |
| patient care. | | | | | | | | |
| | professionals | | | | | | | |
| | can | | | | | | | |
| | effectively | | | | | | | |
| | utilize | | | | | | | |
| | medical aids | | | | | | | |
| medical aids | | | | | | | | |
| and supplies | | | | | | | | |
| fortifies the | situations, | | | | | | | |

| | healthcare leading to a infrastructure more, reflecting coordinated the national value of response to robust healthcare on an systems. leading to a | | |
|-------------------|---|--|---|
| Un - it v | Implementin g this wound approach on a national scale fosters and role-play enhance global improvement in healthcare, readiness by aligning with the national value of promoting excellence in professional development and ensuring the highest standards of patient care across the country | | Ensure healthy lives and promote ring and Consolid ation (10.1-10.14) |
| Un - it- VI | The implementati Utilizing mannequins for | Global utilization of mannequins | Ensure Institutio Corporate/Co healthy nal mpany lives and promote ring and s |

| based | vaccination | for | | | Consolid | |
|---------------|---------------|---------------|--|--|--------------|--|
| vaccination | and injection | vaccination | | | ation | |
| and injection | techniques | and injection | | | (10.1- | |
| techniques | on a global | techniques | | | 10.14) | |
| | scale | enhances | | | | |
| enhances | enhances | healthcare | | | | |
| healthcare | healthcare | professionals | | | | |
| workforce | proficiency, | ' skills, | | | | |
| skills, | ensuring | ensuring | | | | |
| standardizes | standardized | consistent | | | | |
| administratio | administratio | and | | | | |
| n | n practices | standardized | | | | |
| procedures, | and | administratio | | | | |
| and | facilitating | n practices | | | | |
| improves | international | worldwide. | | | | |
| immunizatio | training | | | | | |
| n program | standardizati | | | | | |
| quality, | on | | | | | |
| thereby | | | | | | |
| fostering | | | | | | |
| better public | | | | | | |
| health | | | | | | |
| outcomes | | | | | | |
| across the | | | | | | |
| country. | | | | | | |
| | | | | | | |
| | | | | | | |

ER20-26T: Pharmacy Law and ethics

| Subject Code: ER20-26T | Subject Name: Pharmacy Law and | L | Т | P |
|-------------------------|--------------------------------|---|---|---|
| - | ethics | | | |
| Version 2.0 | | 3 | 1 | 0 |
| Total Contact Hours | 75 hr | | | |
| Pre-requisites/Exposure | Pharmacy Law and ethics | | | |
| Co-requisites | Ethics | | | |
| Course Objectives | | | | |

Upon completion of this course the student should be able to:

- 1. General perspectives, history, evolution of pharmacy law in India
- 2. Act and Rules regulating the profession and practice of pharmacy in India
- 3. Important code of ethical guidelines pertaining to various practice standards
- 4. Brief introduction to the patent laws and their applications in pharmacy

Course Outcomes (CO)

On completion of this course, the students will be able to:

CO1-Describe the history and evolution of pharmacy law in India

CO2- Interpret the act and rules regulating the profession and practice of pharmacy in India

CO3-Discuss the various codes of ethics related to practice standards in pharmacy CO4-Interpret the fundamentals of patent laws from the perspectives of pharmacy

| | _ | 1 | 1 | 1 | _ | | | _ | 1 | _ | 1 | 1 | _ | _ | 1 | _ | |
|---|-----|-----|-----|-----|-----|-----|------------|-----|-----|------|------|------|------|------|------|------|------|
| CO | PO1 | PO2 | PO3 | PO4 | PO5 | PO6 | PO7 | PO8 | PO9 | PO10 | PO11 | PO12 | PSO1 | PSO2 | PSO3 | PSO4 | PSO5 |
| CO1 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 1 | 1 | 1 |
| CO2 | 3 | 2 | 1 | - | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 3 | 3 | 2 | 2 | 2 | 2 |
| CO3 | 2 | 2 | 2 | - | 2 | 3 | 2 | 3 | 2 | 3 | 2 | 2 | 2 | 3 | 2 | 1 | 1 |
| CO4 | 2 | 1 | 2 | 2 | 2 | 4 | 2 | 4 | 2 | 2 | 4 | 4 | 1 | 2 | 2 | 2 | 1 |
| 1=lightly mapped 2= moderately mapped 3=strongly mapped | | | | | | | | | | | | | | | | | |

| Chapt er | natio | onal, reg al devel | o the loca gional and lopmental | l | Relevance To the Employability/ Entrepreneurship/ Skill Development | | | Valu | nce to t es, Ger es, En Sustair | nder, H vironn | SDG | NEP | POE /4 th IR | |
|-------------|--------|-----------------------|---|----------------|--|----------------------|--------------------------|--|--|---------------------------------|--|---|-------------------------------|--------|
| ER2 026T | Lo cal | Regi onal | Natio nal | Gl ob al | Emplo yability | Entrepre neurship | Skill Develo pment | Profes sional Ethics | Ge nde r | Hu ma n Va lue s | Enviro nment & Sustain ability | | | |
| 1-4 | - | | Law provide a framewo rk for regulatin g the pharmac y professi on nationall y, with various Acts and historica l develop ments shaping drug regulatio n and pharmac y practice | | | | | Provide professio nal ethics related to the Pharmac y professio n. Ex-Prohibiti on of Unethica l Practices . | | - | | Skills for Decent Work (SDC 10.3) | sional Educat | sional |

| | | worldwi | | | | | | | | |
|--------|---|----------------|-------|---|-----------|-------|-----|----------|--------|--------|
| | | de. | | | | | | | | |
| | | | | | | | | | | |
| 5-8 - | | Help in | _ | _ | Code of | _ | Sk | ills for | Profes | Profes |
| | | improve | | | Conduct, | | | cent | sional | |
| | | ment | | | Patient | | | ork | Educat | |
| | | and | | | Welfare, | | | (SDG | | |
| | | subsequ | | | Confide | | 10. | | (17.1- | |
| | | ent | | | ntiality, | | | ŕ | 17.5) | |
| | | amendm | | | Compete | | | | | |
| | | ents, | | | nce and | | | | | |
| | | establish | | | Continui | | | | | |
| | | the legal | | | ng | | | | | |
| | | framewo | | | Educatio | | | | | |
| | | rk for | | | n, | | | | | |
| | | the | | | Regulato | | | | | |
| | | regulatio | | | ry | | | | | |
| | | n and | | | Oversigh | | | | | |
| | | quality | | | t. | | | | | |
| | | control | | | | | | | | |
| | | of drugs, | | | | | | | | |
| | | prohibiti | | | | | | | | |
| | | on of magic | | | | | | | | |
| | | remedies | | | | | | | | |
| | | and | | | | | | | | |
| | | cruelty | | | | | | | | |
| | | of | | | | | | | | |
| | | animal. | | | | | | | | |
| 9-12 - | - | Provide | _ | _ | Keep | _ | Sk | ills for | Profes | Profes |
| | | fare | | | the data | | | cent | sional | |
| | | price, | | | confiden | | | ork | Educat | |
| | | equal | | | tial of | | | (SDG | | |
| | | distributi | | | Accordi | | 10. | | (17.1- | |
| | | on and | | | ng MTP | | | | 17.5) | |
| | | availabil | | | act. | | | | | |
| | | ity of | | | Aware | | | | | |
| | | drugs | | | the | | | | | |
| | | througho | | | consume | | | | | |
| | | ut the | | | rs | | | | | |
| | | country. | | | towered | | | | | |
| | | Prohibiti | | | the act. | | | | | |
| | | on of | | | | | | | | |
| | | illegal | | | | | | | | |
| | | terminati | | | | | | | | |
| | | on of | | | | | | | | |
| | | pregnan | | | | | | | | |
| | | cy. | | | j | | | | | |

| 10 | TD1 | | | | | D 1 | г г | | C1 :11 C | D C | D C |
|---------|----------|-----------|----------|---------|----------|--------------|------|---|------------|---------------|--------|
| 13 | - They | - | - | | | Develop | | - | Skills for | | |
| 16 | provid | e | | | | ed ethics | | | Decent | sional | sional |
| | Good | | | | | to keep | | | Work | Educat | Ethics |
| | Regula | to | | | | the data | | | (SDG | | |
| | | | | | | of | | | | (17.1- | |
| | ry | | | | | | | | 10.5) | | |
| | practic | es | | | | confiden | | | | 17.5) | |
| | in | | | | | tial of | | | | | |
| | Comm | u | | | | Intellect | | | | | |
| | nity | | | | | ual | | | | | |
| | Pharm | ac | | | | Property | | | | | |
| | y, | | | | | Rights, | | | | | |
| | Hospit | a1 | | | | Emergen | | | | | |
| | | | | | | | | | | | |
| | pharm | ic | | | | cy Use | | | | | |
| | у, | | | | | Authoriz | | | | | |
| | Pharm | | | | | ation, | | | | | |
| | Manuf | ac | | | | NDA | | | | | |
| | turing, | | | | | and | | | | | |
| | Whole | | | | | ANDA. | | | | | |
| | le | 54 | | | | 111 (12) 11. | | | | | |
| | | | | | | | | | | | |
| | busine | SS | | | | | | | | | |
| | , | _ | | | | | | | | | |
| | inspec | io | | | | | | | | | |
| | ns, | | | | | | | | | | |
| | import | | | | | | | | | | |
| | export | | | | | | | | | | |
| | of dru | | | | | | | | | | |
| | and | gs | | | | | | | | | |
| | | | | | | | | | | | |
| | medica | | | | | | | | | | |
| | device | | | | | | | | | | |
| | And a | so | | | | | | | | | |
| | gives | | | | | | | | | | |
| | basic | | | | | | | | | | |
| | conce | ıt | | | | | | | | | |
| | of | | | | | | | | | | |
| | ANDA | | | | | | | | | | |
| | | •• | | | | | | | | | |
| | NDA, | | | | | | | | | | |
| | and | | | | | | | | | | |
| | clinica | l | | | | | | | | | |
| | trial. | | <u>L</u> | <u></u> | <u> </u> | | | | | | |
| 17-21 - | - Blood | - | - | _ | - | Provide | - - | - | Skills for | Profes | Profes |
| | bank, | | | | | professio | , | | | sional | |
| | disaste | r | | | | nal | | | | Educat | |
| | | | | | | ethics | | | (SDG | | Lunes |
| | manag | | | | | | | | (SDG) | 1011 (17.1 | |
| | ment, | | | | | related | | | 10.3) | (17.1- | |
| | consur | ne | | | | to the | | | | 17.5) | |
| | r | | | | | several | | | | | |
| | protec | io | | | | acts | | | | | |
| | n, all a | | | | | those are | , | | | | |
| | regula | | | | | protect | | | | | |
| | and | | | | | - | | | | | |
| | | | | | | human | | | | | |
| | constr | | | | | being as | } [| | | | |
| | | by | | | | well | | | | | |
| | govern | m | | | | animals. | | | | | |
| | | | • | | | • | · | | | | |

| ent b providir | y 1 | | | | | |
|--------------------|--------|--|--|--|--|--|
| g act | ES | | | | | |
| governi g bodie | | | | | | |
| at | | | | | | |
| national level. | | | | | | |
| | | | | | | |